fluorouracil has been researched along with Neutropenia in 539 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin." | 9.69 | Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023) |
| "The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 9.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
| "Addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer may improve pathological complete response (pCR) rates." | 9.19 | Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. ( Ando, M; Aogi, K; Fujiwara, Y; Hamano, T; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Ohono, S; Shimizu, S; Sukigara, T; Yamamoto, N; Yamauchi, H, 2014) |
| "We conducted a phase II study evaluating safety and efficacy of combination gemcitabine and capecitabine therapy for metastatic breast cancer patients following anthracycline and taxane treatment in Korea." | 9.19 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. ( Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI, 2014) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 9.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "Capecitabine and paclitaxel are established effective treatments, alone and combined with other cytotoxic and targeted agents, for metastatic breast cancer (MBC)." | 9.19 | Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. ( Allred, JB; Fitch, TR; Hobday, TJ; Liu, H; Lyss, AP; Northfelt, DW; Perez, EA; Rodacker, MW, 2014) |
| "Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)." | 9.17 | Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013) |
| "Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have non-overlapping toxic effects and synergy pre-clinically." | 9.17 | A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. ( Dzhelali, MV; Findlay, MP; Harvey, VJ; Hinder, VA; Isaacs, RJ; Jameson, MB; Jeffery, GM; McLaren, BR; Pollard, S; Riley, GA; Scott, JN; Sharples, KJ; Simpson, AB, 2013) |
| "This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)." | 9.17 | Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013) |
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 9.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 9.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
| " We aimed at identifying novel genetic markers that would improve prediction of irinotecan toxicity and response in advanced colorectal cancer patients treated with folic acid (leucovorin), fluorouracil (5-FU), and irinotecan (camptosar)-based regimens." | 9.17 | Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. ( Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G, 2013) |
| "To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of oral metronomic vinorelbine with capecitabine in patients with metastatic breast cancer (MBC)." | 9.16 | A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. ( Androulakis, N; Ardavanis, A; Georgoulias, V; Kalbakis, K; Kourakos, P; Malamos, N; Mavroudis, D; Polyzos, A; Saridaki, Z; Vamvakas, L, 2012) |
| "PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine." | 9.16 | A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012) |
| "This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy." | 9.16 | Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 9.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 9.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "We performed an analysis of the efficacy of capecitabine monotherapy as maintenance treatment for metastatic breast cancer (MBC) after response to capecitabine-based chemotherapy [capecitabine plus docetaxel (XT) or vinorelbine (XN)] as a first-line or a second-line treatment." | 9.16 | Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. ( Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S, 2012) |
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 9.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 9.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
| "Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer." | 9.15 | Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. ( Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M, 2011) |
| " However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the non-time-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963)." | 9.15 | Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Smaaland, R; Tampellini, M; Tumolo, S, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer." | 9.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011) |
| "Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)." | 9.14 | Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 9.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 9.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "The addition of capecitabine to docetaxel significantly improves overall survival in anthracycline-pretreated metastatic breast cancer." | 9.14 | Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. ( Gennatas, K; Gennatas, S; Michalaki, V, 2009) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 9.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "Capecitabine is effective against metastatic breast cancer (MBC)." | 9.14 | Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. ( Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G, 2010) |
| "The purpose of this study was to compare docetaxel plus epirubicin versus docetaxel plus capecitabine combinations as front-line treatment in women with advanced breast cancer (ABC)." | 9.14 | Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. ( Ardavanis, A; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Ziras, N, 2010) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 9.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan." | 9.13 | UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008) |
| "Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)." | 9.12 | Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006) |
| "The aim of the study was to analyse the toxicity and health related quality of life (HRQoL) of breast cancer patients treated with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) and TAC (docetaxel, doxorubicin, cyclophosphamide) with and without primary prophylactic G-CSF (PPG)." | 9.12 | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony sti ( Adrover, E; Antón, A; Arcusa, A; Calvo, L; del Prado, PM; Fernandez-Chacón, C; Grosse, R; Iglesias, L; Isla, D; Lluch, A; López-Vega, JM; Martín, M; Mel, JR; Muñoz, M; Ramos, M; Rodríguez-Lescure, A; Roset, M; Ruiz, A; Seguí, MA; Zaluski, J, 2006) |
| "To evaluate the maximum tolerated dose and dose-limiting toxicity (DLT) of 10-hydroxy-camptothecin (10-HCPT) in HFL regimen for the treatment of advanced colorectal cancer (CRC)." | 9.12 | [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. ( Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG, 2007) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 9.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 9.11 | Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004) |
| "Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)." | 9.11 | Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004) |
| "This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer." | 9.11 | A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. ( Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J, 2004) |
| "A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer." | 9.11 | Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004) |
| "A retrospective source review identifying predictive factors and assessing safety and efficacy in pretreated metastatic breast cancer (MBC) patients treated with capecitabine in a French compassionate-use program." | 9.11 | Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. ( Barats, JC; Baticle, JL; Brewer, Y; Chollet, P; Fumoleau, P; Gil-Delgado, M; Goudier, MJ; Martin, D; Namer, M; Pierga, JY; Sutherland, W; Turpin, FL; Zelek, L, 2004) |
| "To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLT) of the combination of capecitabine and vinorelbine in patients with metastatic breast cancer who relapse after adjuvant and/or first-line treatment." | 9.11 | Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. ( Borquez, D; Harstrick, A; Kaufmann, M; Loibl, S; Oberhoff, C; Schleucher, R; Seeber, S; Vanhoefer, U; von Minckwitz, G; Welt, A, 2005) |
| "Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)." | 9.11 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 9.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 9.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 9.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy." | 9.10 | Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. ( Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H, 2002) |
| "The purpose of this study was to evaluate the efficacy and toxicity of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes." | 9.10 | Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. ( Bountouroglou, N; Farmakis, D; Kosmas, C; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M, 2003) |
| "Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer." | 9.10 | A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. ( Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J, 2003) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 9.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| " irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer." | 9.10 | Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). ( Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 9.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "Paclitaxel has significant antitumor activity in patients with metastaticbreast cancer who have been previously treated with or exposed to anthracycline-containing chemotherapy." | 9.10 | Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. ( Ames, F; Berry, D; Booser, DJ; Buzdar, AU; Frye, DK; Holmes, FA; Hortobagyi, GN; Hoy, E; Hunt, K; Ibrahim, NK; Kau, SW; Manuel, N; McNeese, MD; Rahman, Z; Rivera, E; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Thomas, E; Valero, V; Walters, R, 2002) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)." | 9.10 | Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002) |
| " This phase I study evaluated the addition of capecitabine to epirubicin/docetaxel combination therapy as first-line treatment for advanced breast cancer." | 9.10 | Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. ( Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M, 2002) |
| "To determine the efficacy and safety profile, including the risk for cardiac toxicity, of liposome-encapsulated doxorubicin (TLC D-99), fluorouracil (5-FU), and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer (MBC)." | 9.09 | Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. ( Azarnia, N; Booser, D; Buzdar, AU; Ewer, M; Fonseca, GA; Hortobagyi, GN; Lee, LW; Mackay, B; Podoloff, D; Theriault, RL; Valero, V; Walters, RS; Willey, J, 1999) |
| " cerevisiae fusion protein) on the incidence, duration, and complications of neutropenia and thrombocytopenia after moderate-dose fluorouracil 600 mg/m(2), doxorubicin 60 mg/m(2), and cyclophosphamide 750 mg/m(2) (FAC) chemotherapy in patients with stage II and III breast cancer." | 9.09 | Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. ( Agura, E; Dimitrov, N; Duncan, L; Garrison, L; Hyman, W; Jones, SE; Khandelwal, P; Kirby, R; Lange, M; McIntyre, K; Mennel, R; Orr, D; Regan, D; Roque, T; Schuster, M, 1999) |
| "To compare prospectively the antitumor activity of single-agent paclitaxel to the three-drug combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer." | 9.09 | Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. ( Ames, F; Asmar, L; Booser, DJ; Buzdar, AU; Frye, D; Hortobagyi, GN; Hunt, K; Ibrahim, N; Kau, SW; Manuel, N; McNeese, M; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Valero, V, 1999) |
| "Patients with previously untreated metastatic breast cancer were randomized to receive either paclitaxel 200 mg/m(2) intravenously (IV) over 3 hours for eight cycles (24 weeks) or standard cyclophosphamide 100 mg/m(2)/d orally on days 1 to 14, methotrexate 40 mg/m(2) IV on days 1 and 8, fluorouracil 600 mg/m(2) IV on days 1 and 8, and prednisone 40 mg/m(2)/d orally on days 1 to 14 (CMFP) for six cycles (24 weeks) with epirubicin recommended as second-line therapy." | 9.09 | Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. ( Ackland, S; Bishop, JF; Canetta, R; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, IN; Smith, J; Stephenson, J; Tattersall, MH; Toner, GC; Walpole, E, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 9.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen." | 9.09 | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 9.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 9.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 9.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
| "Gemcitabine alone or 5-fluorouracil (5-FU) according to several schedules are used for palliation of metastatic and locally advanced (LA) pancreatic adenocarcinoma." | 9.09 | Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). ( André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F, 2001) |
| "Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding palliative chemotherapy with fluoropyrimidines leucovorin +/- irinotecan, participated in this study." | 9.09 | Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H, 2001) |
| "38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study." | 9.09 | Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 9.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| " 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas." | 9.09 | A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 9.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "Results of phase II studies have demonstrated high efficacy and low toxicity for a weekly schedule of high-dose 5-fluorouracil/folinic acid (5-FU/FA) when given to intensively pretreated patients with metastatic breast cancer." | 9.08 | Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer. ( Harstrick, A; Klaassen, U; Seeber, S; Wilke, H, 1996) |
| "To determine the effects of sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) on the incidence, duration, and complications of myelosuppression after moderate-dose fluorouracil, doxorubicin, cyclophosphamide (FAC) adjuvant chemotherapy in patients with node-positive breast cancer." | 9.08 | Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. ( Denham, CA; Duncan, LA; George, TK; Good, RH; Hoyes, FA; Jones, SE; Kirby, RL; Mennel, RG; Rubin, AS; Schottstaedt, MW; Snyder, DA; Watkins, DL, 1996) |
| "The Breast Cancer Site Group of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG) undertook two parallel phase I studies to determine the maximum tolerated dose (MTD) and recommended phase II dose of vinorelbine in combination with doxorubicin and fluorouracil (with or without folinic acid) in metastatic breast cancer." | 9.08 | Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. ( Fine, S; Gelmon, K; Goss, PE; James, K; Myles, J; Ottaway, J; Paul, K; Pritchard, KI; Rodgers, A; Rudinskas, L, 1997) |
| "Carboplatin, a platinum analog with single-agent activity in previously untreated breast cancer, is characterized by comparatively less renal toxicity and emesis than cisplatin." | 9.07 | Carboplatin in combination as first-line therapy in advanced breast cancer. ( Bonadonna, G; Brambilla, C; Ferrari, L; Passoni, P, 1993) |
| "Seventeen patients with either newly diagnosed breast cancer with more than four involved axillary nodes (five patients) or metastatic breast cancer (12 patients) were treated with cyclophosphamide 1 g/m2, doxorubicin 50 mg/m2, and fluorouracil 500 mg/m2 (CAF) intravenously (IV) once every 3 weeks." | 9.07 | Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. ( Gelmon, KA; O'Reilly, SE; Onetto, N; Page, RA; Parente, J; Plenderleith, IH; Rubinger, M, 1993) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 9.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer." | 9.07 | Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992) |
| "A multicentre pilot study has been conducted to determine an intensive regimen of cyclophosphamide, epirubicin, and fluorouracil which was tolerable and acceptable to patients with node positive breast cancer." | 9.07 | A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. ( Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Levine, MN; Perrault, D; Pritchard, K; Skillings, J; Warr, D, 1992) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 8.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer." | 8.86 | A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010) |
| "This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use." | 8.85 | The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. ( Boehnke Michaud, L, 2009) |
| "Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer." | 8.84 | Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. ( Arkenau, HT; Arnold, D; Cassidy, J; Diaz-Rubio, E; Douillard, JY; Grothey, A; Hinke, A; Hochster, H; Martoni, A; Porschen, R; Schmiegel, W; Schmoll, HJ, 2008) |
| "The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens." | 8.81 | Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002) |
| "We found that ABCA2 polymorphism was significantly associated with systemic exposure to capecitabine and capecitabine-induced neutropenia in Japanese patients with CRC." | 8.31 | A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer. ( Fujita, KI; Ishida, H; Kubota, Y; Matsumoto, N; Murase, R; Shibata, Y; Shimada, K, 2023) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 8.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "The inclusion criteria were as follows: (1) oesophageal squamous cell carcinoma, (2) a schedule to receive three courses of induction chemotherapy (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-fluorouracil 750 mg/m2 days 1-5, every 3 weeks), (3) stage IB-III, (4) 20-75 years old, (5) 0-1 performance status, (6) preserved organ functions and (7) written informed consent." | 8.02 | A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. ( Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A, 2021) |
| " He suffered from rash and neutropenia after multiple chemotherapy sessions including oxaliplatin, 5-fluorouracil (5- FU), and calcium folinate injection (CF) which are called FOLFOX regimen for short." | 7.96 | Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report. ( Huang, J; Huang, Z; Jiang, C; Liu, Z; Zheng, W; Zhu, X, 2020) |
| "We wished to evaluate the efficacy and safety of liposomal paclitaxel and docetaxel for induction chemotherapy (IC) for nasopharyngeal carcinoma (NPC)." | 7.88 | Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma. ( Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC, 2018) |
| "Previous Japanese trials of the docetaxel, cisplatin, and 5-fluorouracil regimen for oesophageal cancer have demonstrated that a large proportion of patients also develop grade IV neutropenia." | 7.85 | Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen. ( Miwa, Y; Naito, M; Shimamoto, C; Yamamoto, T, 2017) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 7.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| "Irinotecan (CPT-11)-induced neutropenia is associated with UDP-glucuronosyltransferase (UGT) 1A1*6 and *28 polymorphisms." | 7.83 | UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. ( Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T, 2016) |
| " Furthermore and interestingly, in contrast to the currently used antiangiogenic agents, DA also prevented 5-fluorouracil (5FU) induced neutropenia in HT29 colon cancer bearing mice." | 7.81 | Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. ( Basu, S; Chakroborty, D; Dasgupta, PS; Sarkar, C, 2015) |
| "After intraperitoneal administration of carboplatin, each measured characteristics of bone marrow function was more significantly suppressed and the induced neutropenia was more serious in db/db mice than in the controls." | 7.81 | Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus. ( Aradi, J; Benkő, I; Géresi, K; Megyeri, A; Németh, J; Szabó, B; Szabó, Z, 2015) |
| "To retrospectively investigate the incidence of severe neutropenia and elevation of transaminase during neoadjuvant chemotherapy using epirubicin, cyclophosphamide and fluorouracil in breast cancer patients." | 7.81 | [Neoadjuvant chemotherapy using epirubicin, cyclophosphamide and fluorouracil: neutropenia and elevation of transaminase, and their management]. ( Fan, T; Fan, Z; Li, J; Ouyang, T; Wang, T; Wang, X; Xie, Y, 2015) |
| "The aim of this retrospective study was to investigate the relationship between UGT1A1 polymorphisms and toxicities in Chinese patients with pancreatic or biliary tract cancer receiving irinotecan-containing regimens as the second- or third-line chemotherapy." | 7.81 | Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. ( Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG, 2015) |
| "Fluorouracil, doxorubicin, cyclophosphamide protocol (FAC) is a commonly used regimen for breast cancer due to its proven efficacy, acceptable toxicity, high affordability." | 7.79 | Association of creatinine clearance with neutropenia in breast cancer patients undergoing chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC). ( Amparo, JR; Catedral, MM; Cristal-Luna, GR; Lava, AL; Luna, HG; Montoya, JE; Morelos, AB, 2013) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 7.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "The aim of this study was to investigate the association of two genetic polymorphisms, MDM2 SNP309 and TP53 R72P, with incidence of neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide (FEC)." | 7.78 | MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. ( Kim, SJ; Maruyama, N; Nakayama, T; Noguchi, S; Okishiro, M; Shimazu, K; Shimomura, A; Tamaki, Y; Tsunashima, R, 2012) |
| "The risk of treatment-related death (TRD) and febrile neutropaenia (FN) with adjuvant taxane- based chemotherapy for early breast cancer is unknown in Malaysia despite its widespread usage in recent years." | 7.78 | Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. ( Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM, 2012) |
| "For recurrent or metastatic colorectal cancer, a combination of leucovorin and fluorouracil with oxaliplatin (FOLFOX)is a standard first-line regimen." | 7.77 | [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. ( Hasegawa, J; Hirota, M; Kim, Y; Nezu, R; Nishimura, J; Yoshida, Y, 2011) |
| "A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)." | 7.76 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010) |
| "A combination of oxaliplatin(L-OHP), folinic acid and 5-fluorouracil(5-FU)(mFOLFOX6)has been widely administered to treat advanced or recurrent colorectal cancer." | 7.75 | [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction]. ( Chihara, S; Demizu, M; Iwakawa, S; Kimura, F; Maeda, C; Nakanishi, Y; Oosawa, M; Ueda, H; Yano, K, 2009) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 7.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| "70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil." | 7.74 | [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007) |
| "We evaluated the safety and efficacy of primary systemic chemotherapy (PSC) with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda:XLD) in 10 patients with advanced breast cancer." | 7.73 | [Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer]. ( Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N, 2006) |
| " We evaluated the efficacy of a combined antibiotic regimen of monobactam (aztreonam) and antipseudomonal penicillin (piperacillin) in treating neutropenic fever episodes in gynecologic-oncology patients receiving cisplatin-based chemotherapy." | 7.70 | Aztreonam plus piperacillin--empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplatin-based chemotherapy. ( Altaras, M; Beyth, Y; Chowers, M; Fishman, A; Lang, R, 1998) |
| "Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF)." | 7.70 | Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer. ( Hietanen, P; Joensuu, H; Teerenhovi, L, 1999) |
| "The authors report a patient with colorectal carcinoma who developed neutropenic enterocolitis after treatment with 5-fluorouracil and leucovorin." | 7.69 | Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report. ( Blumgart, L; Kemeny, NE; Kronawitter, U, 1997) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 7.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 6.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "The management of metastatic breast cancer becomes increasingly intricate, requiring new drugs and combinations." | 6.73 | Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer. ( Biville, F; Chauffert, B; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Garnier, J; Isambert, N; Mayer, F; Zanetta, S, 2008) |
| "Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI." | 6.73 | A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008) |
| "This study was originally designed as a phase I/II study, with a dose escalation of docetaxel in combination with epirubicin 50 mg m(-2) and 5-fluorouracil (5-FU) 200 mg m(-2) day(-1)." | 6.71 | Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. ( Bradley, C; Crawford, SM; Dent, J; Dodwell, D; Humphreys, AC; Joffe, JK; Perren, TJ; Rodwell, S, 2004) |
| "Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever." | 6.71 | A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005) |
| "For high-risk patients with breast cancer with more than three positive axillary lymph nodes, this series adopted a modified sequential regimen of ACMF first with Adriamycin (A) as a single agent in 3-weekly administration for three courses, and then a combination of cyclophosphamide, methotrexate, fluorouracil (CMF) every 3 to 4 weeks for six courses given in an outpatient setting concurrent with radiation therapy as an adjuvant treatment." | 6.69 | Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. ( Chen, CM; Cheng, SH; Hsieh, CI; Huang, AT; Liu, MC; Liu, TW; Tsou, MH, 2000) |
| "Thirty-two patients (76%) had no oral mucositis." | 6.68 | Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995) |
| "Therapy for metastatic breast cancer has not improved significantly in recent years." | 6.68 | Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997) |
| "To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings." | 6.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 6.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| "Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin." | 5.69 | Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023) |
| "Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chemotherapy." | 5.56 | ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. ( Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Matsuzawa, H; Mochizuki, N; Nomura, H; Tsuji, D; Yano, T, 2020) |
| "Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival." | 5.51 | Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| " The chemotherapy drugs were administered as follows: 135 mg/m(2) paclitaxel on day 1, 25 mg/m(2)/day cisplatin on days 1-3, followed by continuously infused intravenous fluorouracil for 120 h at a variable dosage from 600 to 800 mg/m(2)/day, depending on prior radiation." | 5.43 | A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. ( Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ, 2016) |
| "Population-based studies of adverse events are scarce." | 5.38 | Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 5.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "Biweekly schedule of XELOX-2 (capecitabine plus oxaliplatin) showed interesting results in first-line therapy of patients with metastatic colorectal cancer (mCRC)." | 5.34 | Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). ( Aieta, M; Bordonaro, R; Cinieri, S; Colucci, G; Cordio, S; Di Maggio, G; Di Maio, M; Febbraro, A; Giuliani, F; Latiano, TP; Maiello, E; Pisconti, S; Rinaldi, A; Rizzi, D; Rossi, A, 2020) |
| "Febrile neutropenia was observed in 4." | 5.31 | Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. ( Jagiello-Gruszfeld, A; Pieńkowski, T, 2001) |
| "Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs." | 5.27 | Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. ( Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018) |
| "Irinotecan (CPT-11) in combination with 5-fluorouracil (5FU) is widely used in the treatment of colorectal cancer." | 5.27 | Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. ( Bosman, F; Brauchli, P; Delorenzi, M; Dietrich, D; Fiocca, R; Klingbiel, D; Piessevaux, H; Roth, AD; Tejpar, S; Yan, P, 2018) |
| "The hepatic artery infusion (HAI) of irinotecan, oxaliplatin and 5-fluorouracil with intravenous cetuximab achieved outstanding efficacy in previously treated patients with initially unresectable liver metastases from colorectal cancer." | 5.24 | Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). ( Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J, 2017) |
| "The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) plus bevacizumab, and folinic acid, 5-FU and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer." | 5.22 | Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). ( Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T, 2016) |
| "The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 5.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
| "Addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer may improve pathological complete response (pCR) rates." | 5.19 | Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. ( Ando, M; Aogi, K; Fujiwara, Y; Hamano, T; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Ohono, S; Shimizu, S; Sukigara, T; Yamamoto, N; Yamauchi, H, 2014) |
| "Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation." | 5.19 | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). ( Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S, 2014) |
| "We conducted a phase II study evaluating safety and efficacy of combination gemcitabine and capecitabine therapy for metastatic breast cancer patients following anthracycline and taxane treatment in Korea." | 5.19 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. ( Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI, 2014) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 5.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| " The incidence of adverse events frequently associated with irinotecan and capecitabine were neutropenia (any grade, 55." | 5.19 | A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). ( Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K, 2014) |
| "Capecitabine and paclitaxel are established effective treatments, alone and combined with other cytotoxic and targeted agents, for metastatic breast cancer (MBC)." | 5.19 | Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. ( Allred, JB; Fitch, TR; Hobday, TJ; Liu, H; Lyss, AP; Northfelt, DW; Perez, EA; Rodacker, MW, 2014) |
| "Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)." | 5.17 | Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013) |
| "Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have non-overlapping toxic effects and synergy pre-clinically." | 5.17 | A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. ( Dzhelali, MV; Findlay, MP; Harvey, VJ; Hinder, VA; Isaacs, RJ; Jameson, MB; Jeffery, GM; McLaren, BR; Pollard, S; Riley, GA; Scott, JN; Sharples, KJ; Simpson, AB, 2013) |
| "This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)." | 5.17 | Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013) |
| "Newly diagnosed K-RAS wild-type colorectal cancer patients with unresectable liver-only metastases were treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) plus cetuximab every 2 weeks for a maximum of 12 cycles." | 5.17 | Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. ( Baek, JY; Hong, YS; Ji, JH; Kang, HJ; Kim, KP; Kim, SY; Kim, TW; Lee, J; Park, SH; Park, YS; Shim, BY; Shin, SJ, 2013) |
| " We prospectively evaluated the impact of UGT1A genotypes and haplotypes on severe toxicity and efficacy in patients treated with fluorouracil, leucovorin, and irinotecan combination chemotherapy (FOLFIRI) for metastatic colorectal cancer (mCRC) from the two prospective multicenter phase II studies in Japan." | 5.17 | UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. ( Ando, H; Fujita, Y; Hamamoto, Y; Hazama, S; Hinoda, Y; Inoue, Y; Kanekiyo, S; Kato, T; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Oka, M; Okayama, N; Okuyama, Y; Sakamoto, J; Takahashi, K; Takemoto, H; Tsunedomi, R, 2013) |
| "The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer." | 5.17 | FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013) |
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 5.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 5.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
| " We aimed at identifying novel genetic markers that would improve prediction of irinotecan toxicity and response in advanced colorectal cancer patients treated with folic acid (leucovorin), fluorouracil (5-FU), and irinotecan (camptosar)-based regimens." | 5.17 | Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. ( Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G, 2013) |
| "To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of oral metronomic vinorelbine with capecitabine in patients with metastatic breast cancer (MBC)." | 5.16 | A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. ( Androulakis, N; Ardavanis, A; Georgoulias, V; Kalbakis, K; Kourakos, P; Malamos, N; Mavroudis, D; Polyzos, A; Saridaki, Z; Vamvakas, L, 2012) |
| "PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine." | 5.16 | A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012) |
| "Sequential doxorubicin/paclitaxel (AT) followed by CMF treatment was shown to be an active neoadjuvant chemotherapy regimen in the first European Cooperative Trial in Operable Breast Cancer (ECTO I trial)." | 5.16 | Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). ( Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M, 2012) |
| "This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy." | 5.16 | Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 5.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 5.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "We performed an analysis of the efficacy of capecitabine monotherapy as maintenance treatment for metastatic breast cancer (MBC) after response to capecitabine-based chemotherapy [capecitabine plus docetaxel (XT) or vinorelbine (XN)] as a first-line or a second-line treatment." | 5.16 | Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. ( Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S, 2012) |
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 5.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 5.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
| "Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer." | 5.15 | Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. ( Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M, 2011) |
| "Infusional 5-fluorouracil and leucovorin with oxaliplatin is one of the standard regimens for patients with pretreated metastatic colorectal cancer, as well as for first-line chemotherapy." | 5.15 | A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer. ( Esaki, T; Fujii, H; Inaba, Y; Kato, K; Kusaba, H; Mizuno, T; Mizunuma, N; Muro, K; Shimada, Y; Shirao, K; Tsuji, Y; Yoshioka, A, 2011) |
| " However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the non-time-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963)." | 5.15 | Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Smaaland, R; Tampellini, M; Tumolo, S, 2011) |
| "The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients." | 5.15 | Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. ( Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer." | 5.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011) |
| "Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)." | 5.14 | Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 5.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 5.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "The addition of capecitabine to docetaxel significantly improves overall survival in anthracycline-pretreated metastatic breast cancer." | 5.14 | Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. ( Gennatas, K; Gennatas, S; Michalaki, V, 2009) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 5.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "In this multicentre, open-label, phase III, randomised controlled trial, 4162 women (aged >18 years) with node-positive or high-risk node-negative operable early breast cancer were randomly assigned by computer-generated permuted block randomisation to receive FEC (fluorouracil 600 mg/m(2), epirubicin 60 mg/m(2), cyclophosphamide 600 mg/m(2) at 3-weekly intervals) for four cycles followed by docetaxel (100 mg/m(2) at 3-weekly intervals) for four cycles (n=2073) or control (n=2089)." | 5.14 | Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. ( Barrett-Lee, P; Bartlett, JM; Bliss, JM; Bloomfield, D; Cameron, D; Canney, P; Coleman, R; Dowsett, M; Earl, H; Ellis, I; Ellis, P; Hall, E; Hopwood, P; Johnson, L; Johnston, S; O'Reilly, S; Peckitt, C; Poole, C; Smith, I; Twelves, C; Verrill, M; Wardley, A; Yarnold, J, 2009) |
| "Capecitabine is effective against metastatic breast cancer (MBC)." | 5.14 | Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. ( Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G, 2010) |
| "Combination chemotherapy with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) has become a standard regimen for colorectal cancer." | 5.14 | Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. ( Ikeguchi, M; Kanazawa, A; Katano, K; Kidani, A; Makino, M; Ozaki, N; Sugimoto, S; Takeda, H; Tanaka, T; Yoshimura, H, 2009) |
| "The purpose of this study was to compare docetaxel plus epirubicin versus docetaxel plus capecitabine combinations as front-line treatment in women with advanced breast cancer (ABC)." | 5.14 | Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. ( Ardavanis, A; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Ziras, N, 2010) |
| "This phase II study in breast cancer patients assessed the utility of a single 6 mg subcutaneous dose of pegfilgrastim administered on day 9 of an intravenous (IV) "split" CMF (cyclophosphamide 600 mg/m(2), methotrexate 40 mg/m(2) and 5-fluorouracil 600 mg/m(2)) chemotherapy regimen administered on days 1 and 8 and repeated every 28 days for 6 cycles." | 5.14 | Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. ( Bacon, P; Casas, A; Castellanos, J; Duque, A; Falcone, A; Gridelli, C; Lawrinson, S; Mansutti, M; Mattioli, R; Skacel, T, 2009) |
| "Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma." | 5.14 | A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. ( Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY, 2010) |
| "Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal cancer (CRC) but increases neutropenia frequency." | 5.14 | A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. ( Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F, 2010) |
| "To compare the efficacy and toxicity of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin (5-Fu/LV) plus oxaliplatin (FOLFOX4) regimens as adjuvant chemotherapy for stage III colorectal cancer." | 5.14 | [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. ( Fang, F; Li, DC; Lu, GC, 2010) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 5.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan." | 5.13 | UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008) |
| "Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)." | 5.12 | Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006) |
| "The aim of the study was to analyse the toxicity and health related quality of life (HRQoL) of breast cancer patients treated with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) and TAC (docetaxel, doxorubicin, cyclophosphamide) with and without primary prophylactic G-CSF (PPG)." | 5.12 | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony sti ( Adrover, E; Antón, A; Arcusa, A; Calvo, L; del Prado, PM; Fernandez-Chacón, C; Grosse, R; Iglesias, L; Isla, D; Lluch, A; López-Vega, JM; Martín, M; Mel, JR; Muñoz, M; Ramos, M; Rodríguez-Lescure, A; Roset, M; Ruiz, A; Seguí, MA; Zaluski, J, 2006) |
| "This randomized phase 2 study explored the feasibility of delivering four to six cycles of the dose-intensified regimen FEC-100 (5-fluorouracil, epirubicin, and cyclophosphamide) to elderly patients with stage II-III breast cancer, using pegfilgrastim for neutrophil support." | 5.12 | Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. ( Bacon, P; Brugger, W; Clemens, M; Constenla, M; Easton, V; Fargeot, P; Mahlberg, R; Romieu, G; Schütte, M; Skacel, T, 2007) |
| "Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second-line treatment for advanced colorectal cancer (CRC)." | 5.12 | First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. ( Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007) |
| "To evaluate the maximum tolerated dose and dose-limiting toxicity (DLT) of 10-hydroxy-camptothecin (10-HCPT) in HFL regimen for the treatment of advanced colorectal cancer (CRC)." | 5.12 | [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. ( Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG, 2007) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 5.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "To evaluate tolerance and toxicity of high-dose epirubicin regimen CEF-100 as adjuvant therapy for breast cancer." | 5.12 | [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer]. ( Hao, XM; Hui, R; Zhang, J; Zhang, M, 2007) |
| "This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 5.11 | Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004) |
| "We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer." | 5.11 | Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004) |
| "Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)." | 5.11 | Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004) |
| "This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer." | 5.11 | A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. ( Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J, 2004) |
| "This study investigated the efficacy and tolerability of FEC 100 (epirubicin 100 mg/m2 with 5-fluorouracil 500 mg/m2 and cyclophosphamide 500 mg/m2) every 21 days as neoadjuvant chemotherapy in women with stage I-III primary operable breast cancer." | 5.11 | Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin. ( Abrial, CJ; Amat, S; Chollet, PJ; Curé, HD; Feillel, VA; Ferrière, JP; Kwiatkowski, FG; Lebouëdec, G; Mouret-Reynier, MA; Penault-Llorca, FM, 2004) |
| "A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer." | 5.11 | Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004) |
| "A retrospective source review identifying predictive factors and assessing safety and efficacy in pretreated metastatic breast cancer (MBC) patients treated with capecitabine in a French compassionate-use program." | 5.11 | Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. ( Barats, JC; Baticle, JL; Brewer, Y; Chollet, P; Fumoleau, P; Gil-Delgado, M; Goudier, MJ; Martin, D; Namer, M; Pierga, JY; Sutherland, W; Turpin, FL; Zelek, L, 2004) |
| "To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLT) of the combination of capecitabine and vinorelbine in patients with metastatic breast cancer who relapse after adjuvant and/or first-line treatment." | 5.11 | Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. ( Borquez, D; Harstrick, A; Kaufmann, M; Loibl, S; Oberhoff, C; Schleucher, R; Seeber, S; Vanhoefer, U; von Minckwitz, G; Welt, A, 2005) |
| "Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)." | 5.11 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005) |
| "Cumulative gastrointestinal toxicities and neutropenia were the DLTs of docetaxel, capecitabine, and carboplatin." | 5.11 | Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ( Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 5.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "Recently, high-dose FEC (fluorouracil, epirubicin, and cyclophosphamide) has been increasingly used in adjuvant chemotherapy for breast cancer in Japan." | 5.11 | [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients]. ( Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 5.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "We have investigated the efficacy, safety and quality of life profiles of three therapeutic combinations [irinotecan + leucovorin (LV)/5-fluorouracil (5-FU), oxaliplatin + LV/5-FU and irinotecan +oxaliplatin] in patients with metastatic colorectal cancer after failure of a 5-FU-based regimen, or whose disease had progressed within 6 months of the end of treatment." | 5.10 | Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. ( Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 5.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy." | 5.10 | Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. ( Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H, 2002) |
| "The purpose of this study was to evaluate the efficacy and toxicity of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes." | 5.10 | Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. ( Bountouroglou, N; Farmakis, D; Kosmas, C; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M, 2003) |
| "Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer." | 5.10 | A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. ( Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J, 2003) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 5.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| " irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer." | 5.10 | Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). ( Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 5.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "The aim of this study, using a Fleming single-stage design, was to explore the efficacy and safety of Taxotere 100 x mg x m(-2) docetaxel and FEC 75 cyclophosphamide 500 mg x m(-2), fluorouracil 500 x mg x m(-2) and epirubicin 75 mg x m(-2), in alternating and sequential schedules for the first-line treatment of metastatic breast cancer." | 5.10 | Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial. ( Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N, 2002) |
| "Paclitaxel has significant antitumor activity in patients with metastaticbreast cancer who have been previously treated with or exposed to anthracycline-containing chemotherapy." | 5.10 | Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. ( Ames, F; Berry, D; Booser, DJ; Buzdar, AU; Frye, DK; Holmes, FA; Hortobagyi, GN; Hoy, E; Hunt, K; Ibrahim, NK; Kau, SW; Manuel, N; McNeese, MD; Rahman, Z; Rivera, E; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Thomas, E; Valero, V; Walters, R, 2002) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)." | 5.10 | Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002) |
| " This phase I study evaluated the addition of capecitabine to epirubicin/docetaxel combination therapy as first-line treatment for advanced breast cancer." | 5.10 | Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. ( Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M, 2002) |
| "To determine the efficacy and safety profile, including the risk for cardiac toxicity, of liposome-encapsulated doxorubicin (TLC D-99), fluorouracil (5-FU), and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer (MBC)." | 5.09 | Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. ( Azarnia, N; Booser, D; Buzdar, AU; Ewer, M; Fonseca, GA; Hortobagyi, GN; Lee, LW; Mackay, B; Podoloff, D; Theriault, RL; Valero, V; Walters, RS; Willey, J, 1999) |
| " cerevisiae fusion protein) on the incidence, duration, and complications of neutropenia and thrombocytopenia after moderate-dose fluorouracil 600 mg/m(2), doxorubicin 60 mg/m(2), and cyclophosphamide 750 mg/m(2) (FAC) chemotherapy in patients with stage II and III breast cancer." | 5.09 | Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. ( Agura, E; Dimitrov, N; Duncan, L; Garrison, L; Hyman, W; Jones, SE; Khandelwal, P; Kirby, R; Lange, M; McIntyre, K; Mennel, R; Orr, D; Regan, D; Roque, T; Schuster, M, 1999) |
| "To compare prospectively the antitumor activity of single-agent paclitaxel to the three-drug combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer." | 5.09 | Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. ( Ames, F; Asmar, L; Booser, DJ; Buzdar, AU; Frye, D; Hortobagyi, GN; Hunt, K; Ibrahim, N; Kau, SW; Manuel, N; McNeese, M; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Valero, V, 1999) |
| " Other toxicities included hand-foot syndrome, diarrhea, hyperbilirubinemia, skin rash, myalgia, and arthralgia." | 5.09 | Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. ( Burger, HU; Burris, HA; Drengler, RL; Eckhardt, SG; Griffin, T; Kraynak, M; Moczygemba, J; Reigner, B; Rodrigues, G; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR, 1999) |
| "Patients with previously untreated metastatic breast cancer were randomized to receive either paclitaxel 200 mg/m(2) intravenously (IV) over 3 hours for eight cycles (24 weeks) or standard cyclophosphamide 100 mg/m(2)/d orally on days 1 to 14, methotrexate 40 mg/m(2) IV on days 1 and 8, fluorouracil 600 mg/m(2) IV on days 1 and 8, and prednisone 40 mg/m(2)/d orally on days 1 to 14 (CMFP) for six cycles (24 weeks) with epirubicin recommended as second-line therapy." | 5.09 | Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. ( Ackland, S; Bishop, JF; Canetta, R; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, IN; Smith, J; Stephenson, J; Tattersall, MH; Toner, GC; Walpole, E, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 5.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| " At CDDP 50 mg/m2, raltitrexed 3 mg/m2, 5-FU 900 mg/m2, four out of six patients showed DLT, which was in all cases grade 4 neutropenia." | 5.09 | Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG). ( Avallone, A; Budillon, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Di Gennaro, E; Ionna, F; Manzione, L; Mozzillo, N; Rivellini, F, 2000) |
| "In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen." | 5.09 | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 5.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 5.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "We performed a trial using the combination of epirubicin 50 mg/m2/day 1, carboplatinum AUC 5/day 1 and continuous 5-fluorouracil (5-FU) 200 mg/m2/day (every 4 weeks for 6 months) to confirm the efficacy and low toxicity profile of this regimen in breast cancer." | 5.09 | Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen. ( Anchisi, S; Anguenot, JL; Bonnefoi, H; Hügli, A; Mermillod, B; Sappino, AP; Schafer, P, 2000) |
| "To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 5.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
| "Gemcitabine alone or 5-fluorouracil (5-FU) according to several schedules are used for palliation of metastatic and locally advanced (LA) pancreatic adenocarcinoma." | 5.09 | Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). ( André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F, 2001) |
| "Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding palliative chemotherapy with fluoropyrimidines leucovorin +/- irinotecan, participated in this study." | 5.09 | Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H, 2001) |
| "38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study." | 5.09 | Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 5.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| " 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas." | 5.09 | A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 5.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "To compare the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) versus its inert vehicle in patients with unilateral nonmetastatic inflammatory breast cancer treated with fluorouracil, epirubicin, and cyclophosphamide high-dose (FEC-HD) neoadjuvant chemotherapy." | 5.08 | Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. ( Chevallier, B; Chollet, P; Fargeot, P; Fizames, C; Fumoleau, P; Genot, JY; Kerbrat, P; Merrouche, Y; Olivier, JP; Roche, H, 1995) |
| "Thirty-two patients undergoing adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or doxorubicin-CMF for stages I to II breast cancer were included after having chemotherapy delays due to neutropenia (absolute neutrophil count [ANC] < 1." | 5.08 | Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. ( Albanell, J; Baselga, J; Bellmunt, J; Bermejo, B; Carulla, J; Eres, N; Gallardo, E; Ribas, A; Solé-Calvo, LA; Vera, R; Vidal, R, 1996) |
| "Results of phase II studies have demonstrated high efficacy and low toxicity for a weekly schedule of high-dose 5-fluorouracil/folinic acid (5-FU/FA) when given to intensively pretreated patients with metastatic breast cancer." | 5.08 | Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer. ( Harstrick, A; Klaassen, U; Seeber, S; Wilke, H, 1996) |
| "We conducted a prospective randomized trial to evaluate the ability of the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein, PIXY321, to ameliorate cumulative thrombocytopenia after multiple cycles of 5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide (FLAC) chemotherapy compared with GM-CSF in patients with advanced breast cancer." | 5.08 | Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients ( Chang, V; Cowan, KH; Danforth, D; Giusti, R; Goldspiel, B; Gossard, M; Jacobson, J; Keegan, P; Noone, M; O'Shaughnessy, JA; Riseberg, D; Tolcher, A; Venzon, D; Zujewski, J, 1996) |
| "To determine the effects of sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) on the incidence, duration, and complications of myelosuppression after moderate-dose fluorouracil, doxorubicin, cyclophosphamide (FAC) adjuvant chemotherapy in patients with node-positive breast cancer." | 5.08 | Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. ( Denham, CA; Duncan, LA; George, TK; Good, RH; Hoyes, FA; Jones, SE; Kirby, RL; Mennel, RG; Rubin, AS; Schottstaedt, MW; Snyder, DA; Watkins, DL, 1996) |
| "The Breast Cancer Site Group of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG) undertook two parallel phase I studies to determine the maximum tolerated dose (MTD) and recommended phase II dose of vinorelbine in combination with doxorubicin and fluorouracil (with or without folinic acid) in metastatic breast cancer." | 5.08 | Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. ( Fine, S; Gelmon, K; Goss, PE; James, K; Myles, J; Ottaway, J; Paul, K; Pritchard, KI; Rodgers, A; Rudinskas, L, 1997) |
| "5 micrograms/kg protein dosage per day from day-6-day-4 before each course of adjuvant chemotherapy (cyclophosphamide, epirubicin, 5-fluorouracil/cyclophosphamide, methotrexate, 5-fluorouracil alternate) in patients with node-positive breast cancer." | 5.07 | Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. ( Aglietta, M; Carnino, F; Gavosto, F; Monzeglio, C; Pasquino, P; Stern, AC, 1993) |
| "Carboplatin, a platinum analog with single-agent activity in previously untreated breast cancer, is characterized by comparatively less renal toxicity and emesis than cisplatin." | 5.07 | Carboplatin in combination as first-line therapy in advanced breast cancer. ( Bonadonna, G; Brambilla, C; Ferrari, L; Passoni, P, 1993) |
| "Seventeen patients with either newly diagnosed breast cancer with more than four involved axillary nodes (five patients) or metastatic breast cancer (12 patients) were treated with cyclophosphamide 1 g/m2, doxorubicin 50 mg/m2, and fluorouracil 500 mg/m2 (CAF) intravenously (IV) once every 3 weeks." | 5.07 | Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. ( Gelmon, KA; O'Reilly, SE; Onetto, N; Page, RA; Parente, J; Plenderleith, IH; Rubinger, M, 1993) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 5.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer." | 5.07 | Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992) |
| "A multicentre pilot study has been conducted to determine an intensive regimen of cyclophosphamide, epirubicin, and fluorouracil which was tolerable and acceptable to patients with node positive breast cancer." | 5.07 | A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. ( Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Levine, MN; Perrault, D; Pritchard, K; Skillings, J; Warr, D, 1992) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 4.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "Variable febrile neutropenia (FN) rates reported with adjuvant TC (taxotere®, cyclophosphamide) and FEC-D (5-flurouracil, epirubicin, cyclophosphamide, docetaxel) outside of clinical trials have precluded definitive recommendations for primary G-CSF (granulocyte colony-stimulating factor) prophylaxis in most jurisdictions." | 4.88 | Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. ( Rayson, D; Thompson, K; Younis, T, 2012) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy." | 4.87 | Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. ( Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM, 2011) |
| "We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer." | 4.86 | A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010) |
| "This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use." | 4.85 | The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. ( Boehnke Michaud, L, 2009) |
| "Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer." | 4.84 | Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. ( Arkenau, HT; Arnold, D; Cassidy, J; Diaz-Rubio, E; Douillard, JY; Grothey, A; Hinke, A; Hochster, H; Martoni, A; Porschen, R; Schmiegel, W; Schmoll, HJ, 2008) |
| "The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens." | 4.81 | Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002) |
| "Using WES after a doublet chemotherapy regimen comprising irinotecan and 5-fluorouracil (n = 15), seven single nucleotide polymorphisms (SNPs) were identified as candidate biomarkers for irinotecan-associated toxicity of neutropenia." | 4.31 | Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. ( Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S, 2023) |
| "We found that ABCA2 polymorphism was significantly associated with systemic exposure to capecitabine and capecitabine-induced neutropenia in Japanese patients with CRC." | 4.31 | A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer. ( Fujita, KI; Ishida, H; Kubota, Y; Matsumoto, N; Murase, R; Shibata, Y; Shimada, K, 2023) |
| "Docetaxel, cisplatin, and 5-fluorouracil (DCF) have high response rates, but severe neutropenia is frequently observed." | 4.12 | Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer. ( Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Nomura, H; Tsuji, D; Ueno, S; Yano, T, 2022) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 4.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| " We investigated whether nutritional and inflammatory marker ratios before starting FEC therapy (5-fluorouracil, epirubicin, and cyclophosphamide) predict grade 4 neutropenia as a serious adverse effect." | 4.12 | Search for nutritional and inflammatory marker ratios to predict neutropenia in FEC therapy for breast cancer: A retrospective observational study. ( Matsubara, H; Nakamura, T, 2022) |
| "Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival (OS) of 45%, over 23% with surgery alone." | 4.02 | Results of the observational prospective RealFLOT study. ( Antonuzzo, L; Brugia, M; De Vita, F; Di Donato, S; Fancelli, S; Formica, V; Fornaro, L; Giommoni, E; Giovanardi, F; Iachetta, F; Lavacchi, D; Pecora, I; Pillozzi, S; Pompella, L; Pozzo, C; Prisciandaro, M; Puzzoni, M; Romagnani, A; Satolli, MA; Sisani, M; Spallanzani, A; Stragliotto, S; Strippoli, A; Tirino, G, 2021) |
| "The inclusion criteria were as follows: (1) oesophageal squamous cell carcinoma, (2) a schedule to receive three courses of induction chemotherapy (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-fluorouracil 750 mg/m2 days 1-5, every 3 weeks), (3) stage IB-III, (4) 20-75 years old, (5) 0-1 performance status, (6) preserved organ functions and (7) written informed consent." | 4.02 | A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. ( Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A, 2021) |
| "The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma." | 4.02 | Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis. ( Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D, 2021) |
| "This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice." | 3.96 | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. ( Chin, K; Kitagawa, Y; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2020) |
| " He suffered from rash and neutropenia after multiple chemotherapy sessions including oxaliplatin, 5-fluorouracil (5- FU), and calcium folinate injection (CF) which are called FOLFOX regimen for short." | 3.96 | Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report. ( Huang, J; Huang, Z; Jiang, C; Liu, Z; Zheng, W; Zhu, X, 2020) |
| "We wished to evaluate the efficacy and safety of liposomal paclitaxel and docetaxel for induction chemotherapy (IC) for nasopharyngeal carcinoma (NPC)." | 3.88 | Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma. ( Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC, 2018) |
| "Previous Japanese trials of the docetaxel, cisplatin, and 5-fluorouracil regimen for oesophageal cancer have demonstrated that a large proportion of patients also develop grade IV neutropenia." | 3.85 | Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen. ( Miwa, Y; Naito, M; Shimamoto, C; Yamamoto, T, 2017) |
| "Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C." | 3.85 | Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. ( Aggarwal, S; Bazan, JG; Chang, DT; Golden, DW; Kopec, M; Lee, AY; Liauw, SL; Pelizzari, CA, 2017) |
| "Febrile neutropenia(FN)is one of the serious treatment-related toxicities after FEC100(5-fluorouracil 500mg/m2, epiru- bicin 100mg/m2, cyclophosphamide 500 mg/m2)chemotherapy for breast cancer." | 3.85 | [Influence of Next-Day Administration of Pegfilgrastim after FEC100 Chemotherapy in Japanese with Breast Cancer on Neutrophil Count]. ( Fujiwara, D; Kimura, K; Mashimo, K; Nishida, S; Noda, A; Sakaguchi, K; Takeda, T; Taki, K; Tsubaki, M; Yoshibayashi, H, 2017) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 3.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| "Irinotecan (CPT-11)-induced neutropenia is associated with UDP-glucuronosyltransferase (UGT) 1A1*6 and *28 polymorphisms." | 3.83 | UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. ( Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T, 2016) |
| "The cohort included 45 patients with nonmetastatic anal cancer who underwent FDG-PET imaging prior to definitive chemoradiation with mitomycin-C and 5-fluorouracil." | 3.83 | Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation. ( Allen, JN; Blaszkowsky, LS; Drapek, LC; Hong, TS; Jee, KW; Lee, LK; Murphy, JE; Niemierko, A; Rose, BS; Wang, Y; Wo, JY, 2016) |
| " Furthermore and interestingly, in contrast to the currently used antiangiogenic agents, DA also prevented 5-fluorouracil (5FU) induced neutropenia in HT29 colon cancer bearing mice." | 3.81 | Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. ( Basu, S; Chakroborty, D; Dasgupta, PS; Sarkar, C, 2015) |
| "After intraperitoneal administration of carboplatin, each measured characteristics of bone marrow function was more significantly suppressed and the induced neutropenia was more serious in db/db mice than in the controls." | 3.81 | Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus. ( Aradi, J; Benkő, I; Géresi, K; Megyeri, A; Németh, J; Szabó, B; Szabó, Z, 2015) |
| "To retrospectively investigate the incidence of severe neutropenia and elevation of transaminase during neoadjuvant chemotherapy using epirubicin, cyclophosphamide and fluorouracil in breast cancer patients." | 3.81 | [Neoadjuvant chemotherapy using epirubicin, cyclophosphamide and fluorouracil: neutropenia and elevation of transaminase, and their management]. ( Fan, T; Fan, Z; Li, J; Ouyang, T; Wang, T; Wang, X; Xie, Y, 2015) |
| "The aim of this retrospective study was to investigate the relationship between UGT1A1 polymorphisms and toxicities in Chinese patients with pancreatic or biliary tract cancer receiving irinotecan-containing regimens as the second- or third-line chemotherapy." | 3.81 | Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. ( Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG, 2015) |
| "The time for the neutrophil count to recover after subcutaneous injection of filgrastim BS1 or lenograstim was studied in patients suffering from neutropenia following preoperative combined chemotherapy using docetaxel, nedaplatin, or cisplatin (in divided doses for 5 days)and 5-fluorouracil for oral cancer." | 3.81 | [Clinical Investigation of the Effects of Filgrastim BS1 on Neutropenia Following Oral Cancer Chemotherapy (TPF Therapy)]. ( Iwasaki, K; Mitomo, K; Nakayama, S; Tamate, S; Uchiyama, K; Yamada, M, 2015) |
| "Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC)." | 3.80 | A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. ( Chang, ML; Hsu, CL; Hung, CF; Liang, KH; Lin, CC; Yeh, CT, 2014) |
| "Endogenous G-CSF and ANC were monitored in forty-nine breast cancer patients treated with sequential adjuvant 5-fluorouracil-epirubicin-cyclophosphamide and docetaxel." | 3.80 | Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling. ( Friberg, LE; Karlsson, MO; Lindman, H; Quartino, AL, 2014) |
| "Adjuvant folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy for resected high-risk colon cancer is associated with a low risk of febrile neutropenia (FN)." | 3.80 | Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. ( Gill, S; Javaheri, KR; Smoragiewicz, M; Yin, Y, 2014) |
| "Fluorouracil, doxorubicin, cyclophosphamide protocol (FAC) is a commonly used regimen for breast cancer due to its proven efficacy, acceptable toxicity, high affordability." | 3.79 | Association of creatinine clearance with neutropenia in breast cancer patients undergoing chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC). ( Amparo, JR; Catedral, MM; Cristal-Luna, GR; Lava, AL; Luna, HG; Montoya, JE; Morelos, AB, 2013) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 3.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits." | 3.79 | Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. ( Lee, HJ; Lee, SH; Oh, MJ, 2013) |
| "The aim of this study was to investigate the association of two genetic polymorphisms, MDM2 SNP309 and TP53 R72P, with incidence of neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide (FEC)." | 3.78 | MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. ( Kim, SJ; Maruyama, N; Nakayama, T; Noguchi, S; Okishiro, M; Shimazu, K; Shimomura, A; Tamaki, Y; Tsunashima, R, 2012) |
| "Studies treating adenocarcinoma of the pancreas with gemcitabine alone or in combination with a doublet have demonstrated modest improvements in survival." | 3.78 | A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. ( Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L, 2012) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, it was suggested that leukopenia, neutropenia, and thrombocytopenia were more frequently accompanied by the use of 5-FU than capecitabine, whereas diarrhea, nausea, vomiting, and hand-foot syndrome were more frequently associated with capecitabine." | 3.78 | Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. ( Brown, JB; Kadoyama, K; Miki, I; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| "The risk of treatment-related death (TRD) and febrile neutropaenia (FN) with adjuvant taxane- based chemotherapy for early breast cancer is unknown in Malaysia despite its widespread usage in recent years." | 3.78 | Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. ( Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM, 2012) |
| "We examined the feasibility of regimen selection for first-line irinotecan, 5-fluorouracil and leucovorin or oxaliplatin, 5-fluorouracil and leucovorin in Japanese patients with advanced colorectal cancer based on UDP-glucuronosyltransferase 1A1 genotype as well as physical status of patients related to diarrhea." | 3.77 | Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Ando, Y; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2011) |
| "When applying the topoisomerase inhibitor irinotecan (CPT) with the infusional fluorouracil/levofolinate (FOLFIRI) ± bevacizumab chemotherapy regimen in cases of advanced colorectal carcinoma, the international standard dose for CPT is 180 mg/m(2)." | 3.77 | Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. ( Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y, 2011) |
| "Palliative chemoradiotherapy using 5-fluorouracil plus cisplatin combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival." | 3.77 | Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. ( Doi, T; Fuse, N; Ikeda, E; Kaneko, K; Kojima, T; Minashi, K; Nihei, K; Ohtsu, A; Onozawa, M; Tahara, M; Yano, T; Yoshino, T, 2011) |
| "For recurrent or metastatic colorectal cancer, a combination of leucovorin and fluorouracil with oxaliplatin (FOLFOX)is a standard first-line regimen." | 3.77 | [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. ( Hasegawa, J; Hirota, M; Kim, Y; Nezu, R; Nishimura, J; Yoshida, Y, 2011) |
| "A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)." | 3.76 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010) |
| "Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom." | 3.76 | Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. ( Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW, 2010) |
| "We modelled a theoretical population treated with combined 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for metastatic colorectal cancer." | 3.76 | Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. ( Blasco, H; Bourgoin, H; Le Guellec, C; Le Louarn, A; Lecomte, T; Pichereau, S, 2010) |
| "We conducted a retrospective analysis of 741 patients who had received adjuvant 5-fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy for breast cancer." | 3.75 | Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. ( Freeman, S; Jenkins, P, 2009) |
| "A combination of oxaliplatin(L-OHP), folinic acid and 5-fluorouracil(5-FU)(mFOLFOX6)has been widely administered to treat advanced or recurrent colorectal cancer." | 3.75 | [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction]. ( Chihara, S; Demizu, M; Iwakawa, S; Kimura, F; Maeda, C; Nakanishi, Y; Oosawa, M; Ueda, H; Yano, K, 2009) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 3.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| "To estimate the cost effectiveness of TAC (docetaxel, doxorubicin, and cyclophosphamide) compared with FAC (fluorouracil, doxorubicin, and cyclophosphamide) when administered as adjuvant therapy to women with node-positive early breast cancer in the United Kingdom (UK), both with and without primary prophylaxis with granulocyte colony-stimulating factor (G-CSF)." | 3.74 | Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. ( Bagust, A; Cameron, DA; Tate, HC; Wolowacz, SE, 2008) |
| "Treatment-related safety data from three phase III clinical studies were analyzed by multivariate analysis: two comparing capecitabine with bolus FU/LV in metastatic colorectal cancer (MCRC) and one comparing capecitabine plus oxaliplatin (XELOX) with bolus FU/LV as adjuvant treatment for colon cancer." | 3.74 | Potential regional differences for the tolerability profiles of fluoropyrimidines. ( Allegra, C; Bertino, JR; Cassidy, J; Clarke, SJ; Cunningham, D; Douillard, JY; Gilberg, F; Gustavsson, BG; Haller, DG; Hoff, PM; Milano, G; O'Connell, M; Rothenberg, ML; Rustum, Y; Saltz, LB; Schmoll, HJ; Sirzén, F; Tabernero, J; Twelves, C; Van Cutsem, E, 2008) |
| "70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil." | 3.74 | [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007) |
| "We evaluated the safety and efficacy of primary systemic chemotherapy (PSC) with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda:XLD) in 10 patients with advanced breast cancer." | 3.73 | [Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer]. ( Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N, 2006) |
| " We evaluated the efficacy of a combined antibiotic regimen of monobactam (aztreonam) and antipseudomonal penicillin (piperacillin) in treating neutropenic fever episodes in gynecologic-oncology patients receiving cisplatin-based chemotherapy." | 3.70 | Aztreonam plus piperacillin--empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplatin-based chemotherapy. ( Altaras, M; Beyth, Y; Chowers, M; Fishman, A; Lang, R, 1998) |
| "Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF)." | 3.70 | Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer. ( Hietanen, P; Joensuu, H; Teerenhovi, L, 1999) |
| "The aim of this study was to demonstrate the value of the level of platinum in lymphocytes, plasma and saliva, in order to predict neutropenia during the same cycle after cisplatin chemotherapy." | 3.70 | [Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)]. ( Brès, J; Constans, B; Cupissol, D; Gau, F; Gory-Delabaere, G; Nouguier-Soulé, J, 1999) |
| "The authors report a patient with colorectal carcinoma who developed neutropenic enterocolitis after treatment with 5-fluorouracil and leucovorin." | 3.69 | Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report. ( Blumgart, L; Kemeny, NE; Kronawitter, U, 1997) |
| "Multiple studies have shown that leucovorin-fluorouracil regimens are modestly superior to fluorouracil alone in the treatment of advanced colorectal cancer." | 3.69 | Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine. ( DeLap, RJ; Marshall, JL; Richmond, E, 1996) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 3.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| " Administration of 5-fluorouracil (5-FU) to mice causes prolonged neutropenia." | 3.67 | Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy. ( Abboud, M; Gasparetto, C; Gillio, A; Laver, J; Moore, MA; O'Reilly, RJ; Smith, C, 1989) |
| "44 patients with metastatic colorectal cancer were enrolled in this study." | 3.11 | Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study). ( Fukazawa, A; Hasegawa, S; Hirata, K; Koda, K; Kosugi, C; Kuramochi, H; Matsuda, A; Matsuoka, H; Ohta, R; Otsuka, T; Sakamoto, K; Sonoda, H; Takahashi, M; Watanabe, T; Yamada, T; Yoshida, H; Yoshida, Y, 2022) |
| "The incidence of chemotherapy-related adverse events in colorectal cancer patients with renal insufficiency has been compared to patients with normal renal function in only a few studies." | 3.01 | Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials. ( Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Tanaka, K; Yamagishi, H; Yoshikawa, T, 2023) |
| "This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic adenocarcinoma." | 2.94 | Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. ( Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C, 2020) |
| " However, the current guidelines fail to recommend an optimal dosing schedule of pegfilgrastim along with the DCF regimen to prevent FN." | 2.90 | Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. ( Dohi, O; Fujiwara, H; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Okayama, T; Shiozaki, A; Takagi, T; Teramukai, S; Uchiyama, K; Yasuda, T; Yoshida, N, 2019) |
| " Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284)." | 2.90 | Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). ( Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S, 2019) |
| "vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly." | 2.84 | Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. ( Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L, 2017) |
| "For these patients with metastatic esophageal cancer, chemotherapy is generally indicated." | 2.84 | Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. ( Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2017) |
| " Toxicities are described per treatment arm according to the Common Toxicity Criteria for Adverse Events version 4." | 2.82 | Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. ( Dezentjé, VO; Honkoop, AH; Kemper, I; Linn, SC; Mandjes, IA; Oving, IM; Smorenburg, CH; Sonke, GS; Stouthard, JM; van Ramshorst, MS; van Werkhoven, E, 2016) |
| "Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy." | 2.80 | Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer. ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2015) |
| "Patient survival in esophageal cancer (EC) remains poor." | 2.80 | A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. ( Hayashi, T; Hirakawa, M; Hori, M; Kato, J; Kobune, M; Miyanishi, K; Nakata, K; Ohnuma, H; Okagawa, Y; Osuga, T; Sagawa, T; Sakata, K; Sato, T; Sato, Y; Someya, M; Takayama, T; Takimoto, R, 2015) |
| "Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI (bolus irinotecan, folinic acid, and fluorouracil followed by 46-hour fluorouracil infusion) followed by bevacizumab (5 mg/kg) in Cycle 1." | 2.79 | Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ( Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y, 2014) |
| "Paclitaxel was administered intravenously on day 1 at a dose of 120 mg/m(2), and oral S-1 was administered twice a day from days 1 to 7, followed by a 7-day drug-free interval." | 2.79 | Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. ( Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y, 2014) |
| "In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88." | 2.79 | DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). ( Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014) |
| " Adverse events were evaluated in accordance with the Common Terminology Criteria for Adverse Events version 3." | 2.78 | The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer. ( Fukuma, E; Higaki, K; Masuda, N; Mizutani, M; Ohno, S; Osaki, A; Saeki, T; Sagara, Y; Sato, K; Suzuki, M; Takano, T; Tokuda, Y, 2013) |
| "To evaluate the efficacy and safety of trastuzumab in combination with chemotherapy versus chemotherapy alone in the first-line treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer." | 2.78 | [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]. ( Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ, 2013) |
| "5-fluorouracil continuous infusion for gastric cancer with peritoneal metastasis." | 2.78 | Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). ( Boku, N; Denda, T; Doi, T; Fukuda, H; Goto, M; Hamamoto, Y; Nasu, J; Ohtsu, A; Shirao, K; Takashima, A; Yamada, Y; Yamaguchi, K, 2013) |
| "The primary objective of this Phase I study was to assess the safety and tolerability of the vascular endothelial growth factor signalling inhibitor cediranib in combination with cisplatin plus an oral fluoropyrimidine, in Japanese patients with previously untreated advanced gastric cancer." | 2.77 | Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. ( Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012) |
| "To evaluate the activity and tolerance of gemcitabine in combination with docetaxel and capecitabine in previously untreated patients with advanced pancreatic cancer." | 2.77 | Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. ( Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N, 2012) |
| " The aim of the study was to compare efficacy and safety, including response rate (RR), progression-free survival (PFS), overall survival, and grade ≥3 adverse events, between patients aged ≥65 years and patients aged <65 years." | 2.77 | Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. ( Bang, HY; Cho, YH; Hong Lee, M; Kim, SY; Lee, KY; Yoo, MW; Yoon, SY, 2012) |
| "This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6)." | 2.77 | A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. ( Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J, 2012) |
| "Gemcitabine was administered intravenously at 1,000 mg/m(2)/week (days 1, 8 and 15) and oral capecitabine from day 1 to day 21 at 1,660 mg/m(2)/day." | 2.77 | Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ( Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H, 2012) |
| "Neutropenia was the most common Grade 3-4 toxicity of both ICT and CCRT, with a frequency of 28% and 26." | 2.76 | Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study. ( Ch'ang, HJ; Chang, JY; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Chiu, YF; Hsieh, RK; Hsu, CH; Hwang, TL; Lin, PW; Lin, YL; Shan, YS; Tien, YW; Wang, HP; Whang-Peng, J, 2011) |
| "While the most frequent, surgery for colorectal cancer is avoided in patients with metastases to the regional lymph nodes (stage III) or distant ones (stage IV)." | 2.76 | [Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer]. ( Eropkin, PV; Kashnikov, VN; Panina, MV; Rybakov, EG, 2011) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 2.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "The prognosis of patients with advanced gastric cancer (AGC) remains poor, and no single chemotherapy regimen is recognized as a global standard." | 2.75 | Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. ( Chen, XQ; Li, FH; Li, YH; Luo, HY; Qiu, MZ; Wang, F; Xu, RH; Zhou, ZW, 2010) |
| "Grade 3 neutropenia was seen in seven patients and grade 4 in one patient." | 2.75 | Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. ( Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T, 2010) |
| "Of these, 50 patients had untreated gastric cancer, and 14 had received previous therapy with nonplatinum-based therapy." | 2.74 | Phase II study of capecitabine plus cisplatin in patients with gastric cancer. ( AL-Ashry, MS; Ebrahim, MA; Salah-Eldin, MA, 2009) |
| " Follow-up for potential delayed adverse effects and efficacy is ongoing." | 2.74 | Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. ( Allegra, CJ; Atkins, JN; Azar, CA; Chu, L; Colangelo, LH; Fehrenbacher, L; Goldberg, RM; Lopa, SH; O'Connell, MJ; O'Reilly, S; Petrelli, NJ; Seay, TE; Sharif, S; Wolmark, N; Yothers, G, 2009) |
| "Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy." | 2.74 | [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer]. ( Dai, H; Yan, D, 2009) |
| " This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients." | 2.74 | [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009) |
| "Twenty women with squamous cell cervical cancer were randomly assigned to receive ether standard whole pelvic radiotherapy with concurrent cisplatin and fluorouracil infusion every 4 weeks or the same radiotherapy with concurrent cisplatin every 1 week." | 2.74 | Randomized comparison of fluorouracil plus cisplatin vs. cisplatin as an adjunct to radiation therapy in stage IIB-IVA squamous cell carcinoma of the cervix: pilot study. ( Penpattanagul, S; Porapakkhan, P; Sukhaboon, J, 2009) |
| "To investigate the efficiency, time to progression (TTP), overall survival (OS) and toxicity of epirubicin combined with DDP and 5-Fu (PELF regimen) for the treatment of advanced gastric cancer." | 2.74 | [Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD, 2009) |
| "As prognosis of advanced gastric cancer is still poor, a standard regimen after first-line fluorouracil (FU)-based chemotherapy has not yet been established." | 2.73 | A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial. ( Boku, N; Fukuda, H; Hamaguchi, T; Honma, H; Hyodo, I; Imamura, T; Koizumi, W; Mukai, T; Ohtsu, A; Seki, S; Shirao, K; Yamamichi, N; Yamamoto, S; Yoshida, S, 2008) |
| "Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract." | 2.73 | [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. ( Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY, 2008) |
| "2004, 256 cases with stage III colorectal cancer randomized received de Gramont, modified FOLFOX4 (mFOLFOX4) and XELOX regimens." | 2.73 | [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer]. ( Cheng, RC; Diao, C; Liu, QY; Su, YJ; Wei, XP; Xu, JB; Zhang, JM, 2008) |
| "Irinotecan 180 mg/m2 was administered biweekly on D1, LV 200 mg/m2 by intravenous infusion in 2 hours before bolus intravenous injection of 5-Fu 400 mg/m2, then followed immediately by intravenous infusion of 5-Fu 2." | 2.73 | [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. ( Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD, 2008) |
| "This concurrent chemoradiotherapy with PFML was safe and well tolerated." | 2.73 | Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. ( Katori, H; Taguchi, T; Tsukuda, M, 2007) |
| "Irinotecan was given as a 30 min infusion on days 1 and 8, and capecitabine on days 1-14 of a 21-day cycle." | 2.73 | Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. ( Baker, S; Bulgaru, A; Camacho, F; Chaudhary, I; Desai, K; Einstein, M; Goel, S; Goldberg, G; Gollamudi, R; Karri, S; Kaubisch, A; Mani, S, 2007) |
| " The dosage of chemotherapy was as follows: DOC 60 mg/m(2) on day 1 by infusion over 2 hours; CDGP 20-30 mg/m(2)/day on day 1 to 5 by infusion over 1 hour, and 5-FU 600 mg/m(2)/day on day 1 to 5 by 5 days continuous infusion." | 2.73 | [Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck]. ( Iwabuchi, H; Nakayama, S; Uchiyama, K, 2007) |
| "The management of metastatic breast cancer becomes increasingly intricate, requiring new drugs and combinations." | 2.73 | Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer. ( Biville, F; Chauffert, B; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Garnier, J; Isambert, N; Mayer, F; Zanetta, S, 2008) |
| "Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI." | 2.73 | A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008) |
| " Thus, the recommended dosing schedule is level 2." | 2.72 | A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. ( Abe, S; Araki, H; Hareyama, M; Iyama, S; Kato, J; Miyanishi, K; Murase, K; Nagakura, H; Niitsu, Y; Okamoto, T; Sagawa, T; Sato, T; Sato, Y; Takayama, T; Takimoto, R, 2006) |
| "The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions." | 2.72 | A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. ( Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J, 2006) |
| "Bacterial infections are major life-threatening complications in patients receiving cytotoxic drugs." | 2.72 | Granulocyte function is stimulated by a novel hexapeptide, WKYMVm, in chemotherapy-treated cancer patients. ( Heo, SK; Kim, BS; Kim, H; Kim, MJ; Lee, EH; Min, YJ; Park, JH; Park, SK, 2006) |
| "169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)." | 2.72 | Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006) |
| " Leucovorin (LV) dosage was fixed at 500 mg/m(2)." | 2.71 | Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. ( Fleming, GF; Hong, AM; Meyerson, A; Ratain, MJ; Schilsky, RL; Schumm, LP; Vogelzang, NJ, 2003) |
| " Pharmacokinetic and neurotoxicity assessments were performed at the cohort 2 MTD." | 2.71 | Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. ( Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ, 2003) |
| "Weight gain was observed in 12 of 33 (36%) patients." | 2.71 | Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. ( Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N, 2004) |
| "This study was originally designed as a phase I/II study, with a dose escalation of docetaxel in combination with epirubicin 50 mg m(-2) and 5-fluorouracil (5-FU) 200 mg m(-2) day(-1)." | 2.71 | Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. ( Bradley, C; Crawford, SM; Dent, J; Dodwell, D; Humphreys, AC; Joffe, JK; Perren, TJ; Rodwell, S, 2004) |
| "Grade 2/3 neutropenia was observed in 4 (3%) treatment cycles." | 2.71 | Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. ( Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N, 2004) |
| "Grade 4 neutropenia was observed in one patient." | 2.71 | Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. ( Castellano, D; Cortés-Funes, H; Hitt, R; Jimeno, A; Millán, JM, 2004) |
| "Patients with previously untreated esophageal cancer were eligible if they had performance status 0-1, were 75 years or younger and had adequate organ function." | 2.71 | Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2004) |
| "Neutropenia was the only grade-4 toxicity that occurred in 2 patients." | 2.71 | Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity. ( Ernst-Stecken, A; Grabenbauer, G; Iro, H; Plasswilm, L; Sauer, R, 2004) |
| "Esophageal cancer has a poor prognosis." | 2.71 | [Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer]. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2005) |
| " This phase I pharmacokinetic and clinical study evaluated escalating CPT-11 doses administered every 3 weeks combined with a fixed dose of 5-FU CI over 14 days to find the maximum tolerated dose (MTD) of this combined chemotherapy." | 2.71 | A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours. ( Alfonso, R; Carcas, A; Cortés-Funes, H; Díaz-Rubio, E; Frías, J; Grávalos, C; Guerra, P; Paz-Ares, L; Pronk, L; Sastre, J, 2005) |
| "Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever." | 2.71 | A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005) |
| "Four of 22 patients with colorectal cancer had partial responses, two of which had prior bolus CPT-11/5-FU." | 2.71 | A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. ( Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA, 2005) |
| "Patients with advanced or recurrent gastric cancer were treated with escalating doses of weekly paclitaxel as a 60 min intravenous (i." | 2.71 | Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. ( Araki, K; Hirabayashi, N; Kataoka, M; Kobayashi, M; Kojima, H; Kondo, K; Matsui, T; Miyashita, Y; Nakao, A; Nakazato, H; Sakamoto, J; Takiyama, W, 2005) |
| "25 patients with locally advanced head and neck cancer were treated with 4 cycles of vinorelbine (20 mg i." | 2.70 | Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer. ( Catalano, G; Chiesa, F; De Braud, F; De Paoli, F; De Pas, T; DePas, T; Jereczek-Fossa, BA; Krengli, M; Marrocco, E; Masci, G; Orecchia, R; Robertson, C; Vavassori, A, 2002) |
| "Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)." | 2.70 | Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002) |
| "Nine patients with colorectal cancer and one with gastric cancer had partial or minor responses." | 2.70 | A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. ( Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA, 2002) |
| "Febrile neutropenia was observed in 10% of patients and 2." | 2.70 | Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. ( Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P, 2002) |
| " 5-FU dosage was fixed at 1,600 mg/m2 while docetaxel was evaluated at weekly 1-hour infusion dosages of 30, 40 and 50 mg/m2 to determine the MTD." | 2.70 | A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. ( Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002) |
| "Raltitrexed has been shown to be devoid of clinical activity against SCCHN when used alone; however, both preclinical and early clinical data regarding the combination raltitrexed-CDDP hold promise." | 2.70 | Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Lucia, L; De Rosa, P; De Rosa, V; Rosati, G, 2002) |
| "Fatigue was a frequent side-effect during both PELF and docetaxel chemotherapy." | 2.70 | A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. ( Baldelli, AM; Barni, S; Casaretti, R; Cascinu, S; Catalano, G; Catalano, V; Comella, G; Frontini, L; Graziano, F; Labianca, R, 2001) |
| " Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m(2)/week when combined with 5-fluorouracil (5-FU) at 200 mg/m(2)/day (Days 1-21) repeated every 4 weeks." | 2.70 | Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. ( Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ, 2001) |
| "Gemcitabine was administered as a 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break." | 2.70 | Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. ( Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 2002) |
| " Pharmacokinetic parameters of capecitabine and its metabolites (5'-deoxy-5-fluorouridine, 5-fluorouracil and alpha-fluoro-beta-alanine) were similar to those reported by other authors." | 2.70 | Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. ( Budd, GT; Bukowski, R; Chang, DZ; Ganapathi, R; Olencki, T; Osterwalder, B; Peereboom, D, 2001) |
| ", Carlsbad, CA) when administered in combination with 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.70 | Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. ( Dorr, FA; Geary, RS; Holmlund, JT; Kindler, HL; Kunkel, K; Mani, S; Ratain, MJ; Rudin, CM, 2002) |
| " The recommended 5-FU dosage for phase II evaluations is 1,250 mg/m(2)/wk for 3 weeks every 4 weeks with the intensified PN401 dose schedule (schedule 2)." | 2.69 | Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. ( Campbell, E; Davidson, K; Diab, SG; Drengler, RL; Eckhardt, SG; Garner, AM; Hammond, LA; Hidalgo, M; Louie, A; O'Neil, JD; Rodriguez, G; Rowinsky, EK; Villalona-Calero, MA; von Borstel, R; Von Hoff, DD; Weiss, G, 2000) |
| " infusion of 5FU in patients with advanced solid tumors to determine the maximum tolerated dose, the recommended dose for Phase II studies, and the safety and pharmacokinetic profiles of this combination." | 2.69 | A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. ( Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H, 2000) |
| "Febrile neutropenia was recorded in 15% of courses." | 2.69 | Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. ( Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E, 2000) |
| "For high-risk patients with breast cancer with more than three positive axillary lymph nodes, this series adopted a modified sequential regimen of ACMF first with Adriamycin (A) as a single agent in 3-weekly administration for three courses, and then a combination of cyclophosphamide, methotrexate, fluorouracil (CMF) every 3 to 4 weeks for six courses given in an outpatient setting concurrent with radiation therapy as an adjuvant treatment." | 2.69 | Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. ( Chen, CM; Cheng, SH; Hsieh, CI; Huang, AT; Liu, MC; Liu, TW; Tsou, MH, 2000) |
| " This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds." | 2.69 | A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. ( Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J, 2000) |
| "For advanced irresectible gastric cancer, sequential high-dose methotrexate and 5-fluorouracil (both on day 1) combined with adriamycin on day 15 (FAMTX regimen), cycled every 28 days, is a fairly effective but toxic treatment, with a high incidence of neutropenic fever, dose reductions and dose delays." | 2.69 | Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study. ( Boot, H; Craanen, M; Gerritsen, WR; Swart, M; Taal, BG; Westermann, AM, 2000) |
| "To determine the dose-limiting toxicity of CPT-11 in combination with oxaliplatin, and the maximal tolerated dose (MTD) and the recommended dose (RD) of CPT-11 using an every two weeks schedule." | 2.69 | Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. ( Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A, 2000) |
| "Diarrhea was dose-limiting; 6/13 patients had grade II or worse diarrhea at 2,600 mg/m2." | 2.68 | Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. ( Brennan, J; Hageboutros, A; Hudes, GR; LaCreta, FP; McAleer, C; Newman, EM; O'Dwyer, PJ; Ozols, RF; Rogatko, A, 1995) |
| "Stomatitis was seen more in arm B and C than in arm A." | 2.68 | [A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group]. ( Akazawa, S; Konishi, T; Kumai, K; Kurihara, M; Ogawa, M; Ogawa, N; Ota, K; Sasaki, T; Taguchi, T; Tominaga, T, 1995) |
| "Thirty-two patients (76%) had no oral mucositis." | 2.68 | Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995) |
| " Recommendations are made concerning initial dosing, dose reductions and delays to minimize adverse patient outcomes from myelosuppression." | 2.68 | Concurrent chemoradiation for oesophageal cancer: factors influencing myelotoxicity. ( Burmeister, BH; Denham, JW; Lamb, DS; MacKean, J, 1996) |
| " Laboratory studies of IFN-beta suggest that this agent may offer theoretical advantages over IFN-alpha in combination with 5-FU." | 2.68 | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. ( Bradley, C; Hallam, S; Illingworth, JM; Joffe, JK; Perren, TJ; Primrose, J; Selby, PJ; Ward, U, 1997) |
| " Following encouraging preclinical results of taxoid combinations, this phase I, nonrandomized trial was designed to evaluate a 1-hour intravenous infusion of docetaxel (Taxotere) on day 1 combined with fluorouracil (5-FU) as a daily intravenous bolus for 5 consecutive days." | 2.68 | Docetaxel in combination with fluorouracil: study design and preliminary results. ( Aylesworth, C; Bellet, R; Burris, H; Drengler, R; Peacock, N; Ravdin, P; Rodriguez, G; Rowinsky, E; Smith, L; Von Hoff, D; White, L, 1997) |
| "5-fluorouracil was given at a dose of 1000 mg/m2 for 5 consecutive days and cisplatin was given on day 2 at a dose of 100 mg/m2." | 2.68 | The French experience with infusional 5-FU in gastric and pancreatic cancer. ( Ducreux, M; Rougier, P, 1996) |
| "Therapy for metastatic breast cancer has not improved significantly in recent years." | 2.68 | Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997) |
| "Hypotension was observed in three of five patients at the highest dose level (0." | 2.67 | A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. ( Botet, J; Crown, J; Gasparetto, C; Gordon, M; Jakubowski, A; Kemeny, N; Meisenberg, B; Sheridan, C; Toner, G; Wong, G, 1991) |
| "Oral tegafur and I." | 2.65 | A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. ( Bedikian, AY; Bodey, GP; Karlin, D; Korinek, J; Stroehlein, J, 1983) |
| "Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with methotrexate (250 mg/m2) followed 1 hour later by 5-FU (600 mg/m2)." | 2.65 | Use of methotrexate and 5-FU for recurrent head and neck cancer. ( Jacobs, C, 1982) |
| "We searched Cochrane Breast Cancer's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials." | 2.61 | Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. ( Goodwin, A; O'Connell, DL; Wilcken, N; Willson, ML; Zaheed, M, 2019) |
| "FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects." | 2.58 | The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. ( Fan, Z; Liu, B; Lu, T; Tong, H, 2018) |
| "To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings." | 2.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| "Bevacizumab (Bev) combined with chemotherapy significantly improves progression-free survival (PFS) but not overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC)." | 2.52 | The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials. ( Chen, F; Chen, Y; Cheng, B; Fang, Y; Qu, X; Wang, Z; Xiong, B, 2015) |
| " Many drugs have been used for the treatment of this disease, but there is little information about how predictive factors can be used to aid treatment response and anticipate toxic effects related to anticancer treatment in colorectal cancer." | 2.44 | Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. ( Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B, 2008) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| " Hand-foot syndrome (HFS) is the only clinical adverse event occurring more often during capecitabine treatment." | 2.42 | Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). ( Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E, 2004) |
| " Each chemotherapeutic drug has the potential to induce various adverse events in the patients receiving chemotherapy." | 2.41 | [Prevention and treatment for adverse events induced by chemotherapy]. ( Tsukuda, M, 2002) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 2.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| "Irinotecan (CPT11) is a synthetic camptothecin-derived DNA topoisomerase I inhibitor." | 2.40 | [Irinotecan: various administration schedules, study of drug combinations, phase I experience]. ( Armand, JP; Boige, V; Raymond, E, 1998) |
| " This study aimed to determine genetic and non-genetic predictors of adverse effects." | 1.91 | Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy. ( Ball, IA; Bowen, JM; Coller, JK; Gibson, RJ; Karapetis, CS; Keefe, DM; Korver, SK; Logan, RM; Mead, KR; Richards, AM; Secombe, KR; Tuke, J; Wain, TJ, 2023) |
| " The prognosis, predictive factors (including systemic inflammation-based prognostic indicators), and adverse events were investigated." | 1.72 | Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. ( Aihara, R; Araki, K; Hatanaka, T; Hosaka, H; Hoshino, T; Hosouchi, Y; Ijima, M; Ishida, F; Ishii, N; Kakizaki, S; Kobatake, T; Kurihara, E; Naganuma, A; Shirabe, K; Suzuki, Y; Tamura, Y; Uraoka, T; Yasuoka, H; Yoshida, S, 2022) |
| "Grade ≥ 3 neutropenia was significantly more common in patients with than without osteopenia (p = 0." | 1.72 | Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study. ( Kashihara, H; Nakao, T; Nishi, M; Shimada, M; Takasu, C; Tokunaga, T; Wada, Y; Yamashita, S; Yoshikawa, K; Yoshimoto, T, 2022) |
| " Demographics, clinical and dosing characteristics, and treatment outcomes were collected." | 1.56 | Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. ( Ahn, D; Barzi, A; Bekaii-Saab, T; Corvino, FA; Mamlouk, K; Miksad, R; Pulgar, S; Surinach, A; Torres, AZ; Valderrama, A; Wang, S, 2020) |
| " This pharmacokinetic/pharmacodynamic (PK/PD) study was performed to determine the effect of different G-CSF regimens on the incidence and duration of neutropenia following FOLFIRINOX administration in order to propose an optimal G-CSF dosing schedule." | 1.56 | Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach. ( Bengrine-Lefevre, L; Ghiringhelli, F; Macaire, P; Paris, J; Schmitt, A; Vincent, J, 2020) |
| "Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chemotherapy." | 1.56 | ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. ( Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Matsuzawa, H; Mochizuki, N; Nomura, H; Tsuji, D; Yano, T, 2020) |
| "Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival." | 1.51 | Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| "Patients with advanced gastric cancer and severe peritoneal metastasis were included if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support." | 1.51 | Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. ( Arai, H; Boku, N; Fukuda, N; Hironaka, S; Iwasa, S; Kawahira, M; Masuishi, T; Minashi, K; Muro, K; Nakajima, TE; Takahari, D; Yasui, H, 2019) |
| "Chemotherapy-induced interstitial lung disease in colorectal cancer patients is rare but represents a life-threatening adverse reaction." | 1.48 | Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report. ( Aizawa, K; Furukawa, T; Kozakai, H; Mitsuboshi, S; Nagai, K; Yamada, H, 2018) |
| "DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation." | 1.48 | Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. ( Heishi, T; Ishida, H; Ito, K; Kamei, T; Konno-Kumagai, T; Maruyama, S; Okamoto, H; Onodera, Y; Sakurai, T; Sato, C; Taniyama, Y; Teshima, J, 2018) |
| "Grade 3-4 neutropenia was seen in 10/23 patients (43%)." | 1.46 | PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. ( Beer, J; Bodis, S; Oehler, C; Vlachopoulou, V; von Moos, R; Zimmermann, M; Zwahlen, DR, 2017) |
| "This study shows a promising possibility that administering pegfilgrastim <14 days from the next chemotherapy cycle could be a safe and effective practice." | 1.46 | Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion. ( Donkor, KN; Lewis, K; Selim, JH; Waworuntu, A, 2017) |
| "Locally advanced anal cancer patients, especially with T4 disease and fistula, have a dismal prognosis." | 1.46 | Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer. ( Allal, AS; Cacheux, W; Dietrich, PY; Fernandez, E; Ho, L; Koessler, T; Puppa, G; Ris, F; Roche, B; Roth, A; Zilli, T, 2017) |
| "Neoadjuvant RT for rectal cancer has lasting effects on the pelvic BM, which are demonstrable during adjuvant OxF." | 1.43 | Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy. ( Baby, R; Chen, T; Jabbour, SK; Lu, SE; Moss, RA; Newman, NB; Nissenblatt, MJ; Sidhu, MK, 2016) |
| " The chemotherapy drugs were administered as follows: 135 mg/m(2) paclitaxel on day 1, 25 mg/m(2)/day cisplatin on days 1-3, followed by continuously infused intravenous fluorouracil for 120 h at a variable dosage from 600 to 800 mg/m(2)/day, depending on prior radiation." | 1.43 | A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. ( Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ, 2016) |
| " This relationship favors new treatment strategies with white blood cell growth factors or chemotherapy dosing based on muscle value." | 1.43 | Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. ( Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A, 2016) |
| "Metastases were mostly in the lung (43%), lymph nodes (51%) and liver (46%)." | 1.43 | Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer. ( Chen, Q; Xue, H; Zhang, S, 2016) |
| "Febrile neutropenia was not reported." | 1.43 | Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. ( Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C, 2016) |
| "Patients with advanced pancreatic cancer who received FOLFIRINOX with G-CSF prophylaxis during the first cycle of treatment from January 2014 to August 2014 were investigated and the frequency of adverse events during the first cycle was measured." | 1.42 | Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study. ( Asaishi, K; Goto, M; Higuchi, K; Kii, T; Kuwakado, S; Miyamoto, T; Nishitani, H; Shimamoto, F; Terazawa, T, 2015) |
| " Simultaneous heterozygous UGT1A1 28 and UGT1A1 6 polymorphisms may produce higher exposure to SN-38 and a higher risk of adverse effects related to irinotecan." | 1.39 | Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. ( Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM, 2013) |
| " National Cancer Institute Common Toxicity Criteria (version 4) for classification of adverse events." | 1.39 | Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer. ( Atrash, F; Billan, S; Doweck, I; Haim, N; Kaidar-Person, O; Kuten, A; Ronen, O, 2013) |
| "Patients with cancer often receive chemotherapeutic agents concurrently with other medications to treat comorbidity." | 1.39 | Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer. ( Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2013) |
| "Population-based studies of adverse events are scarce." | 1.38 | Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012) |
| "Irinotecan was given as a combined regimen for median 6 cycles (range, 3-12) and as a single agent for median 3 cycles (range, 1-10)." | 1.38 | Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. ( Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO, 2012) |
| " FOLFIRI regimen is safe and effective in the second-line treatment of AGC patients pre-treated with cisplatin and taxanes." | 1.38 | The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. ( Alkis, N; Arpacı, E; Benekli, M; Berk, V; Bilici, A; Budakoglu, B; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Gumus, M; Inal, A; Isıkdogan, A; Kaya, AO; Ozkan, M; Yumuk, F, 2012) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 1.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | 1.36 | [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| " Prospective trials are required to assess whether dosing adjustments based on neutropaenia may improve chemotherapy efficacy." | 1.35 | Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. ( Inaba, Y; Matsuo, K; Muro, K; Najima, M; Sato, Y; Shitara, K; Takahari, D; Ura, T; Yamaura, H; Yokota, T, 2009) |
| "We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy." | 1.35 | Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. ( Aydogan, B; Chmura, SJ; Devisetty, K; Jani, AB; Kindler, HL; Mell, LK; Miller, RC; Mundt, AJ; Roeske, JC; Salama, JK; Schomas, DA, 2008) |
| "19 out of 29 patients were colon cancer, and the other 10 were rectal cancer." | 1.34 | [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer]. ( Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2007) |
| "Grade 3/4 neutropenia was seen in 12 patients (60%), and neuropathy was observed in 11 patients (55%)." | 1.34 | Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. ( Kasai, M; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K, 2007) |
| "The data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed." | 1.34 | [Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer]. ( Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD, 2007) |
| "The major clinical problem was the deep venous thrombosis related to the central venous catheter, which occurred in 5 patients (17%)." | 1.33 | Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. ( Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D, 2005) |
| "Treatment of non operable esophageal cancer still remains debatable." | 1.33 | [Role of an exclusive concomitant radio-chemotherapy treatment in non operable esophageal cancer: results of a 10-year experience in Antoine-Lacassagne Center]. ( François, E; Lagrange, JL; Magné, N; Marcy, PY; Touati, L; Van Houtte, P, 2005) |
| "Paclitaxel was administered at a dose of 80 mg/m(2), 3 times every 4 weeks." | 1.33 | [Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma]. ( Ito, S; Kodera, Y; Mochizuki, Y; Yamamura, Y, 2005) |
| "In metastatic colorectal cancer, a combination of Leucovorin (LV) and fluorouraci (l FU) with oxaliplatin (FOLFOX) is a standard first-line regimen." | 1.33 | [FOLFOX]. ( Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Mishima, H; Miyazaki, M; Nakamori, S; Tsujinaka, T; Yasui, M, 2006) |
| "In patients with liver metastases from colorectal cancer, survival can be increased by hepatic resection." | 1.32 | Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. ( Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D, 2004) |
| "Twenty-four patients with advanced gastric cancer who had been treated by multiple chemotherapy regimens presenting poor responses were allotted." | 1.32 | [Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer]. ( Chen, YX; He, ZM; Mei, JF; Qian, J; Qin, SK; Shao, ZJ, 2004) |
| "All of them had stage IV, unresectable squamous cell carcinoma of the pharynx and they received continuous bid radiotherapy (two daily fractions of 1." | 1.31 | [Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]. ( Bensadoun, RJ; Chauvel, P; Courdi, A; Dassonville, O; Demard, F; Ettore, F; Falewee, MN; Lagrange, JL; Magné, N; Marcy, PY; Milano, G; Pivot, X; Poissonnet, G; Santini, J; Schneider, M; Vallicioni, J, 2001) |
| "Febrile neutropenia was observed in 4." | 1.31 | Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. ( Jagiello-Gruszfeld, A; Pieńkowski, T, 2001) |
| "In stade II and III breast cancer, neoadjuvant chemotherapy with FEC-HD obtains an important histological response with an acceptable toxicity." | 1.30 | [Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer]. ( Arnoud, L; Belichard, C; Coudert, B; Darut-Jouve, A; Guerrin, J; Jolimoy, G, 1999) |
| "To determine the maximum-tolerated dose (MTD) and recommended dose of irinotecan (CPT-11) in combination with fluorouracil (5-FU) and leucovorin (LV), using a biweekly LV5FU2 regimen and increasing doses of CPT-11, and to assess the efficacy of this combination in pretreated patients with colorectal cancer (CRC)." | 1.30 | Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ( Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M, 1999) |
| "We present a patient with metastatic breast cancer treated with high-dose chemotherapy and bone marrow transplantation." | 1.29 | Clostridium septicum abscess in hepatic metastases: successful medical management. ( Ciaccia, D; Corey, GR; Peters, W; Thel, MC; Vredenburgh, JJ, 1994) |
| " Mice bearing murine renal cancer (Renca) were also protected from the acute toxic effects of Cy (450 mg/kg) by pretreatment with rhIL-1 alpha." | 1.28 | Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy. ( Futami, H; Jansen, R; Keller, J; Longo, DL; MacPhee, MJ; McCormick, K; Oppenheim, JJ; Ruscetti, FW; Wiltrout, RH, 1990) |
| "Neutropenic enterocolitis is a recognized complication of immunosuppression or chemotherapy for leukemia." | 1.28 | Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy. ( de Vries, EJ; Johnson, JT; Petruzzelli, GJ, 1990) |
| " Thus, TMTX can be given with 5-FU (400 mg/m2) on a daily x 5-day bolus schedule at the 12 mg/m2 per day dose level, which was the recommended dose of TMTX as a single agent for phase II studies using the 5-day bolus schedule." | 1.28 | Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ( Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F, 1989) |
| " Further evaluation of vindesine will require dosage modification." | 1.26 | Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea. ( Bedikian, AY; Bennetts, RW; Bodey, GP; Karlin, DA; Stroehlein, JR; Valdivieso, M, 1982) |
| " Gastrointestinal and hematologic toxic effects were mild and infrequent." | 1.26 | High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule. ( Campbell, TN; House, BA; Howell, SB; Pfeifle, C, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (2.97) | 18.7374 |
| 1990's | 70 (12.99) | 18.2507 |
| 2000's | 215 (39.89) | 29.6817 |
| 2010's | 203 (37.66) | 24.3611 |
| 2020's | 35 (6.49) | 2.80 |
| Authors | Studies |
|---|---|
| Giommoni, E | 1 |
| Lavacchi, D | 1 |
| Tirino, G | 1 |
| Fornaro, L | 2 |
| Iachetta, F | 1 |
| Pozzo, C | 2 |
| Satolli, MA | 1 |
| Spallanzani, A | 1 |
| Puzzoni, M | 1 |
| Stragliotto, S | 1 |
| Sisani, M | 1 |
| Formica, V | 1 |
| Giovanardi, F | 1 |
| Strippoli, A | 1 |
| Prisciandaro, M | 1 |
| Di Donato, S | 1 |
| Pompella, L | 1 |
| Pecora, I | 1 |
| Romagnani, A | 1 |
| Fancelli, S | 1 |
| Brugia, M | 1 |
| Pillozzi, S | 1 |
| De Vita, F | 2 |
| Antonuzzo, L | 1 |
| Park, SJ | 1 |
| Kim, H | 2 |
| Shin, K | 1 |
| Hong, TH | 1 |
| Suh, JH | 1 |
| Lee, MA | 1 |
| Nomura, H | 2 |
| Tsuji, D | 2 |
| Ueno, S | 1 |
| Kojima, T | 4 |
| Fujii, S | 2 |
| Yano, T | 4 |
| Daiko, H | 2 |
| Demachi, K | 2 |
| Itoh, K | 2 |
| Kawasaki, T | 3 |
| Matsubara, Y | 1 |
| Masuishi, T | 3 |
| Ogata, T | 1 |
| Nakazawa, T | 1 |
| Kato, K | 3 |
| Nozawa, K | 1 |
| Narita, Y | 2 |
| Honda, K | 3 |
| Bando, H | 1 |
| Taniguchi, H | 2 |
| Kadowaki, S | 2 |
| Ando, M | 3 |
| Tajika, M | 1 |
| Muro, K | 8 |
| Kim, G | 1 |
| Cockrum, P | 1 |
| Surinach, A | 2 |
| Wang, S | 2 |
| Wainberg, Z | 1 |
| Okamoto, K | 1 |
| Ninomiya, I | 1 |
| Saito, H | 1 |
| Shimada, M | 2 |
| Yamaguchi, T | 3 |
| Terai, S | 1 |
| Moriyama, H | 1 |
| Kinoshita, J | 1 |
| Nakamura, K | 2 |
| Inaki, N | 1 |
| Endo, Y | 1 |
| Ishikawa, T | 3 |
| Oka, K | 1 |
| Sakakida, T | 1 |
| Matsumura, S | 2 |
| Mizushima, K | 1 |
| Doi, T | 6 |
| Okayama, T | 3 |
| Katada, K | 1 |
| Kamada, K | 3 |
| Uchiyama, K | 5 |
| Takagi, T | 3 |
| Fujiwara, H | 3 |
| Konishi, H | 4 |
| Naito, Y | 3 |
| Itoh, Y | 3 |
| Yasuoka, H | 1 |
| Naganuma, A | 1 |
| Kurihara, E | 1 |
| Kobatake, T | 1 |
| Ijima, M | 1 |
| Tamura, Y | 1 |
| Suzuki, Y | 1 |
| Hoshino, T | 1 |
| Ishida, F | 1 |
| Hosaka, H | 1 |
| Hatanaka, T | 1 |
| Yoshida, S | 3 |
| Aihara, R | 1 |
| Hosouchi, Y | 2 |
| Ishii, N | 1 |
| Araki, K | 2 |
| Shirabe, K | 2 |
| Uraoka, T | 1 |
| Kakizaki, S | 1 |
| Nakao, T | 1 |
| Yoshikawa, K | 1 |
| Tokunaga, T | 1 |
| Nishi, M | 1 |
| Kashihara, H | 1 |
| Takasu, C | 1 |
| Wada, Y | 2 |
| Yoshimoto, T | 1 |
| Yamashita, S | 1 |
| Nakamura, T | 2 |
| Matsubara, H | 1 |
| Irisawa, A | 1 |
| Takeno, M | 1 |
| Watanabe, K | 1 |
| Takahashi, H | 2 |
| Mitsunaga, S | 1 |
| Ikeda, M | 1 |
| Matsuoka, H | 2 |
| Yamada, T | 1 |
| Ohta, R | 1 |
| Yoshida, Y | 3 |
| Watanabe, T | 2 |
| Takahashi, M | 1 |
| Kosugi, C | 1 |
| Fukazawa, A | 1 |
| Kuramochi, H | 1 |
| Matsuda, A | 1 |
| Sonoda, H | 1 |
| Yoshida, H | 1 |
| Hasegawa, S | 1 |
| Sakamoto, K | 1 |
| Otsuka, T | 2 |
| Hirata, K | 1 |
| Koda, K | 1 |
| Kanesada, K | 1 |
| Tsunedomi, R | 2 |
| Hazama, S | 3 |
| Ogihara, H | 1 |
| Hamamoto, Y | 8 |
| Shindo, Y | 1 |
| Matsui, H | 1 |
| Tokumitsu, Y | 1 |
| Iida, M | 1 |
| Suzuki, N | 2 |
| Takeda, S | 1 |
| Ioka, T | 1 |
| Nagano, H | 2 |
| Chen, J | 2 |
| Wang, L | 3 |
| Tong, G | 1 |
| Ma, J | 2 |
| Liu, C | 2 |
| Umeki, Y | 1 |
| Fujita, M | 2 |
| Goto, A | 3 |
| Serizawa, A | 1 |
| Akimoto, S | 1 |
| Nakauchi, M | 1 |
| Tanaka, T | 5 |
| Shibasaki, S | 1 |
| Inaba, K | 1 |
| Uyama, I | 1 |
| Suda, K | 1 |
| Korver, SK | 1 |
| Bowen, JM | 1 |
| Gibson, RJ | 1 |
| Ball, IA | 1 |
| Secombe, KR | 1 |
| Wain, TJ | 1 |
| Logan, RM | 1 |
| Tuke, J | 1 |
| Mead, KR | 1 |
| Richards, AM | 1 |
| Karapetis, CS | 1 |
| Keefe, DM | 1 |
| Coller, JK | 1 |
| Mayanagi, S | 1 |
| Oba, K | 4 |
| Aoyama, T | 1 |
| Tanaka, K | 3 |
| Kanda, M | 1 |
| Honda, M | 2 |
| Maeda, H | 1 |
| Kashiwabara, K | 1 |
| Muto, M | 4 |
| Sakamoto, J | 7 |
| Yamagishi, H | 1 |
| Yoshikawa, T | 1 |
| Shibata, Y | 1 |
| Matsumoto, N | 1 |
| Murase, R | 1 |
| Kubota, Y | 1 |
| Ishida, H | 6 |
| Shimada, K | 2 |
| Fujita, KI | 1 |
| Tran, NH | 1 |
| Sahai, V | 1 |
| Griffith, KA | 2 |
| Nathan, H | 1 |
| Kaza, R | 1 |
| Cuneo, KC | 1 |
| Shi, J | 1 |
| Kim, E | 1 |
| Sonnenday, CJ | 1 |
| Cho, CS | 1 |
| Lawrence, TS | 1 |
| Zalupski, MM | 3 |
| Yasuda, T | 3 |
| Dohi, O | 2 |
| Yoshida, N | 2 |
| Shiozaki, A | 2 |
| Teramukai, S | 1 |
| Hammel, P | 2 |
| Fabienne, P | 1 |
| Mineur, L | 1 |
| Metges, JP | 1 |
| Andre, T | 3 |
| De La Fouchardiere, C | 2 |
| Louvet, C | 5 |
| El Hajbi, F | 1 |
| Faroux, R | 1 |
| Guimbaud, R | 3 |
| Tougeron, D | 1 |
| Bouche, O | 1 |
| Lecomte, T | 4 |
| Rebischung, C | 1 |
| Tournigand, C | 2 |
| Cros, J | 1 |
| Kay, R | 1 |
| Hamm, A | 1 |
| Gupta, A | 1 |
| Bachet, JB | 1 |
| El Hariry, I | 1 |
| Saito, S | 1 |
| Yanagisawa, R | 1 |
| Minami, K | 2 |
| Uchida, E | 1 |
| Komori, K | 2 |
| Kurata, T | 1 |
| Sakashita, K | 1 |
| Barzi, A | 1 |
| Miksad, R | 1 |
| Corvino, FA | 1 |
| Torres, AZ | 1 |
| Mamlouk, K | 1 |
| Pulgar, S | 1 |
| Valderrama, A | 1 |
| Bekaii-Saab, T | 1 |
| Ahn, D | 1 |
| Maiello, E | 3 |
| Di Maggio, G | 1 |
| Cordio, S | 1 |
| Cinieri, S | 1 |
| Giuliani, F | 1 |
| Pisconti, S | 1 |
| Rinaldi, A | 1 |
| Febbraro, A | 1 |
| Latiano, TP | 1 |
| Aieta, M | 1 |
| Rossi, A | 2 |
| Rizzi, D | 1 |
| Di Maio, M | 1 |
| Colucci, G | 1 |
| Bordonaro, R | 4 |
| Kitagawa, Y | 1 |
| Osumi, H | 2 |
| Shinozaki, E | 2 |
| Ota, Y | 2 |
| Nakayama, I | 2 |
| Suzuki, T | 2 |
| Wakatsuki, T | 2 |
| Ogura, M | 2 |
| Ooki, A | 2 |
| Takahari, D | 6 |
| Suenaga, M | 2 |
| Chin, K | 2 |
| Yamaguchi, K | 4 |
| Macaire, P | 1 |
| Paris, J | 1 |
| Vincent, J | 2 |
| Ghiringhelli, F | 2 |
| Bengrine-Lefevre, L | 1 |
| Schmitt, A | 1 |
| Park, H | 1 |
| Jin, RU | 1 |
| Wang-Gillam, A | 4 |
| Suresh, R | 2 |
| Rigden, C | 1 |
| Amin, M | 1 |
| Tan, BR | 2 |
| Pedersen, KS | 1 |
| Lim, KH | 2 |
| Trikalinos, NA | 1 |
| Acharya, A | 1 |
| Copsey, ML | 1 |
| Navo, KA | 1 |
| Morton, AE | 1 |
| Gao, F | 3 |
| Lockhart, AC | 3 |
| Mochizuki, N | 1 |
| Matsuzawa, H | 1 |
| Draper, AS | 1 |
| Lafollette, J | 1 |
| Kim, C | 1 |
| Wu, CS | 1 |
| Huang, J | 1 |
| Jiang, C | 1 |
| Liu, Z | 1 |
| Zheng, W | 1 |
| Zhu, X | 2 |
| Huang, Z | 1 |
| Kobayashi, N | 1 |
| Omae, K | 1 |
| Horita, Y | 1 |
| Ueno, H | 1 |
| Mizuno, N | 1 |
| Uesugi, K | 1 |
| Sudo, K | 1 |
| Ozaka, M | 1 |
| Hayashi, H | 2 |
| Okano, N | 1 |
| Kamei, K | 1 |
| Yamaguchi, A | 1 |
| Kobayashi, S | 2 |
| Suzuki, S | 2 |
| Ishihara, S | 1 |
| Uchiyama, T | 1 |
| Todaka, A | 1 |
| Fukutomi, A | 2 |
| Katada, C | 3 |
| Sugawara, M | 1 |
| Hara, H | 1 |
| Fujii, H | 3 |
| Nakajima, TE | 4 |
| Ando, T | 2 |
| Watanabe, A | 1 |
| Sakamoto, Y | 1 |
| Ishikawa, H | 2 |
| Hosokawa, A | 4 |
| Tahara, M | 2 |
| Koizumi, W | 3 |
| Kamiimabeppu, D | 1 |
| Sato, T | 3 |
| Kim, S | 3 |
| Kang, SI | 1 |
| Kim, JH | 4 |
| Caron, B | 1 |
| Reimund, JM | 1 |
| Ben Abdelghani, M | 1 |
| Sondag, D | 1 |
| Noirclerc, M | 1 |
| Duclos, B | 1 |
| Kurtz, JE | 1 |
| Nguimpi-Tambou, M | 1 |
| Arima, S | 1 |
| Kawahira, M | 2 |
| Shimokawa, M | 2 |
| Ido, A | 1 |
| Koga, F | 1 |
| Ueda, Y | 2 |
| Nakazawa, J | 1 |
| Komori, A | 2 |
| Otsu, S | 1 |
| Fukahori, M | 1 |
| Makiyama, A | 1 |
| Taguchi, H | 1 |
| Honda, T | 1 |
| Shibuki, T | 1 |
| Mitsugi, K | 1 |
| Nio, K | 1 |
| Ide, Y | 1 |
| Ureshino, N | 1 |
| Mizuta, T | 1 |
| Shirakawa, T | 1 |
| Lee, JC | 2 |
| Kim, JW | 1 |
| Ahn, S | 1 |
| Kim, HW | 1 |
| Lee, J | 3 |
| Kim, YH | 1 |
| Paik, KH | 1 |
| Kim, J | 1 |
| Hwang, JH | 2 |
| Chen, Y | 3 |
| Wang, Y | 7 |
| Shi, Y | 2 |
| Dai, G | 1 |
| Fang, M | 1 |
| Song, T | 1 |
| Liang, X | 1 |
| Lv, S | 1 |
| Li, J | 12 |
| Xu, H | 1 |
| Luo, L | 1 |
| Jia, Y | 1 |
| Naito, M | 1 |
| Yamamoto, T | 2 |
| Shimamoto, C | 1 |
| Miwa, Y | 1 |
| Horimatsu, T | 1 |
| Nakayama, N | 2 |
| Moriwaki, T | 2 |
| Hirashima, Y | 1 |
| Asayama, M | 1 |
| Moriyama, I | 1 |
| Nakashima, K | 1 |
| Baba, E | 1 |
| Kitamura, H | 1 |
| Tamura, T | 2 |
| Yoshimura, K | 2 |
| Miyata, H | 2 |
| Sugimura, K | 2 |
| Motoori, M | 2 |
| Fujiwara, Y | 2 |
| Omori, T | 1 |
| Yanagimoto, Y | 1 |
| Ohue, M | 1 |
| Yasui, M | 2 |
| Miyoshi, N | 1 |
| Tomokuni, A | 1 |
| Akita, H | 1 |
| Yano, M | 3 |
| Zimmermann, M | 1 |
| Beer, J | 1 |
| Bodis, S | 1 |
| von Moos, R | 1 |
| Vlachopoulou, V | 1 |
| Zwahlen, DR | 1 |
| Oehler, C | 1 |
| Donkor, KN | 1 |
| Selim, JH | 1 |
| Waworuntu, A | 1 |
| Lewis, K | 1 |
| Zhang, L | 5 |
| Xing, X | 1 |
| Meng, F | 1 |
| Zhong, D | 1 |
| Park, JJ | 1 |
| Hajj, C | 1 |
| Reyngold, M | 1 |
| Shi, W | 1 |
| Zhang, Z | 1 |
| Cuaron, JJ | 1 |
| Crane, CH | 1 |
| O'Reilly, EM | 2 |
| Lowery, MA | 1 |
| Yu, KH | 1 |
| Goodman, KA | 2 |
| Wu, AJ | 2 |
| Mitsuboshi, S | 1 |
| Kozakai, H | 1 |
| Yamada, H | 1 |
| Nagai, K | 1 |
| Furukawa, T | 1 |
| Aizawa, K | 1 |
| Xu, C | 2 |
| Yang, SP | 1 |
| Zhang, Y | 1 |
| Tang, LL | 1 |
| Zhou, GQ | 1 |
| Liu, X | 1 |
| Mao, YP | 1 |
| Guo, R | 1 |
| Li, WF | 1 |
| Chen, L | 1 |
| Lin, AH | 1 |
| Sun, Y | 2 |
| Wang, YR | 1 |
| Dai, GH | 1 |
| Lévi, F | 2 |
| Karaboué, A | 2 |
| Saffroy, R | 1 |
| Desterke, C | 1 |
| Boige, V | 3 |
| Smith, D | 1 |
| Hebbar, M | 1 |
| Innominato, P | 1 |
| Taieb, J | 2 |
| Carvalho, C | 2 |
| Focan, C | 2 |
| Bouchahda, M | 1 |
| Adam, R | 1 |
| Ducreux, M | 7 |
| Milano, G | 6 |
| Lemoine, A | 1 |
| Chao, YL | 1 |
| Anders, CK | 1 |
| Cacheux, W | 1 |
| Koessler, T | 1 |
| Puppa, G | 1 |
| Fernandez, E | 1 |
| Ho, L | 1 |
| Dietrich, PY | 1 |
| Zilli, T | 1 |
| Allal, AS | 2 |
| Roche, B | 1 |
| Ris, F | 1 |
| Roth, A | 1 |
| Ji, WB | 1 |
| Hong, KD | 1 |
| Kim, JS | 1 |
| Joung, SY | 1 |
| Um, JW | 1 |
| Min, BW | 1 |
| Kondo, M | 1 |
| Sugiyama, K | 1 |
| Mitani, S | 1 |
| Ura, T | 6 |
| Mishima, H | 4 |
| Pastorino, A | 1 |
| Di Bartolomeo, M | 4 |
| Iaffaioli, V | 1 |
| Ciuffreda, L | 1 |
| Fasola, G | 1 |
| Di Costanzo, F | 1 |
| Frassineti, GL | 2 |
| Marchetti, P | 1 |
| Antoniotti, C | 1 |
| Leone, F | 1 |
| Zaniboni, A | 3 |
| Aprile, G | 1 |
| Zilocchi, C | 1 |
| Sobrero, A | 5 |
| Mnejja, W | 1 |
| Toumi, N | 1 |
| Fourati, N | 1 |
| Bouzguenda, R | 1 |
| Ghorbel, A | 1 |
| Frikha, M | 1 |
| Siala, W | 1 |
| Daoud, J | 1 |
| Liu, GY | 1 |
| Lv, X | 1 |
| Wu, YS | 2 |
| Mao, MJ | 1 |
| Ye, YF | 1 |
| Yu, YH | 1 |
| Liang, H | 1 |
| Yang, J | 1 |
| Ke, LR | 1 |
| Qiu, WZ | 1 |
| Huang, XJ | 1 |
| Li, WZ | 1 |
| Guo, X | 4 |
| Xiang, YQ | 2 |
| Xia, WX | 1 |
| Tong, H | 1 |
| Fan, Z | 2 |
| Liu, B | 1 |
| Lu, T | 1 |
| Cohen, PR | 1 |
| Tejpar, S | 2 |
| Yan, P | 1 |
| Piessevaux, H | 1 |
| Dietrich, D | 1 |
| Brauchli, P | 1 |
| Klingbiel, D | 1 |
| Fiocca, R | 1 |
| Delorenzi, M | 1 |
| Bosman, F | 1 |
| Roth, AD | 2 |
| Okamoto, H | 1 |
| Taniyama, Y | 1 |
| Sakurai, T | 1 |
| Heishi, T | 1 |
| Teshima, J | 1 |
| Sato, C | 1 |
| Maruyama, S | 2 |
| Ito, K | 1 |
| Onodera, Y | 1 |
| Konno-Kumagai, T | 1 |
| Kamei, T | 1 |
| Deng, B | 1 |
| Jia, L | 1 |
| Tan, H | 1 |
| Lou, Y | 1 |
| Li, X | 1 |
| Li, Y | 4 |
| Yu, L | 1 |
| Aranda, E | 4 |
| García-Alfonso, P | 5 |
| Benavides, M | 5 |
| Sánchez Ruiz, A | 1 |
| Guillén-Ponce, C | 1 |
| Safont, MJ | 1 |
| Alcaide, J | 1 |
| Gómez, A | 3 |
| López, R | 1 |
| Manzano, JL | 1 |
| Méndez Ureña, M | 1 |
| Sastre, J | 3 |
| Rivera, F | 3 |
| Grávalos, C | 2 |
| García, T | 1 |
| Martín-Valadés, JI | 1 |
| Falcó, E | 1 |
| Navalón, M | 1 |
| González Flores, E | 1 |
| Ma García Tapiador, A | 1 |
| Ma López Muñoz, A | 1 |
| Barrajón, E | 1 |
| Reboredo, M | 2 |
| García Teijido, P | 1 |
| Viudez, A | 1 |
| Cárdenas, N | 1 |
| Díaz-Rubio, E | 6 |
| Shui, L | 1 |
| Lin, H | 1 |
| Shui, P | 1 |
| Sun, Q | 2 |
| Chen, X | 2 |
| Aoki, M | 1 |
| Sandou, M | 1 |
| Takagi, M | 1 |
| Uejima, E | 1 |
| Liu, SL | 1 |
| Sun, XS | 1 |
| Li, XY | 1 |
| Chen, QY | 4 |
| Lin, HX | 3 |
| Wen, YF | 1 |
| Guo, SS | 1 |
| Liu, LT | 1 |
| Xie, HJ | 1 |
| Tang, QN | 1 |
| Liang, YJ | 1 |
| Yan, JJ | 1 |
| Lin, C | 1 |
| Yang, ZC | 1 |
| Tang, LQ | 1 |
| Guo, L | 3 |
| Mai, HQ | 2 |
| Ohta, T | 1 |
| Yoshida, J | 1 |
| Handa, O | 1 |
| Wei, X | 1 |
| Cai, J | 1 |
| Sun, H | 1 |
| Li, N | 1 |
| Zhang, G | 1 |
| Sui, Y | 1 |
| Zhuang, J | 1 |
| Zheng, B | 1 |
| Zaheed, M | 1 |
| Wilcken, N | 1 |
| Willson, ML | 1 |
| O'Connell, DL | 1 |
| Goodwin, A | 1 |
| Oyaga-Iriarte, E | 1 |
| Insausti, A | 1 |
| Sayar, O | 1 |
| Aldaz, A | 1 |
| Riechelmann, RP | 1 |
| Srimuninnimit, V | 1 |
| Kavan, P | 1 |
| Cicin, I | 1 |
| Chau, I | 3 |
| Fedyanin, MY | 1 |
| Martos, CF | 2 |
| Ter-Ovanesov, M | 1 |
| Peeters, M | 1 |
| Ko, YJ | 1 |
| Yalcin, S | 1 |
| Karthaus, M | 1 |
| Aparicio, J | 2 |
| Heinemann, V | 1 |
| Picard, P | 1 |
| Bury, D | 1 |
| Drea, E | 1 |
| Arai, H | 1 |
| Iwasa, S | 1 |
| Boku, N | 7 |
| Yasui, H | 2 |
| Minashi, K | 2 |
| Hironaka, S | 4 |
| Fukuda, N | 1 |
| Hubner, RA | 2 |
| Worsnop, F | 1 |
| Cunningham, D | 8 |
| Tonyali, O | 1 |
| Benekli, M | 3 |
| Berk, V | 3 |
| Coskun, U | 2 |
| Ozkan, M | 3 |
| Yildiz, R | 1 |
| Ucgul, E | 1 |
| Sevinc, A | 2 |
| Uncu, D | 3 |
| Demirci, U | 2 |
| Buyukberber, S | 3 |
| Harvey, VJ | 1 |
| Sharples, KJ | 1 |
| Isaacs, RJ | 1 |
| Jameson, MB | 1 |
| Jeffery, GM | 1 |
| McLaren, BR | 1 |
| Pollard, S | 1 |
| Riley, GA | 1 |
| Simpson, AB | 1 |
| Hinder, VA | 1 |
| Scott, JN | 1 |
| Dzhelali, MV | 1 |
| Findlay, MP | 1 |
| Tabernero, J | 3 |
| Garcia-Carbonero, R | 1 |
| Cassidy, J | 6 |
| Van Cutsem, E | 5 |
| Köhne, CH | 2 |
| Gladkov, O | 1 |
| Davidenko, I | 1 |
| Salazar, R | 1 |
| Vladimirova, L | 1 |
| Cheporov, S | 1 |
| Burdaeva, O | 1 |
| Samuel, L | 2 |
| Bulavina, I | 1 |
| Potter, V | 1 |
| Chang, YL | 1 |
| Lokker, NA | 1 |
| O'Dwyer, PJ | 3 |
| Tanriverdi, O | 1 |
| Saridaki, Z | 2 |
| Lambrodimou, G | 1 |
| Kachris, S | 1 |
| Makrantonakis, P | 1 |
| Boukovinas, I | 1 |
| Polyzos, A | 4 |
| Anagnostopoulos, A | 1 |
| Athanasiadis, A | 2 |
| Stoltidis, D | 1 |
| Georgoulias, V | 7 |
| Souglakos, J | 3 |
| Ito, Y | 1 |
| Ishiyama, H | 2 |
| Tokunaga, SY | 1 |
| Tanaka, M | 1 |
| Hashimoto, T | 1 |
| Kodaira, T | 1 |
| Montoya, JE | 1 |
| Luna, HG | 1 |
| Morelos, AB | 1 |
| Catedral, MM | 1 |
| Lava, AL | 1 |
| Amparo, JR | 1 |
| Cristal-Luna, GR | 1 |
| McPartlin, AJ | 1 |
| Mais, K | 1 |
| Barker, C | 1 |
| Swindell, R | 1 |
| Mitchell, K | 1 |
| Sykes, A | 1 |
| Lee, L | 1 |
| Yap, B | 1 |
| Slevin, NJ | 1 |
| Ji, JH | 1 |
| Park, SH | 1 |
| Kim, TW | 5 |
| Hong, YS | 2 |
| Kim, KP | 2 |
| Kim, SY | 2 |
| Baek, JY | 1 |
| Kang, HJ | 2 |
| Shin, SJ | 2 |
| Shim, BY | 1 |
| Park, YS | 2 |
| Hua, YJ | 1 |
| Luo, DH | 1 |
| Sun, R | 1 |
| Qiu, F | 3 |
| Mo, HY | 1 |
| Xian, LJ | 1 |
| Hong, MH | 3 |
| Xu, JM | 6 |
| Ge, FJ | 2 |
| Lin, L | 2 |
| Liu, ZY | 1 |
| Sharma, MR | 1 |
| Billan, S | 1 |
| Kaidar-Person, O | 1 |
| Atrash, F | 1 |
| Doweck, I | 1 |
| Haim, N | 1 |
| Kuten, A | 1 |
| Ronen, O | 1 |
| Sagara, Y | 1 |
| Sato, K | 1 |
| Fukuma, E | 1 |
| Higaki, K | 1 |
| Mizutani, M | 1 |
| Osaki, A | 1 |
| Takano, T | 1 |
| Tokuda, Y | 1 |
| Ohno, S | 1 |
| Masuda, N | 3 |
| Suzuki, M | 1 |
| Saeki, T | 1 |
| Moretto, R | 1 |
| Raimondo, L | 1 |
| De Stefano, A | 1 |
| Cella, CA | 1 |
| Matano, E | 2 |
| De Placido, S | 2 |
| Carlomagno, C | 2 |
| Curigliano, G | 1 |
| Pivot, X | 2 |
| Cortés, J | 2 |
| Elias, A | 1 |
| Cesari, R | 1 |
| Khosravan, R | 2 |
| Collier, M | 1 |
| Huang, X | 1 |
| Cataruozolo, PE | 1 |
| Kern, KA | 1 |
| Goldhirsch, A | 1 |
| Yeh, CT | 1 |
| Liang, KH | 1 |
| Lin, CC | 2 |
| Chang, ML | 1 |
| Hsu, CL | 1 |
| Hung, CF | 1 |
| Shen, L | 6 |
| Feng, FY | 2 |
| Jiao, SC | 2 |
| Wang, LW | 2 |
| Guan, ZZ | 3 |
| Qin, SK | 3 |
| Wang, JJ | 2 |
| Yu, SY | 2 |
| Wang, YJ | 1 |
| Jin, YN | 1 |
| Tao, M | 1 |
| Zheng, LZ | 1 |
| Pan, LX | 2 |
| Shirao, K | 6 |
| Yamada, Y | 5 |
| Goto, M | 2 |
| Nasu, J | 1 |
| Denda, T | 1 |
| Takashima, A | 1 |
| Fukuda, H | 2 |
| Ohtsu, A | 5 |
| Saif, MW | 2 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 3 |
| Rodriguez, T | 1 |
| Okuyama, Y | 2 |
| Kato, T | 4 |
| Takahashi, K | 2 |
| Nozawa, H | 2 |
| Ando, H | 1 |
| Kobayashi, M | 3 |
| Takemoto, H | 1 |
| Nagata, N | 2 |
| Kanekiyo, S | 1 |
| Inoue, Y | 1 |
| Fujita, Y | 1 |
| Hinoda, Y | 1 |
| Okayama, N | 1 |
| Oka, M | 1 |
| Kochi, M | 1 |
| Akiyama, Y | 2 |
| Aoki, T | 1 |
| Hagiwara, K | 1 |
| Takahashi, T | 1 |
| Hironaka, K | 1 |
| Teranishi, F | 1 |
| Osuka, F | 1 |
| Takeuchi, M | 1 |
| Fujii, M | 1 |
| Nakajima, T | 2 |
| Oh, MJ | 1 |
| Lee, HJ | 1 |
| Lee, SH | 2 |
| Lakomý, R | 1 |
| Prausová, J | 1 |
| Ruff, P | 1 |
| van Hazel, GA | 1 |
| Moiseyenko, VM | 1 |
| Ferry, DR | 1 |
| McKendrick, JJ | 1 |
| Soussan-Lazard, K | 1 |
| Chevalier, S | 1 |
| Allegra, CJ | 2 |
| Mahaseth, H | 1 |
| Brutcher, E | 1 |
| Kauh, J | 1 |
| Hawk, N | 1 |
| Chen, Z | 2 |
| Kooby, DA | 1 |
| Maithel, SK | 1 |
| Landry, J | 1 |
| El-Rayes, BF | 1 |
| Bazan, JG | 2 |
| Luxton, G | 1 |
| Kozak, MM | 1 |
| Anderson, EM | 1 |
| Hancock, SL | 1 |
| Kapp, DS | 1 |
| Kidd, EA | 1 |
| Koong, AC | 1 |
| Chang, DT | 2 |
| Ueda, S | 1 |
| Nishina, T | 2 |
| Tsuda, M | 1 |
| Tsumura, T | 1 |
| Sugimoto, N | 1 |
| Shimodaira, H | 1 |
| Tokunaga, S | 4 |
| Esaki, T | 2 |
| Nagase, M | 2 |
| Fujitani, K | 4 |
| Morita, S | 3 |
| Okamoto, I | 1 |
| Hyodo, I | 2 |
| Toshima, T | 1 |
| Kodera, M | 1 |
| Yamashita, Y | 1 |
| Oishi, M | 1 |
| Seshimo, K | 1 |
| Yamamura, M | 1 |
| Kato, H | 2 |
| Ikeda, H | 1 |
| Mizuno, K | 2 |
| Tomasello, G | 1 |
| Liguigli, W | 1 |
| Poli, R | 1 |
| Lazzarelli, S | 2 |
| Brighenti, M | 1 |
| Negri, F | 1 |
| Curti, A | 1 |
| Martinotti, M | 1 |
| Olivetti, L | 1 |
| Rovatti, M | 1 |
| Donati, G | 1 |
| Passalacqua, R | 1 |
| Di Lauro, L | 1 |
| Vici, P | 1 |
| Belli, F | 1 |
| Tomao, S | 1 |
| Fattoruso, SI | 1 |
| Arena, MG | 1 |
| Pizzuti, L | 1 |
| Giannarelli, D | 1 |
| Paoletti, G | 1 |
| Barba, M | 1 |
| Sergi, D | 1 |
| Maugeri-Saccà, M | 1 |
| Kajiura, S | 1 |
| Yoshita, H | 1 |
| Ueda, A | 1 |
| Mihara, H | 1 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Ogawa, K | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 1 |
| Fuse, N | 2 |
| Yamanaka, Y | 2 |
| Motomura, S | 1 |
| Matsumoto, H | 1 |
| Mizunuma, N | 3 |
| Hatake, K | 1 |
| Iwasaki, J | 1 |
| Lee, MG | 1 |
| Lee, SJ | 1 |
| Lee, YS | 1 |
| Ryu, JK | 1 |
| Kim, YT | 1 |
| Kim, DU | 1 |
| Woo, SM | 1 |
| Rambach, L | 1 |
| Bertaut, A | 1 |
| Lorgis, V | 1 |
| Ladoire, S | 1 |
| Yamauchi, H | 1 |
| Aogi, K | 1 |
| Shimizu, S | 1 |
| Iwata, H | 1 |
| Yamamoto, N | 1 |
| Inoue, K | 1 |
| Ohono, S | 1 |
| Kuroi, K | 1 |
| Hamano, T | 1 |
| Sukigara, T | 1 |
| Higuchi, K | 2 |
| Komori, S | 1 |
| Tanabe, S | 1 |
| Azuma, M | 1 |
| Sasaki, T | 4 |
| Ishido, K | 1 |
| Katada, N | 1 |
| Hayakawa, K | 1 |
| Quartino, AL | 1 |
| Karlsson, MO | 1 |
| Lindman, H | 1 |
| Friberg, LE | 1 |
| Middleton, G | 1 |
| Silcocks, P | 1 |
| Cox, T | 1 |
| Valle, J | 1 |
| Wadsley, J | 1 |
| Propper, D | 1 |
| Coxon, F | 1 |
| Ross, P | 1 |
| Madhusudan, S | 1 |
| Roques, T | 1 |
| Falk, S | 1 |
| Wadd, N | 1 |
| Harrison, M | 1 |
| Corrie, P | 1 |
| Iveson, T | 1 |
| Robinson, A | 1 |
| McAdam, K | 1 |
| Eatock, M | 1 |
| Evans, J | 1 |
| Archer, C | 1 |
| Hickish, T | 1 |
| Garcia-Alonso, A | 1 |
| Nicolson, M | 1 |
| Steward, W | 1 |
| Anthoney, A | 1 |
| Greenhalf, W | 1 |
| Shaw, V | 1 |
| Costello, E | 1 |
| Naisbitt, D | 1 |
| Rawcliffe, C | 1 |
| Nanson, G | 1 |
| Neoptolemos, J | 1 |
| Yanagihara, Y | 1 |
| Tanji, N | 1 |
| Miura, N | 1 |
| Shirato, A | 1 |
| Nishimura, K | 1 |
| Fukumoto, T | 1 |
| Azuma, K | 1 |
| Miyauchi, Y | 1 |
| Kikugawa, T | 1 |
| Yokoyama, M | 1 |
| Smoragiewicz, M | 1 |
| Javaheri, KR | 1 |
| Yin, Y | 1 |
| Gill, S | 1 |
| Zheng, Y | 2 |
| Fang, W | 1 |
| Mao, C | 1 |
| Qian, J | 2 |
| Zhao, P | 1 |
| Zhang, X | 1 |
| Jiang, H | 1 |
| Xu, N | 4 |
| Park, JS | 1 |
| Jeung, HC | 1 |
| Rha, SY | 1 |
| Ahn, JB | 3 |
| Kang, B | 1 |
| Chon, HJ | 1 |
| Lim, S | 1 |
| Yang, WI | 1 |
| Nam, CM | 1 |
| Chung, HC | 1 |
| Li, C | 1 |
| Gu, Y | 1 |
| Zhao, M | 1 |
| Yuan, Y | 1 |
| Wang, F | 3 |
| Wang, Z | 2 |
| Li, W | 1 |
| Luo, H | 1 |
| Chen, C | 1 |
| Chen, G | 1 |
| Ding, P | 1 |
| Wu, X | 1 |
| Lu, Z | 1 |
| Pan, Z | 1 |
| Xu, R | 1 |
| He, Y | 1 |
| Wan, D | 1 |
| Yamazaki, K | 2 |
| Chen, HM | 1 |
| Lin, JK | 1 |
| Chen, WS | 1 |
| Jiang, JK | 1 |
| Yang, SH | 1 |
| Lan, YT | 1 |
| Teng, HW | 1 |
| Ruzzo, A | 1 |
| Graziano, F | 2 |
| Galli, F | 2 |
| Giacomini, E | 1 |
| Floriani, I | 1 |
| Rulli, E | 1 |
| Lonardi, S | 1 |
| Ronzoni, M | 1 |
| Massidda, B | 2 |
| Zagonel, V | 1 |
| Pella, N | 1 |
| Mucciarini, C | 1 |
| Labianca, R | 3 |
| Ionta, MT | 1 |
| Veltri, E | 1 |
| Sozzi, P | 1 |
| Barni, S | 3 |
| Ricci, V | 1 |
| Foltran, L | 1 |
| Nicolini, M | 1 |
| Biondi, E | 1 |
| Bramati, A | 1 |
| Turci, D | 2 |
| Verusio, C | 1 |
| Bergamo, F | 1 |
| Frontini, L | 3 |
| Magnani, M | 1 |
| Lee, AM | 1 |
| Shi, Q | 1 |
| Pavey, E | 1 |
| Alberts, SR | 2 |
| Sargent, DJ | 2 |
| Sinicrope, FA | 1 |
| Berenberg, JL | 1 |
| Goldberg, RM | 6 |
| Diasio, RB | 1 |
| Fang, Y | 1 |
| Qu, X | 1 |
| Cheng, B | 1 |
| Chen, F | 1 |
| Xiong, B | 1 |
| Sarkar, C | 1 |
| Chakroborty, D | 1 |
| Dasgupta, PS | 1 |
| Basu, S | 1 |
| Géresi, K | 1 |
| Megyeri, A | 2 |
| Szabó, B | 1 |
| Szabó, Z | 1 |
| Aradi, J | 1 |
| Németh, J | 1 |
| Benkő, I | 3 |
| Miyazaki, T | 1 |
| Ojima, H | 2 |
| Fukuchi, M | 1 |
| Sakai, M | 1 |
| Sohda, M | 1 |
| Tanaka, N | 1 |
| Ieta, K | 1 |
| Saito, K | 1 |
| Sano, A | 1 |
| Yokobori, T | 1 |
| Inose, T | 1 |
| Nakajima, M | 1 |
| Kuwano, H | 2 |
| Wang, X | 1 |
| Fan, T | 1 |
| Wang, T | 2 |
| Xie, Y | 1 |
| Ouyang, T | 1 |
| Julie, DA | 1 |
| Oh, JH | 1 |
| Apte, AP | 1 |
| Deasy, JO | 1 |
| Tom, A | 1 |
| Miwa, K | 3 |
| Oki, E | 4 |
| Emi, Y | 4 |
| Saeki, H | 3 |
| Kusumoto, T | 2 |
| Akagi, Y | 3 |
| Ogata, Y | 4 |
| Samura, H | 2 |
| Sueyoshi, S | 1 |
| Higashi, H | 2 |
| Matsuda, H | 1 |
| Touyama, T | 3 |
| Maehara, Y | 4 |
| Badiyan, SN | 1 |
| Olsen, JR | 1 |
| Lee, AY | 2 |
| Menias, CO | 1 |
| Khwaja, S | 1 |
| Strasberg, SM | 1 |
| Hawkins, WG | 1 |
| Linehan, DC | 1 |
| Myerson, RJ | 1 |
| Parikh, PJ | 1 |
| Yang, C | 1 |
| Liu, Y | 1 |
| Xi, WQ | 1 |
| Zhou, CF | 1 |
| Jiang, JL | 1 |
| Ma, T | 2 |
| Ye, ZB | 1 |
| Zhang, J | 3 |
| Zhu, ZG | 1 |
| Ohnuma, H | 1 |
| Sato, Y | 3 |
| Hirakawa, M | 1 |
| Okagawa, Y | 1 |
| Osuga, T | 1 |
| Hayashi, T | 1 |
| Miyanishi, K | 2 |
| Kobune, M | 1 |
| Takimoto, R | 2 |
| Sagawa, T | 2 |
| Hori, M | 1 |
| Someya, M | 1 |
| Nakata, K | 1 |
| Sakata, K | 1 |
| Takayama, T | 2 |
| Kato, J | 2 |
| Sadanaga, N | 2 |
| Kimura, M | 1 |
| Baba, H | 3 |
| Shirouzu, K | 2 |
| Yamada, M | 1 |
| Tamate, S | 1 |
| Iwasaki, K | 1 |
| Mitomo, K | 1 |
| Nakayama, S | 2 |
| Liu, R | 1 |
| Huang, M | 1 |
| Zhao, X | 1 |
| Peng, W | 1 |
| Sun, S | 1 |
| Cao, J | 1 |
| Ji, D | 1 |
| Wang, C | 1 |
| Guo, W | 1 |
| Yin, J | 1 |
| Li, CP | 1 |
| Bodoky, G | 1 |
| Dean, A | 1 |
| Shan, YS | 2 |
| Jameson, G | 1 |
| Macarulla, T | 1 |
| Lee, KH | 2 |
| Blanc, JF | 1 |
| Chiu, CF | 1 |
| Schwartsmann, G | 1 |
| Siveke, JT | 1 |
| Braiteh, F | 1 |
| Moyo, V | 1 |
| Belanger, B | 1 |
| Dhindsa, N | 1 |
| Bayever, E | 1 |
| Von Hoff, DD | 4 |
| Chen, LT | 4 |
| Terazawa, T | 1 |
| Miyamoto, T | 1 |
| Asaishi, K | 1 |
| Shimamoto, F | 1 |
| Kuwakado, S | 1 |
| Nishitani, H | 1 |
| Kii, T | 1 |
| Miyata, Y | 2 |
| Kusumi, T | 1 |
| Morita, Y | 1 |
| Taniguchi, F | 1 |
| Manabe, M | 1 |
| Ojima, T | 2 |
| Nakamori, M | 2 |
| Nakamura, M | 2 |
| Katsuda, M | 2 |
| Hayata, K | 2 |
| Iwahashi, M | 2 |
| Yamaue, H | 2 |
| Kitadani, J | 1 |
| Tabata, H | 1 |
| Takeuchi, A | 1 |
| Wulaningsih, W | 1 |
| Wardhana, A | 1 |
| Watkins, J | 1 |
| Yoshuantari, N | 1 |
| Repana, D | 1 |
| Van Hemelrijck, M | 1 |
| Rose, BS | 1 |
| Jee, KW | 1 |
| Niemierko, A | 1 |
| Murphy, JE | 1 |
| Blaszkowsky, LS | 1 |
| Allen, JN | 1 |
| Lee, LK | 1 |
| Drapek, LC | 1 |
| Hong, TS | 1 |
| Wo, JY | 1 |
| Newman, NB | 1 |
| Sidhu, MK | 1 |
| Baby, R | 1 |
| Moss, RA | 1 |
| Nissenblatt, MJ | 1 |
| Chen, T | 1 |
| Lu, SE | 1 |
| Jabbour, SK | 1 |
| Cortejoso, L | 1 |
| García-González, X | 1 |
| García, MI | 1 |
| Sanjurjo, M | 1 |
| López-Fernández, LA | 1 |
| Wang, ZQ | 2 |
| Jiang, YX | 1 |
| Wang, FH | 2 |
| Luo, HY | 3 |
| Liang, Y | 1 |
| Wang, DS | 1 |
| Li, YH | 4 |
| Chemama, S | 1 |
| Bayar, MA | 1 |
| Lanoy, E | 1 |
| Ammari, S | 1 |
| Stoclin, A | 1 |
| Goéré, D | 1 |
| Elias, D | 2 |
| Raynard, B | 1 |
| Antoun, S | 1 |
| Zhang, S | 2 |
| Xue, H | 1 |
| Chen, Q | 1 |
| van Ramshorst, MS | 1 |
| van Werkhoven, E | 1 |
| Honkoop, AH | 1 |
| Dezentjé, VO | 1 |
| Oving, IM | 1 |
| Mandjes, IA | 1 |
| Kemper, I | 1 |
| Smorenburg, CH | 1 |
| Stouthard, JM | 1 |
| Linn, SC | 1 |
| Sonke, GS | 1 |
| Pasquini, G | 1 |
| Vasile, E | 1 |
| Caparello, C | 1 |
| Vivaldi, C | 1 |
| Musettini, G | 1 |
| Lencioni, M | 2 |
| Petrini, I | 1 |
| Falcone, A | 3 |
| Golden, DW | 1 |
| Kopec, M | 1 |
| Pelizzari, CA | 1 |
| Aggarwal, S | 1 |
| Liauw, SL | 1 |
| Sakaguchi, M | 1 |
| Maebayashi, T | 1 |
| Aizawa, T | 1 |
| Ishibashi, N | 1 |
| Saito, T | 1 |
| Fujiwara, D | 1 |
| Mashimo, K | 1 |
| Kimura, K | 1 |
| Noda, A | 1 |
| Taki, K | 1 |
| Yoshibayashi, H | 1 |
| Takeda, T | 1 |
| Tsubaki, M | 2 |
| Nishida, S | 1 |
| Sakaguchi, K | 1 |
| Hamaguchi, T | 3 |
| Yamamichi, N | 1 |
| Seki, S | 1 |
| Imamura, T | 1 |
| Honma, H | 1 |
| Mukai, T | 1 |
| Yamamoto, S | 1 |
| Vincenzi, B | 1 |
| Schiavon, G | 1 |
| Pantano, F | 1 |
| Santini, D | 1 |
| Tonini, G | 1 |
| Kweekel, DM | 1 |
| Gelderblom, H | 1 |
| Van der Straaten, T | 1 |
| Antonini, NF | 1 |
| Punt, CJ | 1 |
| Guchelaar, HJ | 2 |
| Yu, ZY | 1 |
| Ouyang, XN | 1 |
| Chen, ZS | 1 |
| Xie, FW | 1 |
| Diao, C | 1 |
| Cheng, RC | 1 |
| Zhang, JM | 1 |
| Wei, XP | 1 |
| Su, YJ | 1 |
| Liu, QY | 1 |
| Xu, JB | 1 |
| Jenkins, P | 1 |
| Freeman, S | 1 |
| Valladares, M | 1 |
| Martinez-Villacampa, M | 1 |
| Massutti, B | 2 |
| Marcuello, E | 3 |
| Constenla, M | 3 |
| Cámara, JC | 1 |
| Carrato, A | 4 |
| Dueñas, R | 2 |
| Navarro, M | 1 |
| Zhang, XD | 3 |
| Bai, Y | 1 |
| Chu, YP | 1 |
| Wang, YH | 1 |
| Liu, DQ | 1 |
| Jin, ML | 1 |
| Vermorken, JB | 1 |
| Mesia, R | 1 |
| Remenar, E | 1 |
| Kawecki, A | 1 |
| Rottey, S | 1 |
| Erfan, J | 1 |
| Zabolotnyy, D | 1 |
| Kienzer, HR | 1 |
| Cupissol, D | 2 |
| Peyrade, F | 1 |
| Benasso, M | 1 |
| Vynnychenko, I | 1 |
| De Raucourt, D | 1 |
| Bokemeyer, C | 1 |
| Schueler, A | 1 |
| Amellal, N | 1 |
| Hitt, R | 3 |
| Attia, S | 1 |
| Morgan-Meadows, S | 1 |
| Holen, KD | 1 |
| Bailey, HH | 1 |
| Eickhoff, JC | 1 |
| Schelman, WR | 1 |
| Traynor, AM | 1 |
| Mulkerin, DL | 1 |
| Campbell, TC | 1 |
| McFarland, TA | 1 |
| Huie, MS | 1 |
| Cleary, JF | 1 |
| Tevaarwerk, AJ | 1 |
| Alberti, DB | 1 |
| Wilding, G | 1 |
| Liu, G | 1 |
| Sirohi, B | 1 |
| Pluzanska, A | 1 |
| Utracka-Hutka, B | 1 |
| Zaluski, J | 4 |
| Glynne-Jones, R | 2 |
| Koralewski, P | 2 |
| Bridgewater, J | 1 |
| Mainwaring, P | 1 |
| Wasan, H | 1 |
| Wang, JY | 1 |
| Szczylik, C | 2 |
| Clingan, P | 1 |
| Chan, RT | 1 |
| Tabah-Fisch, I | 1 |
| Bajetta, E | 2 |
| Buzzoni, R | 2 |
| Ferrario, E | 2 |
| Dotti, KF | 1 |
| Mariani, L | 2 |
| Bajetta, R | 1 |
| Gevorgyan, A | 2 |
| Venturino, P | 1 |
| Galassi, M | 1 |
| Arkenau, HT | 1 |
| Arnold, D | 2 |
| Douillard, JY | 4 |
| Hochster, H | 1 |
| Martoni, A | 1 |
| Grothey, A | 2 |
| Hinke, A | 1 |
| Schmiegel, W | 1 |
| Schmoll, HJ | 2 |
| Porschen, R | 2 |
| Goekkurt, E | 1 |
| Al-Batran, SE | 2 |
| Mogck, U | 1 |
| Pauligk, C | 1 |
| Hartmann, JT | 1 |
| Kramer, M | 1 |
| Jaeger, E | 1 |
| Ehninger, G | 1 |
| Stoehlmacher, J | 1 |
| Boehnke Michaud, L | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Gennatas, K | 1 |
| Cao, W | 1 |
| Yang, W | 1 |
| Lou, G | 1 |
| Jiang, J | 1 |
| Geng, M | 1 |
| Xi, W | 1 |
| Li, H | 1 |
| Jin, Y | 1 |
| Shitara, K | 3 |
| Matsuo, K | 1 |
| Yokota, T | 1 |
| Inaba, Y | 2 |
| Yamaura, H | 1 |
| Najima, M | 1 |
| Ku, GY | 1 |
| Saltz, LB | 4 |
| Schrag, D | 1 |
| Maki, RG | 1 |
| Kelsen, DP | 2 |
| Ilson, DH | 1 |
| Zhao, JG | 2 |
| Xiong, JP | 2 |
| Xiang, XJ | 2 |
| Yu, F | 2 |
| Yan, J | 2 |
| Zhan, ZY | 2 |
| Feng, M | 2 |
| Moore, S | 1 |
| Chen, ML | 1 |
| Fang, CH | 1 |
| Liang, LS | 1 |
| Dai, LH | 1 |
| Wang, XK | 1 |
| Skof, E | 1 |
| Rebersek, M | 1 |
| Hlebanja, Z | 1 |
| Ocvirk, J | 1 |
| Salah-Eldin, MA | 1 |
| Ebrahim, MA | 1 |
| AL-Ashry, MS | 1 |
| Yothers, G | 1 |
| O'Connell, MJ | 1 |
| Sharif, S | 1 |
| Colangelo, LH | 1 |
| Lopa, SH | 1 |
| Petrelli, NJ | 1 |
| Atkins, JN | 1 |
| Seay, TE | 2 |
| Fehrenbacher, L | 2 |
| O'Reilly, S | 2 |
| Chu, L | 1 |
| Azar, CA | 1 |
| Wolmark, N | 1 |
| Kovács, AF | 1 |
| Eberlein, K | 1 |
| Hülsmann, T | 1 |
| Ellis, P | 1 |
| Barrett-Lee, P | 1 |
| Johnson, L | 1 |
| Cameron, D | 1 |
| Wardley, A | 1 |
| Verrill, M | 1 |
| Smith, I | 1 |
| Yarnold, J | 1 |
| Coleman, R | 1 |
| Earl, H | 1 |
| Canney, P | 1 |
| Twelves, C | 5 |
| Poole, C | 1 |
| Bloomfield, D | 1 |
| Hopwood, P | 1 |
| Johnston, S | 1 |
| Dowsett, M | 1 |
| Bartlett, JM | 1 |
| Ellis, I | 1 |
| Peckitt, C | 1 |
| Hall, E | 1 |
| Bliss, JM | 1 |
| Ueda, H | 1 |
| Demizu, M | 1 |
| Oosawa, M | 1 |
| Chihara, S | 1 |
| Nakanishi, Y | 1 |
| Maeda, C | 1 |
| Yano, K | 1 |
| Kimura, F | 1 |
| Iwakawa, S | 1 |
| Zemanova, M | 1 |
| Petruzelka, L | 1 |
| Pazdro, A | 1 |
| Kralova, D | 1 |
| Smejkal, M | 1 |
| Pazdrova, G | 1 |
| Honova, H | 1 |
| Nieto, Y | 1 |
| Aramendía, JM | 2 |
| Espinós, J | 1 |
| De la Cruz, S | 1 |
| Fernández-Hidalgo, O | 2 |
| Santisteban, M | 1 |
| Arbea, L | 1 |
| Aristu, J | 1 |
| Martínez-Monge, R | 2 |
| Moreno, M | 1 |
| Pina, L | 1 |
| Sola, J | 1 |
| Zornoza, G | 1 |
| Regueira, FM | 1 |
| Lorenzen, S | 1 |
| Schuster, T | 1 |
| Hofheinz, R | 1 |
| Thuss-Patience, P | 1 |
| Moehler, M | 1 |
| Grabowski, P | 1 |
| Greten, T | 1 |
| Müller, L | 1 |
| Röthling, N | 1 |
| Peschel, C | 2 |
| Langer, R | 1 |
| Lordick, F | 1 |
| Yan, D | 1 |
| Dai, H | 1 |
| Dong, NN | 1 |
| Wang, MY | 1 |
| Zhang, Q | 1 |
| Liu, ZF | 1 |
| Ozdemir, NY | 1 |
| Abali, H | 1 |
| Oksüzoğlu, B | 1 |
| Budakoglu, B | 3 |
| Güler, T | 1 |
| Odabaşi, H | 1 |
| Zengin, N | 2 |
| Sugimoto, S | 1 |
| Katano, K | 1 |
| Kanazawa, A | 1 |
| Yoshimura, H | 1 |
| Kidani, A | 1 |
| Takeda, H | 1 |
| Makino, M | 1 |
| Ozaki, N | 1 |
| Ikeguchi, M | 1 |
| Jones, A | 1 |
| O'Brien, M | 1 |
| Sommer, H | 1 |
| Nowara, E | 1 |
| Welt, A | 2 |
| Pienkowski, T | 2 |
| Rolski, J | 1 |
| Pham, ML | 1 |
| Perraud, K | 1 |
| Trillet-Lenoir, V | 2 |
| Orphanos, G | 1 |
| Alexopoulos, A | 1 |
| Malliou, S | 1 |
| Ioannidis, G | 1 |
| Ardavanis, A | 3 |
| Kandylis, C | 1 |
| Stavrakakis, J | 1 |
| Rigatos, G | 1 |
| Stec, R | 1 |
| Bodnar, L | 1 |
| Sukhaboon, J | 1 |
| Porapakkhan, P | 1 |
| Penpattanagul, S | 1 |
| Zhang, DS | 1 |
| Feng, F | 1 |
| Xu, RH | 5 |
| Jiang, WQ | 3 |
| He, YJ | 2 |
| Li, M | 1 |
| Wang, D | 2 |
| Zhong, B | 1 |
| Tucker, S | 1 |
| Lu, C | 1 |
| Cheng, J | 2 |
| Cao, C | 1 |
| Xu, J | 2 |
| Pan, H | 1 |
| Kim, BG | 1 |
| Oh, SY | 2 |
| Kwon, HC | 2 |
| Lee, S | 2 |
| Lee, DM | 2 |
| Kim, SG | 1 |
| Kim, DK | 1 |
| Jang, JS | 2 |
| Kim, MC | 2 |
| Kim, SH | 2 |
| Kim, HJ | 2 |
| Yim, KL | 1 |
| Jager, A | 1 |
| Verweij, J | 3 |
| Sleijfer, S | 1 |
| Lu, M | 2 |
| Bae, WK | 1 |
| Hwang, JE | 1 |
| Shim, HJ | 1 |
| Cho, SH | 1 |
| Lee, JK | 1 |
| Lim, SC | 1 |
| Chung, WK | 1 |
| Chung, IJ | 1 |
| Kitada, N | 1 |
| Nishino, M | 1 |
| Yasuda, J | 1 |
| Fujii, C | 1 |
| Minegaki, T | 1 |
| Kondoh, M | 1 |
| Anami, S | 1 |
| Takara, K | 1 |
| Watari, M | 1 |
| Yu, Z | 1 |
| Luo, W | 1 |
| Zhou, QC | 1 |
| Zhang, QH | 1 |
| Kang, DH | 1 |
| Liu, MZ | 1 |
| Mavroudis, D | 5 |
| Papakotoulas, P | 2 |
| Syrigos, K | 3 |
| Kakolyris, S | 6 |
| Ziras, N | 3 |
| Kouroussis, C | 2 |
| Malamos, N | 2 |
| Christophyllakis, C | 1 |
| Kentepozidis, N | 1 |
| Mattioli, R | 1 |
| Gridelli, C | 1 |
| Castellanos, J | 1 |
| Duque, A | 1 |
| Mansutti, M | 3 |
| Bacon, P | 2 |
| Lawrinson, S | 1 |
| Skacel, T | 2 |
| Casas, A | 1 |
| Bin, Q | 1 |
| Liao, C | 1 |
| Cao, Y | 2 |
| Xu, M | 1 |
| Wang, CT | 1 |
| Huang, PY | 1 |
| Lu, X | 1 |
| Zeng, Q | 1 |
| Koukourakis, MI | 1 |
| Giatromanolaki, A | 1 |
| Pitiakoudis, M | 1 |
| Kouklakis, G | 1 |
| Tsoutsou, P | 1 |
| Abatzoglou, I | 1 |
| Panteliadou, M | 1 |
| Sismanidou, K | 1 |
| Sivridis, E | 1 |
| Boulikas, T | 1 |
| Glimelius, B | 3 |
| Garmo, H | 2 |
| Berglund, A | 3 |
| Fredriksson, LA | 1 |
| Berglund, M | 1 |
| Kohnke, H | 1 |
| Byström, P | 2 |
| Sørbye, H | 3 |
| Wadelius, M | 1 |
| Guo, JF | 1 |
| Zhang, B | 1 |
| Wu, F | 2 |
| Wang, B | 1 |
| Xing, H | 1 |
| Zhu, GY | 1 |
| Nie, XY | 1 |
| Peng, J | 1 |
| Bao, HY | 2 |
| Fang, WJ | 1 |
| Zhang, XC | 1 |
| Shi, GM | 1 |
| Huang, S | 1 |
| Yu, LF | 1 |
| Mou, HB | 1 |
| Deng, J | 1 |
| Shen, P | 1 |
| Yao, S | 1 |
| Barlow, WE | 1 |
| Albain, KS | 1 |
| Choi, JY | 1 |
| Zhao, H | 1 |
| Livingston, RB | 1 |
| Davis, W | 1 |
| Rae, JM | 1 |
| Yeh, IT | 1 |
| Hutchins, LF | 1 |
| Ravdin, PM | 1 |
| Martino, S | 1 |
| Lyss, AP | 2 |
| Osborne, CK | 1 |
| Abeloff, MD | 1 |
| Hortobagyi, GN | 5 |
| Hayes, DF | 1 |
| Ambrosone, CB | 1 |
| Qiu, MZ | 1 |
| Li, FH | 1 |
| Zhou, ZW | 1 |
| Chen, XQ | 1 |
| Hecht, JR | 1 |
| Pillai, M | 1 |
| Gollard, R | 1 |
| Heim, W | 1 |
| Swan, F | 1 |
| Patel, R | 1 |
| Dreiling, L | 1 |
| Mo, M | 1 |
| Malik, I | 1 |
| Lu, GC | 1 |
| Fang, F | 1 |
| Li, DC | 1 |
| Taguchi, T | 4 |
| Nakayama, T | 2 |
| Yoshidome, K | 1 |
| Akagi, K | 1 |
| Nishida, Y | 1 |
| Yoshikawa, Y | 1 |
| Ogino, N | 1 |
| Abe, C | 1 |
| Noguchi, S | 3 |
| Kong, L | 1 |
| Zhang, YW | 1 |
| Hu, CS | 1 |
| Guo, Y | 1 |
| Avallone, A | 3 |
| Delrio, P | 1 |
| Pecori, B | 1 |
| Tatangelo, F | 1 |
| Petrillo, A | 1 |
| Scott, N | 1 |
| Marone, P | 1 |
| Aloi, L | 1 |
| Sandomenico, C | 1 |
| Lastoria, S | 1 |
| Iaffaioli, VR | 1 |
| Scala, D | 1 |
| Iodice, G | 1 |
| Budillon, A | 2 |
| Comella, P | 3 |
| Miura, A | 1 |
| Izumi, Y | 1 |
| Ryotokuji, T | 1 |
| Monma, K | 1 |
| Fujiwara, J | 1 |
| Egashira, H | 1 |
| Nemoto, T | 1 |
| Shabaruddin, FH | 1 |
| Elliott, RA | 1 |
| Valle, JW | 1 |
| Newman, WG | 1 |
| Payne, K | 1 |
| Savva-Bordalo, J | 1 |
| Ramalho-Carvalho, J | 1 |
| Pinheiro, M | 1 |
| Costa, VL | 1 |
| Rodrigues, A | 1 |
| Dias, PC | 1 |
| Veiga, I | 1 |
| Machado, M | 1 |
| Teixeira, MR | 1 |
| Henrique, R | 1 |
| Jerónimo, C | 1 |
| Tsuji, Y | 2 |
| Yoshioka, A | 1 |
| Mizuno, T | 1 |
| Kusaba, H | 1 |
| Shimada, Y | 4 |
| Schønnemann, KR | 1 |
| Yilmaz, M | 1 |
| Andersen, M | 1 |
| Pfeiffer, P | 2 |
| Dipetrillo, T | 1 |
| Pricolo, V | 1 |
| Lagares-Garcia, J | 1 |
| Vrees, M | 1 |
| Klipfel, A | 1 |
| Cataldo, T | 1 |
| Sikov, W | 1 |
| McNulty, B | 1 |
| Shipley, J | 1 |
| Anderson, E | 1 |
| Khurshid, H | 1 |
| Oconnor, B | 1 |
| Oldenburg, NB | 1 |
| Radie-Keane, K | 1 |
| Husain, S | 1 |
| Safran, H | 2 |
| Aydoğan, S | 1 |
| Kuştimur, S | 1 |
| Kalkancı, A | 1 |
| Liu, LJ | 1 |
| Zhao, CH | 1 |
| Li, SS | 1 |
| Liu, JZ | 1 |
| Li, ZQ | 1 |
| Gallerani, E | 1 |
| Bauer, J | 1 |
| Hess, D | 1 |
| Boehm, S | 1 |
| Droege, C | 1 |
| Jeckelmann, S | 1 |
| Miani, M | 1 |
| Herrmann, R | 1 |
| Marsoni, S | 1 |
| Sperka, S | 1 |
| Sessa, C | 1 |
| Chilimoniuk, M | 1 |
| Olszewska, E | 1 |
| Maksimowicz, T | 1 |
| Fujikawa, K | 1 |
| Kimura, H | 1 |
| Fujita, K | 2 |
| Sunakawa, Y | 2 |
| Yamashita, K | 2 |
| Kawara, K | 1 |
| Ichikawa, W | 1 |
| Ando, Y | 1 |
| Saji, S | 2 |
| Sasaki, Y | 2 |
| Nishi, T | 1 |
| Warita, E | 1 |
| Miyamoto, J | 1 |
| Akutsu, N | 1 |
| Ch'ang, HJ | 1 |
| Lin, YL | 1 |
| Wang, HP | 1 |
| Chiu, YF | 1 |
| Chang, MC | 1 |
| Hsu, CH | 1 |
| Tien, YW | 1 |
| Chen, JS | 1 |
| Hsieh, RK | 2 |
| Lin, PW | 1 |
| Cheng, AL | 2 |
| Chang, JY | 3 |
| Whang-Peng, J | 2 |
| Hwang, TL | 1 |
| Hara, T | 1 |
| Nishikawa, K | 1 |
| Sakatoku, M | 1 |
| Omura, K | 1 |
| Pichereau, S | 1 |
| Le Louarn, A | 1 |
| Blasco, H | 1 |
| Le Guellec, C | 1 |
| Bourgoin, H | 1 |
| Kourakos, P | 1 |
| Androulakis, N | 4 |
| Kalbakis, K | 2 |
| Vamvakas, L | 1 |
| Reni, M | 1 |
| Cereda, S | 1 |
| Rognone, A | 1 |
| Belli, C | 1 |
| Ghidini, M | 1 |
| Longoni, S | 1 |
| Fugazza, C | 1 |
| Rezzonico, S | 1 |
| Passoni, P | 2 |
| Slim, N | 1 |
| Balzano, G | 1 |
| Nicoletti, R | 1 |
| Cappio, S | 1 |
| Doglioni, C | 1 |
| Villa, E | 2 |
| Blanke, CD | 3 |
| Bot, BM | 1 |
| Thomas, DM | 1 |
| Bleyer, A | 1 |
| Seymour, MT | 1 |
| de Gramont, A | 5 |
| Okishiro, M | 1 |
| Kim, SJ | 2 |
| Tsunashima, R | 1 |
| Shimazu, K | 1 |
| Shimomura, A | 1 |
| Maruyama, N | 1 |
| Tamaki, Y | 2 |
| Ikeda, E | 1 |
| Kaneko, K | 1 |
| Onozawa, M | 1 |
| Nihei, K | 1 |
| Yoshino, T | 2 |
| Zambetti, M | 1 |
| Gomez, P | 1 |
| Lluch, A | 3 |
| Dittrich, C | 1 |
| Zamagni, C | 1 |
| Ciruelos, E | 1 |
| Pavesi, L | 1 |
| Semiglazov, V | 1 |
| De Benedictis, E | 1 |
| Gaion, F | 1 |
| Bari, M | 1 |
| Morandi, P | 1 |
| Valagussa, P | 1 |
| Luca, G | 1 |
| Kambe, M | 1 |
| Kikuchi, H | 1 |
| Gamo, M | 1 |
| Yoshioka, T | 1 |
| Ohashi, Y | 1 |
| Kanamaru, R | 1 |
| De Jesus-Acosta, A | 1 |
| Oliver, GR | 1 |
| Blackford, A | 1 |
| Kinsman, K | 1 |
| Flores, EI | 1 |
| Wilfong, LS | 1 |
| Zheng, L | 1 |
| Donehower, RC | 1 |
| Cosgrove, D | 1 |
| Laheru, D | 1 |
| Le, DT | 1 |
| Chung, K | 1 |
| Diaz, LA | 1 |
| Eropkin, PV | 1 |
| Rybakov, EG | 1 |
| Kashnikov, VN | 1 |
| Panina, MV | 1 |
| Amarantidis, K | 4 |
| Xenidis, N | 3 |
| Chelis, L | 2 |
| Chamalidou, E | 2 |
| Dimopoulos, P | 2 |
| Michailidis, P | 1 |
| Tentes, A | 2 |
| Deftereos, S | 1 |
| Karanikas, M | 1 |
| Karayiannakis, A | 2 |
| Hasegawa, J | 1 |
| Nishimura, J | 1 |
| Hirota, M | 1 |
| Kim, Y | 1 |
| Nezu, R | 1 |
| Satoh, T | 1 |
| Taku, K | 1 |
| Shi, X | 1 |
| Brown, KH | 1 |
| Courcoutsakis, N | 1 |
| Chiotis, A | 1 |
| Prassopoulos, P | 1 |
| Innominato, PF | 1 |
| Giacchetti, S | 1 |
| Moreau, T | 1 |
| Smaaland, R | 1 |
| Bjarnason, GA | 1 |
| Garufi, C | 1 |
| Iacobelli, S | 1 |
| Tampellini, M | 1 |
| Tumolo, S | 1 |
| Huang, CE | 1 |
| Lu, CH | 1 |
| Chen, PT | 1 |
| Chan, CH | 1 |
| Chen, WC | 1 |
| Wang, WH | 1 |
| Wu, JY | 1 |
| Kuan, FC | 1 |
| Lee, KD | 1 |
| Chen, CC | 1 |
| Luo, RC | 1 |
| Ba, Y | 1 |
| Liang, J | 1 |
| He, J | 1 |
| Qi, C | 1 |
| Hayashi, N | 1 |
| Kakeji, Y | 2 |
| Egashira, A | 1 |
| Toyama, T | 1 |
| Ohga, T | 1 |
| Yamamoto, M | 1 |
| Hasegawa, H | 1 |
| Kohakura, F | 1 |
| Niwa, K | 1 |
| Fujita, F | 1 |
| Kohnoe, S | 1 |
| Inomata, M | 1 |
| Mohammadianpanah, M | 1 |
| Ashouri, Y | 1 |
| Hoseini, S | 1 |
| Amadloo, N | 1 |
| Talei, A | 1 |
| Tahmasebi, S | 1 |
| Nasrolahi, H | 1 |
| Mosalaei, A | 1 |
| Omidvari, S | 1 |
| Ansari, M | 1 |
| Mosleh-Shirazi, MA | 1 |
| Su, NW | 1 |
| Leu, YS | 1 |
| Chen, YJ | 1 |
| Chen, HW | 1 |
| Liu, CJ | 1 |
| Chang, YF | 1 |
| Michal, SA | 1 |
| Adelstein, DJ | 1 |
| Rybicki, LA | 1 |
| Rodriguez, CP | 1 |
| Saxton, JP | 1 |
| Wood, BG | 1 |
| Scharpf, J | 1 |
| Ives, DI | 1 |
| Cen, P | 1 |
| Du, XL | 1 |
| Hamano, R | 1 |
| Yamasaki, M | 1 |
| Hou, E | 1 |
| Shiraishi, O | 1 |
| Mori, M | 2 |
| Doki, Y | 1 |
| Kadoyama, K | 1 |
| Miki, I | 1 |
| Brown, JB | 1 |
| Sakaeda, T | 1 |
| Okuno, Y | 1 |
| Cho, YH | 1 |
| Hong Lee, M | 1 |
| Yoo, MW | 1 |
| Bang, HY | 1 |
| Lee, KY | 1 |
| Yoon, SY | 1 |
| Younis, T | 1 |
| Rayson, D | 1 |
| Thompson, K | 1 |
| Pericay, C | 1 |
| Valladares-Ayerbes, M | 1 |
| Gil-Calle, S | 2 |
| Massutí, B | 1 |
| González-Flores, E | 1 |
| Cabrera, E | 1 |
| Queralt, B | 1 |
| Gómez, MJ | 1 |
| Guasch, I | 1 |
| Etxeberría, A | 1 |
| Alfaro, J | 1 |
| Campos, JM | 1 |
| Reina, JJ | 1 |
| Leong, S | 1 |
| Eckhardt, SG | 3 |
| Chan, E | 1 |
| Messersmith, WA | 1 |
| Spratlin, J | 1 |
| Camidge, DR | 1 |
| Diab, S | 1 |
| Lin, X | 2 |
| Chow Maneval, E | 1 |
| Kato, Y | 1 |
| Karachaliou, N | 1 |
| Tryfonidis, K | 1 |
| Papadimitraki, E | 1 |
| Kontopodis, E | 1 |
| Bozionelou, V | 1 |
| Kalykaki, A | 1 |
| Huang, H | 2 |
| Jiang, Z | 1 |
| Bian, L | 1 |
| Wu, S | 2 |
| Song, S | 1 |
| Zarogoulidis, P | 1 |
| Chatzaki, E | 2 |
| Hohenforst-Schmidt, W | 1 |
| Goldberg, EP | 1 |
| Galaktidou, G | 1 |
| Kontakiotis, T | 1 |
| Karamanos, N | 1 |
| Zarogoulidis, K | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 2 |
| Kim, TY | 2 |
| Bang, YJ | 1 |
| Tsutsumi, S | 1 |
| Ishibashi, K | 1 |
| Uchida, N | 1 |
| Yashuda, N | 1 |
| Kigure, W | 1 |
| Yamauchi, S | 1 |
| Asao, T | 1 |
| Qi, WX | 1 |
| Tang, LN | 1 |
| He, AN | 1 |
| Shen, Z | 1 |
| Yao, Y | 1 |
| Kucukzeybek, Y | 1 |
| Dirican, A | 1 |
| Erten, C | 1 |
| Somali, I | 1 |
| Can, A | 1 |
| Demir, L | 1 |
| Bayoglu, IV | 1 |
| Akyol, M | 1 |
| Medeni, M | 1 |
| Tarhan, MO | 1 |
| Peddi, PF | 1 |
| Lubner, S | 1 |
| McWilliams, R | 1 |
| Picus, J | 1 |
| Sorscher, SM | 1 |
| Wang, J | 1 |
| Menias, C | 1 |
| Linehan, D | 1 |
| Kaya, AO | 1 |
| Gumus, M | 1 |
| Dane, F | 2 |
| Isıkdogan, A | 2 |
| Alkis, N | 2 |
| Yumuk, F | 1 |
| Bilici, A | 1 |
| Inal, A | 2 |
| Arpacı, E | 1 |
| Lee, SS | 1 |
| Lee, JL | 1 |
| Kang, YK | 4 |
| Jung, KH | 1 |
| Phua, CE | 1 |
| Bustam, AZ | 1 |
| Yusof, MM | 1 |
| Saad, M | 1 |
| Yip, CH | 1 |
| Taib, NA | 1 |
| Ng, CH | 1 |
| Teh, YC | 1 |
| Northfelt, DW | 1 |
| Allred, JB | 1 |
| Liu, H | 1 |
| Hobday, TJ | 1 |
| Rodacker, MW | 1 |
| Fitch, TR | 1 |
| Perez, EA | 1 |
| Francois, E | 4 |
| Bennouna, J | 2 |
| Chamorey, E | 1 |
| Etienne-Grimaldi, MC | 2 |
| Renée, N | 2 |
| Senellart, H | 1 |
| Michel, C | 1 |
| Follana, P | 1 |
| Mari, V | 1 |
| Péron, J | 1 |
| Derbel, O | 1 |
| Penet, AS | 1 |
| Stella, M | 1 |
| Méeus, P | 1 |
| Orlandini, F | 1 |
| Pérol, M | 1 |
| Chen, MY | 1 |
| Luo, JC | 1 |
| Wei, L | 1 |
| Adenis, A | 2 |
| Pignon, JP | 1 |
| Chauffert, B | 2 |
| Ichanté, JL | 1 |
| Boucher, E | 1 |
| Ychou, M | 3 |
| Pierga, JY | 2 |
| Montoto-Grillot, C | 1 |
| Conroy, T | 2 |
| Swieboda-Sadlej, A | 1 |
| Staszewska-Skurczynska, M | 1 |
| Lim, R | 2 |
| Roman, L | 1 |
| Shparyk, Y | 1 |
| Bondarenko, I | 1 |
| Jonker, DJ | 1 |
| De la Cruz, JA | 1 |
| Williams, JA | 1 |
| Korytowsky, B | 1 |
| Christensen, JG | 1 |
| Tursi, JM | 1 |
| Lechuga, MJ | 1 |
| Lévesque, E | 1 |
| Bélanger, AS | 1 |
| Harvey, M | 1 |
| Couture, F | 1 |
| Jonker, D | 1 |
| Innocenti, F | 2 |
| Cecchin, E | 1 |
| Toffoli, G | 1 |
| Guillemette, C | 1 |
| Nishimaki, T | 1 |
| Natsugoe, S | 1 |
| Aksoy, S | 1 |
| Çetin, B | 1 |
| Yetişyiğit, T | 1 |
| Özdemir, N | 1 |
| Harputluoğlu, H | 1 |
| Koca, D | 1 |
| Cihan, S | 1 |
| Durnalı, AG | 1 |
| Öztürk, MA | 1 |
| Köş, T | 1 |
| Karaca, H | 1 |
| Turhal, NS | 1 |
| Tsukuda, M | 2 |
| Mitry, E | 2 |
| Artru, P | 2 |
| Ezenfis, J | 1 |
| Clavero-Fabri, MC | 1 |
| Vaillant, JN | 1 |
| Rougier, P | 7 |
| Van Kuilenburg, AB | 1 |
| Meinsma, R | 1 |
| Zoetekouw, L | 1 |
| Van Gennip, AH | 1 |
| Orecchia, R | 1 |
| Jereczek-Fossa, BA | 1 |
| Catalano, G | 3 |
| Chiesa, F | 1 |
| De Pas, T | 1 |
| Masci, G | 1 |
| Krengli, M | 1 |
| Vavassori, A | 1 |
| De Paoli, F | 1 |
| Robertson, C | 1 |
| Marrocco, E | 1 |
| De Braud, F | 3 |
| DePas, T | 1 |
| Francini, G | 1 |
| Petrioli, R | 1 |
| Messinese, S | 1 |
| Pozzessere, D | 1 |
| Marsili, S | 1 |
| Correale, P | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Lepille, D | 1 |
| Marre, A | 1 |
| Mignot, L | 1 |
| Hua, A | 1 |
| Méry-Mignard, D | 2 |
| Rothenberg, ML | 5 |
| Benedetti, JK | 1 |
| Macdonald, JS | 2 |
| Neubauer, MA | 1 |
| George, CS | 1 |
| Tanaka, MS | 1 |
| Giguere, JK | 1 |
| Pruitt, BT | 1 |
| Abbruzzese, JL | 1 |
| Kaufmann, SH | 1 |
| Atherton, P | 2 |
| Sloan, JA | 2 |
| Adjei, AA | 2 |
| Pitot, HC | 1 |
| Rubin, J | 2 |
| Miller, LL | 4 |
| Erlichman, C | 3 |
| Garcia-Arroyo, R | 1 |
| Lorenzo, I | 1 |
| Carrete, N | 1 |
| Campos, B | 1 |
| Palacios, P | 1 |
| Liu, TW | 2 |
| Wu, CW | 1 |
| Chung, TR | 1 |
| Shiah, HS | 1 |
| Jan, CM | 1 |
| Liu, JM | 1 |
| Caponigro, F | 2 |
| Rosati, G | 2 |
| De Rosa, P | 1 |
| De Rosa, V | 2 |
| De Lucia, L | 1 |
| Comella, G | 4 |
| Calvo, E | 1 |
| González-Cao, M | 1 |
| Rodríguez, J | 1 |
| Martín-Algarra, S | 1 |
| Salgado, JE | 1 |
| de Irala, J | 1 |
| Brugarolas, A | 1 |
| Bonneterre, J | 2 |
| Roché, H | 2 |
| Monnier, A | 1 |
| Guastalla, JP | 1 |
| Namer, M | 5 |
| Fargeot, P | 3 |
| Assadourian, S | 1 |
| Gowda, RV | 1 |
| Stout, R | 1 |
| Bocci, G | 1 |
| Danesi, R | 1 |
| Allegrini, G | 1 |
| Di Paolo, A | 1 |
| Conte, PF | 1 |
| Del Tacca, M | 1 |
| Pectasides, D | 1 |
| Pectasides, M | 1 |
| Farmakis, D | 1 |
| Bountouroglou, N | 1 |
| Nikolaou, M | 1 |
| Koumpou, M | 1 |
| Mylonakis, N | 1 |
| Kosmas, C | 1 |
| Vermes, A | 1 |
| Kuijper, EJ | 1 |
| Dankert, J | 1 |
| Kelleher, M | 1 |
| Tebbutt, NC | 1 |
| Andreyev, J | 1 |
| Allen, M | 1 |
| Hill, M | 2 |
| Norman, A | 2 |
| Chang, HM | 3 |
| Lee, JR | 1 |
| Ryu, MH | 1 |
| Ahn, JH | 1 |
| Lee, JS | 3 |
| Bouzid, K | 1 |
| Khalfallah, S | 1 |
| Tujakowski, J | 2 |
| Piko, B | 1 |
| Purkalne, G | 1 |
| Plate, S | 1 |
| Padrik, P | 1 |
| Serafy, M | 1 |
| Pshevloutsky, EM | 1 |
| Boussard, B | 1 |
| Fleming, GF | 1 |
| Schilsky, RL | 3 |
| Schumm, LP | 1 |
| Meyerson, A | 1 |
| Hong, AM | 1 |
| Vogelzang, NJ | 4 |
| Ratain, MJ | 4 |
| Cassinello, J | 1 |
| Escudero, P | 1 |
| Salud, A | 1 |
| Marcos, F | 1 |
| Pujol, E | 1 |
| Pérez-Carrión, R | 1 |
| Colmenarejo, A | 1 |
| González del Val, R | 1 |
| Valero, J | 1 |
| Oruezábal, MJ | 1 |
| Guillem, V | 1 |
| García, I | 1 |
| Arcediano, A | 1 |
| Marfà, X | 1 |
| Goetz, MP | 1 |
| Windebank, AJ | 1 |
| Reid, JM | 1 |
| Pitot, H | 1 |
| Galanis, E | 1 |
| Ames, MM | 1 |
| Zelek, L | 2 |
| Bugat, R | 4 |
| Cherqui, D | 1 |
| Ganem, G | 2 |
| Valleur, P | 1 |
| Dupuis, O | 1 |
| Aziza, T | 1 |
| Fagniez, PL | 1 |
| Auroux, J | 1 |
| Kobeiter, H | 1 |
| Tayar, C | 1 |
| Braud, AC | 1 |
| Haddad, E | 1 |
| Piolot, A | 1 |
| Buyse, M | 1 |
| Piedbois, P | 1 |
| Djazayeri, K | 1 |
| Abrahám, C | 1 |
| Zsuga, J | 1 |
| Szilvássy, Z | 1 |
| Han, JY | 1 |
| Lee, DH | 1 |
| Kim, HY | 1 |
| Hong, EK | 1 |
| Yoon, SM | 1 |
| Chun, JH | 1 |
| Lee, HG | 1 |
| Lee, SY | 1 |
| Shin, EH | 1 |
| Cameron, DA | 2 |
| Massie, C | 1 |
| Kerr, G | 1 |
| Leonard, RC | 1 |
| Scheithauer, W | 4 |
| McKendrick, J | 1 |
| Begbie, S | 1 |
| Borner, M | 1 |
| Burns, WI | 1 |
| Burris, HA | 3 |
| Jodrell, D | 2 |
| Levine, EL | 1 |
| Marschner, N | 1 |
| Maroun, J | 1 |
| Van Hazel, G | 1 |
| Wong, A | 2 |
| Antón, A | 3 |
| Cervantes, A | 3 |
| Abad, A | 1 |
| Fenández-Martos, C | 1 |
| Gallén, M | 1 |
| Huarte, L | 1 |
| Balcells, M | 2 |
| Fokstuen, T | 1 |
| Tveit, KM | 1 |
| Braendengen, M | 1 |
| Øgreid, D | 1 |
| Dahl, O | 1 |
| Kalofonos, HP | 1 |
| Skarlos, D | 1 |
| Bafaloukos, D | 1 |
| Papakostas, P | 1 |
| Bamias, A | 1 |
| Janinis, J | 2 |
| Timotheadou, E | 1 |
| Kouvatseas, G | 1 |
| Stavropoulos, M | 1 |
| Economopulos, T | 1 |
| Fountzilas, G | 2 |
| Stathopoulos, GP | 2 |
| Rigatos, SK | 2 |
| Potamiannou, A | 1 |
| Tsiakopoulos, I | 1 |
| Aravantinos, G | 1 |
| Park, YH | 2 |
| Ryoo, BY | 2 |
| Choi, SJ | 2 |
| Kim, HT | 1 |
| Ghi, MG | 1 |
| Paccagnella, A | 1 |
| D'Amanzo, P | 1 |
| Mione, CA | 1 |
| Fasan, S | 1 |
| Paro, S | 1 |
| Mastromauro, C | 1 |
| Carnuccio, R | 1 |
| Turcato, G | 1 |
| Gatti, C | 1 |
| Pallini, A | 1 |
| Nascimben, O | 1 |
| Biason, R | 1 |
| Oniga, F | 1 |
| Medici, M | 1 |
| Rossi, F | 1 |
| Fila, G | 1 |
| Humphreys, AC | 1 |
| Dent, J | 1 |
| Rodwell, S | 1 |
| Crawford, SM | 1 |
| Joffe, JK | 2 |
| Bradley, C | 2 |
| Dodwell, D | 1 |
| Perren, TJ | 2 |
| Hussain, SA | 1 |
| Stocken, DD | 1 |
| Peake, DR | 1 |
| Glaholm, JG | 1 |
| Zarkar, A | 1 |
| Wallace, DM | 1 |
| James, ND | 1 |
| Cals, L | 1 |
| Rixe, O | 1 |
| Favre, R | 1 |
| Merad, L | 1 |
| Deplanque, G | 1 |
| Laadem, A | 1 |
| Juin, P | 1 |
| Bereder, JM | 1 |
| Bernardini, D | 1 |
| Herait, P | 3 |
| Samonis, G | 2 |
| Vardakis, N | 2 |
| Agelaki, S | 2 |
| Chao, Y | 1 |
| Yeh, KH | 1 |
| Chang, CJ | 1 |
| Chao, TY | 1 |
| Wu, MF | 1 |
| Chang, CS | 1 |
| Chung, CY | 1 |
| Kao, WY | 1 |
| Carlo, WF | 1 |
| Hummer, AJ | 1 |
| Schwartz, L | 1 |
| Sullivan, D | 1 |
| Gonen, M | 1 |
| Jarnagin, W | 1 |
| Fong, Y | 1 |
| Kemeny, N | 2 |
| Lu, JW | 1 |
| Gao, CM | 1 |
| Wu, JZ | 1 |
| Sun, XF | 1 |
| Feng, JF | 1 |
| Jimeno, A | 1 |
| Millán, JM | 1 |
| Castellano, D | 1 |
| Cortés-Funes, H | 5 |
| Marsé, H | 1 |
| Valverde, S | 1 |
| Hirao, M | 3 |
| Tsujinaka, T | 3 |
| Cobo, M | 1 |
| Muñoz-Martín, A | 1 |
| Carabantes, F | 1 |
| Villar, E | 1 |
| Graupera, J | 1 |
| Pérez-Manga, G | 1 |
| Lebowitz, PF | 1 |
| Eng-Wong, J | 1 |
| Swain, SM | 1 |
| Berman, A | 1 |
| Merino, MJ | 1 |
| Chow, CK | 1 |
| Venzon, D | 2 |
| Zia, F | 1 |
| Danforth, D | 3 |
| Liu, E | 1 |
| Zujewski, J | 2 |
| Waters, JS | 2 |
| Moss, C | 1 |
| Pyle, L | 1 |
| James, M | 1 |
| Hackett, S | 1 |
| A'hern, R | 1 |
| Gore, M | 1 |
| Eisen, T | 1 |
| Mouret-Reynier, MA | 1 |
| Abrial, CJ | 1 |
| Ferrière, JP | 2 |
| Amat, S | 1 |
| Curé, HD | 1 |
| Kwiatkowski, FG | 1 |
| Feillel, VA | 1 |
| Lebouëdec, G | 1 |
| Penault-Llorca, FM | 1 |
| Chollet, PJ | 1 |
| Arai, T | 2 |
| Barone, C | 2 |
| Szanto, J | 1 |
| Padi, E | 1 |
| Bükki, J | 1 |
| Gorbunova, V | 1 |
| Valvere, V | 1 |
| Biakhov, M | 1 |
| Zuber, E | 1 |
| Jacques, C | 1 |
| Fumoleau, P | 4 |
| Brewer, Y | 1 |
| Martin, D | 1 |
| Turpin, FL | 1 |
| Goudier, MJ | 1 |
| Gil-Delgado, M | 1 |
| Baticle, JL | 1 |
| Chollet, P | 3 |
| Sutherland, W | 1 |
| Barats, JC | 1 |
| BitMansour, A | 1 |
| Cao, TM | 1 |
| Chao, S | 1 |
| Shashidhar, S | 1 |
| Brown, JM | 1 |
| Ernst-Stecken, A | 1 |
| Grabenbauer, G | 1 |
| Iro, H | 1 |
| Plasswilm, L | 1 |
| Sauer, R | 1 |
| Schena, M | 1 |
| Birocco, N | 1 |
| Dongiovanni, D | 1 |
| Numico, G | 1 |
| Colantonio, I | 1 |
| Bertetto, O | 1 |
| von Minckwitz, G | 2 |
| Blohmer, JU | 1 |
| Raab, G | 1 |
| Löhr, A | 1 |
| Gerber, B | 1 |
| Heinrich, G | 1 |
| Eidtmann, H | 1 |
| Kaufmann, M | 2 |
| Hilfrich, J | 1 |
| Jackisch, C | 1 |
| Zuna, I | 1 |
| Costa, SD | 1 |
| Oberhoff, C | 1 |
| Borquez, D | 1 |
| Schleucher, R | 1 |
| Loibl, S | 1 |
| Harstrick, A | 2 |
| Seeber, S | 3 |
| Vanhoefer, U | 1 |
| Carlini, LE | 1 |
| Meropol, NJ | 1 |
| Bever, J | 1 |
| Andria, ML | 1 |
| Hill, T | 1 |
| Gold, P | 1 |
| Rogatko, A | 2 |
| Wang, H | 1 |
| Blanchard, RL | 1 |
| Cantore, M | 1 |
| Mambrini, A | 1 |
| Fiorentini, G | 1 |
| Rabbi, C | 1 |
| Zamagni, D | 1 |
| Caudana, R | 1 |
| Pennucci, C | 1 |
| Sanguinetti, F | 1 |
| Lombardi, M | 1 |
| Nicoli, N | 1 |
| Mei, JF | 1 |
| Chen, YX | 1 |
| Shao, ZJ | 1 |
| He, ZM | 1 |
| Magné, N | 2 |
| Touati, L | 1 |
| Marcy, PY | 2 |
| Van Houtte, P | 1 |
| Lagrange, JL | 2 |
| Paz-Ares, L | 2 |
| Carcas, A | 1 |
| Alfonso, R | 1 |
| Frías, J | 1 |
| Guerra, P | 1 |
| Pronk, L | 1 |
| Orditura, M | 1 |
| Bianco, R | 1 |
| Infusino, S | 1 |
| Damiano, V | 1 |
| Simeone, E | 1 |
| Diadema, MR | 1 |
| Lieto, E | 1 |
| Castellano, P | 1 |
| Pepe, S | 1 |
| Galizia, G | 1 |
| Di Martino, N | 1 |
| Ciardiello, F | 1 |
| Bianco, AR | 1 |
| Veronese, ML | 1 |
| Sun, W | 1 |
| Giantonio, B | 1 |
| Berlin, J | 2 |
| Shults, J | 1 |
| Davis, L | 1 |
| Haller, DG | 3 |
| Ryu, BY | 1 |
| Kim, WK | 1 |
| Wright, MA | 1 |
| Morrison, G | 1 |
| Lin, P | 1 |
| Leonard, GD | 1 |
| Nguyen, D | 1 |
| Szabo, E | 1 |
| Hopkins, JL | 1 |
| Leguizamo, JP | 1 |
| Harold, N | 1 |
| Fioravanti, S | 1 |
| Schuler, B | 1 |
| Monahan, BP | 1 |
| Quinn, MG | 1 |
| Pang, J | 1 |
| Grem, JL | 1 |
| Kondo, K | 1 |
| Kojima, H | 1 |
| Hirabayashi, N | 1 |
| Kataoka, M | 1 |
| Matsui, T | 1 |
| Takiyama, W | 1 |
| Miyashita, Y | 1 |
| Nakazato, H | 1 |
| Nakao, A | 1 |
| Tsai, JY | 1 |
| Iannitti, D | 1 |
| Berkenblit, A | 1 |
| Akerman, P | 1 |
| Nadeem, A | 1 |
| Rathore, R | 1 |
| Harrington, D | 1 |
| Roye, D | 1 |
| Miner, T | 1 |
| Barnett, JM | 1 |
| Maia, C | 1 |
| Stuart, K | 2 |
| Kang, WK | 2 |
| Park, JO | 1 |
| Ahn, JS | 1 |
| Zang, DY | 1 |
| Kim, SR | 1 |
| Kim, HK | 1 |
| Prévost, A | 1 |
| Mérol, JC | 1 |
| Aimé, P | 1 |
| Moutel, K | 1 |
| Roger-Liautaud, F | 1 |
| Nasca, S | 1 |
| Legros, M | 1 |
| Coninx, P | 1 |
| Ho, WM | 1 |
| Ma, B | 1 |
| Mok, T | 1 |
| Yeo, W | 1 |
| Lai, P | 1 |
| Koh, J | 1 |
| Wong, YY | 1 |
| King, A | 1 |
| Leow, CK | 1 |
| Chan, AT | 1 |
| Fakih, MG | 1 |
| Creaven, PJ | 1 |
| Ramnath, N | 1 |
| Trump, D | 1 |
| Javle, M | 1 |
| Strychor, S | 1 |
| Repinski, TV | 1 |
| Zamboni, BA | 1 |
| Schwarz, JK | 1 |
| French, RA | 1 |
| Zamboni, WC | 1 |
| Ahluwalia, MS | 1 |
| Daw, HA | 1 |
| Noronha, V | 1 |
| Lee, KE | 1 |
| Im, YH | 1 |
| Park, K | 1 |
| Kim, K | 1 |
| Shim, YM | 1 |
| Ito, S | 1 |
| Kodera, Y | 1 |
| Mochizuki, Y | 1 |
| Yamamura, Y | 1 |
| López-Pousa, A | 1 |
| Martínez-Trufero, J | 1 |
| Escrig, V | 1 |
| Carles, J | 1 |
| Rizo, A | 1 |
| Isla, D | 2 |
| Vega, ME | 1 |
| Martí, JL | 1 |
| Lobo, F | 1 |
| Pastor, P | 1 |
| Valentí, V | 1 |
| Belón, J | 1 |
| Sánchez, MA | 1 |
| Chaib, C | 1 |
| Pallarés, C | 1 |
| Ferrari, V | 1 |
| Valcamonico, F | 1 |
| Amoroso, V | 1 |
| Simoncini, E | 1 |
| Vassalli, L | 1 |
| Marpicati, P | 1 |
| Rangoni, G | 1 |
| Grisanti, S | 1 |
| Pasinetti, N | 1 |
| Marini, G | 2 |
| Miyoshi, Y | 1 |
| Tanji, Y | 1 |
| Mackay, HJ | 1 |
| Billingsley, K | 1 |
| Gallinger, S | 1 |
| Berry, S | 1 |
| Smith, A | 1 |
| Yeung, R | 1 |
| Pond, GR | 1 |
| Croitoru, M | 1 |
| Swanson, PE | 1 |
| Krishnamurthi, S | 1 |
| Siu, LL | 1 |
| Stathopoulos, JG | 1 |
| Xynotroulas, JP | 1 |
| Dimou, E | 1 |
| Kohno, N | 1 |
| Levy, C | 1 |
| Santasusana, JM | 1 |
| García López, JL | 1 |
| García, JJ | 1 |
| Carbonero, AI | 1 |
| Plazas, JG | 1 |
| Rovira, PS | 1 |
| Guzmán, MC | 1 |
| Jericó, JF | 1 |
| Delgado, FJ | 1 |
| Espinosa, JC | 1 |
| Muñoz, ML | 1 |
| Aguilar, EA | 1 |
| Valera, JS | 1 |
| García Ribas, I | 1 |
| Mena, AC | 1 |
| Maltezos, E | 1 |
| Trichas, M | 1 |
| Vasiliadis, M | 1 |
| Toromanidou, M | 1 |
| Tsaroucha, A | 1 |
| Romanidis, K | 1 |
| Tagaya, N | 1 |
| Nakagawa, A | 1 |
| Mori, S | 1 |
| Hamada, K | 1 |
| Kubota, K | 1 |
| Martinez, J | 1 |
| Martin, C | 1 |
| Chacon, M | 1 |
| Korbenfeld, E | 1 |
| Bella, S | 1 |
| Senna, S | 1 |
| Richardet, E | 1 |
| Coppola, F | 1 |
| Bas, C | 1 |
| Hidalgo, J | 1 |
| Escobar, E | 1 |
| Reale, M | 1 |
| Smilovich, AM | 1 |
| Wasserman, E | 2 |
| Okamoto, T | 1 |
| Araki, H | 1 |
| Iyama, S | 1 |
| Abe, S | 1 |
| Murase, K | 1 |
| Nagakura, H | 1 |
| Hareyama, M | 1 |
| Niitsu, Y | 1 |
| Cho, BC | 1 |
| Kim, CB | 1 |
| Sohn, JH | 1 |
| Choi, HJ | 1 |
| Lee, YC | 1 |
| Felici, A | 1 |
| Loos, WJ | 1 |
| Cirillo, I | 1 |
| de Bruijn, P | 1 |
| Nooter, K | 1 |
| Mathijssen, RH | 1 |
| de Jonge, MJ | 1 |
| Park, JH | 1 |
| Lee, EH | 1 |
| Kim, MJ | 1 |
| Park, SK | 1 |
| Heo, SK | 1 |
| Kim, BS | 1 |
| Min, YJ | 1 |
| Ryan, DP | 1 |
| Niedzwiecki, D | 1 |
| Hollis, D | 1 |
| Mediema, BE | 1 |
| Wadler, S | 1 |
| Tepper, JE | 1 |
| Mayer, RJ | 2 |
| Mera, K | 1 |
| Tanigawara, Y | 1 |
| Martín, M | 1 |
| Seguí, MA | 1 |
| Ruiz, A | 1 |
| Ramos, M | 1 |
| Adrover, E | 1 |
| Rodríguez-Lescure, A | 1 |
| Grosse, R | 1 |
| Calvo, L | 1 |
| Fernandez-Chacón, C | 1 |
| Roset, M | 1 |
| del Prado, PM | 1 |
| Iglesias, L | 1 |
| Arcusa, A | 1 |
| López-Vega, JM | 1 |
| Muñoz, M | 1 |
| Mel, JR | 1 |
| Ikenaga, M | 1 |
| Kashiwazaki, M | 1 |
| Miyazaki, M | 1 |
| Nakamori, S | 2 |
| Ueda, M | 1 |
| Endo, I | 1 |
| Fujii, Y | 1 |
| Miura, Y | 1 |
| Kubota, T | 1 |
| Ichikawa, Y | 1 |
| Togo, S | 1 |
| Shimada, H | 1 |
| Tsujie, M | 1 |
| Tanaka, E | 1 |
| Umeshita, K | 1 |
| Dono, K | 1 |
| Sakon, M | 1 |
| Inoue, T | 2 |
| Monden, M | 1 |
| Eguchi, T | 1 |
| Demizu, Y | 1 |
| Sasaki, R | 1 |
| Soejima, T | 1 |
| Maruta, T | 1 |
| Okamoto, Y | 1 |
| Yamada, K | 1 |
| Yoden, E | 1 |
| Ejima, Y | 1 |
| Nibu, K | 1 |
| Katori, H | 1 |
| Fortner, BV | 1 |
| Houts, AC | 1 |
| Schwartzberg, LS | 1 |
| Shi, YX | 2 |
| Ma, ZY | 1 |
| Wang, JH | 1 |
| Hu, XH | 1 |
| Xie, WM | 1 |
| Li, XG | 1 |
| Liu, YL | 1 |
| Dai, AD | 1 |
| Zhuang, W | 1 |
| Zhang, C | 1 |
| Goel, S | 1 |
| Desai, K | 1 |
| Karri, S | 1 |
| Gollamudi, R | 1 |
| Chaudhary, I | 1 |
| Bulgaru, A | 1 |
| Kaubisch, A | 1 |
| Goldberg, G | 1 |
| Einstein, M | 1 |
| Camacho, F | 1 |
| Baker, S | 1 |
| Mani, S | 3 |
| Munakata, M | 2 |
| Kudo, T | 1 |
| Kasai, M | 2 |
| Muto, O | 2 |
| Okada, R | 2 |
| Mitobe, S | 2 |
| Ishiguro, A | 1 |
| Sakuraba, H | 1 |
| Ikami, I | 1 |
| Sakata, Y | 2 |
| Iwabuchi, H | 1 |
| Tanaka, S | 1 |
| Tsushima, T | 1 |
| Ohura, K | 1 |
| Sumiyoshi, T | 1 |
| Yoshizaki, N | 1 |
| Kondo, H | 1 |
| Romieu, G | 1 |
| Clemens, M | 1 |
| Mahlberg, R | 1 |
| Schütte, M | 1 |
| Easton, V | 1 |
| Brugger, W | 1 |
| Zhang, W | 1 |
| Zhao, ZY | 1 |
| Wu, Q | 1 |
| Wu, CP | 1 |
| Xu, LG | 1 |
| Kameda, A | 1 |
| Tsutani, Y | 1 |
| Miyahara, E | 1 |
| Noso, Y | 1 |
| Park, JY | 1 |
| Ahn, SH | 1 |
| Yoon, YJ | 1 |
| Kim, JK | 1 |
| Lee, HW | 1 |
| Lee, DY | 1 |
| Chon, CY | 1 |
| Moon, YM | 1 |
| Han, KH | 1 |
| Zampino, MG | 1 |
| Magni, E | 1 |
| Massacesi, C | 1 |
| Martignetti, A | 1 |
| Zorzino, L | 1 |
| Lorizzo, K | 1 |
| Santoro, L | 1 |
| Boselli, S | 1 |
| Schneider, BJ | 1 |
| El-Rayes, B | 1 |
| Muler, JH | 1 |
| Philip, PA | 1 |
| Kalemkerian, GP | 1 |
| Favier, L | 1 |
| Isambert, N | 1 |
| Zanetta, S | 1 |
| Ferrant, E | 1 |
| Mayer, F | 1 |
| Garnier, J | 1 |
| Biville, F | 1 |
| Coudert, B | 2 |
| Onozawa, Y | 1 |
| Yamaguchi, Y | 1 |
| Hasuike, N | 1 |
| Machida, N | 1 |
| Ono, H | 1 |
| Zhou, YD | 1 |
| Huan, HY | 1 |
| Mao, F | 1 |
| Guan, JH | 1 |
| Zhang, HG | 1 |
| Cai, RG | 1 |
| Chen, SS | 1 |
| Chu, DT | 1 |
| Miyazaki, A | 1 |
| Kobayashi, J | 1 |
| Kido, Y | 1 |
| Takemura, K | 1 |
| Abe, M | 1 |
| Tomihara, K | 1 |
| Dehari, H | 1 |
| Nakamori, K | 1 |
| Nagai, I | 1 |
| Hiratsuka, H | 1 |
| Zandvliet, AS | 1 |
| Siegel-Lakhai, WS | 1 |
| Beijnen, JH | 1 |
| Copalu, W | 1 |
| Schellens, JH | 1 |
| Huitema, AD | 1 |
| Katia, D | 1 |
| Zilembo, N | 1 |
| Bochicchio, AM | 1 |
| Ardizzoia, A | 1 |
| Ardizzoni, A | 1 |
| Aitini, E | 1 |
| Schieppati, G | 1 |
| Pinotti, G | 1 |
| Palazzo, S | 1 |
| Cicero, G | 1 |
| Fagnani, D | 1 |
| Reguzzoni, G | 1 |
| Agostana, B | 1 |
| Oliani, C | 1 |
| Kildani, B | 1 |
| Duro, M | 1 |
| Botta, M | 1 |
| Mozzana, R | 1 |
| Mantovani, G | 1 |
| Torres, MA | 1 |
| Jhingran, A | 1 |
| Thames, HD | 1 |
| Levenback, CF | 1 |
| Bodurka, DC | 1 |
| Ramondetta, LM | 1 |
| Eifel, PJ | 1 |
| Mell, LK | 1 |
| Schomas, DA | 1 |
| Salama, JK | 1 |
| Devisetty, K | 1 |
| Aydogan, B | 1 |
| Miller, RC | 1 |
| Jani, AB | 1 |
| Kindler, HL | 3 |
| Mundt, AJ | 1 |
| Roeske, JC | 1 |
| Chmura, SJ | 1 |
| Balteskard, L | 1 |
| Tveit, K | 1 |
| Heikkilä, R | 1 |
| Keldsen, N | 1 |
| Albertsson, M | 1 |
| Starkhammar, H | 1 |
| Yoo, HS | 1 |
| Jeong, JS | 1 |
| Wolowacz, SE | 1 |
| Tate, HC | 1 |
| Bagust, A | 1 |
| Hui, R | 1 |
| Zhang, M | 1 |
| Hao, XM | 1 |
| Clarke, SJ | 1 |
| Hoff, PM | 1 |
| Allegra, C | 1 |
| Bertino, JR | 1 |
| Gustavsson, BG | 1 |
| O'Connell, M | 1 |
| Rustum, Y | 1 |
| Gilberg, F | 1 |
| Sirzén, F | 1 |
| Meadows, H | 1 |
| Wan, S | 1 |
| Gollins, S | 1 |
| Leslie, M | 1 |
| Levine, E | 1 |
| McDonald, AC | 1 |
| Myint, S | 1 |
| Sebag-Montefiore, D | 1 |
| Wang, JW | 1 |
| Zhang, JS | 1 |
| Song, ST | 1 |
| Yang, L | 1 |
| Li, F | 1 |
| Bedikian, AY | 2 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Bodey, GP | 2 |
| Aboud, A | 1 |
| Buzdar, AU | 4 |
| Yap, HY | 1 |
| Blumenschein, GR | 1 |
| Shildt, RA | 1 |
| Kennedy, PS | 1 |
| Chen, TT | 1 |
| Athens, JW | 1 |
| O'Bryan, RM | 1 |
| Balcerzak, SP | 1 |
| Jacobs, C | 1 |
| Bancewicz, J | 1 |
| Calman, KC | 1 |
| Macpherson, SG | 1 |
| McArdle, CS | 1 |
| McVie, JG | 1 |
| Soukop, M | 2 |
| Stroehlein, JR | 1 |
| Karlin, DA | 1 |
| Valdivieso, M | 1 |
| Bennetts, RW | 1 |
| Campbell, TN | 1 |
| Howell, SB | 1 |
| Pfeifle, C | 1 |
| House, BA | 1 |
| Thel, MC | 1 |
| Ciaccia, D | 1 |
| Vredenburgh, JJ | 1 |
| Peters, W | 1 |
| Corey, GR | 1 |
| Elias, AD | 1 |
| Ayash, L | 1 |
| Tepler, I | 1 |
| Wheeler, C | 1 |
| Schwartz, G | 1 |
| Mazanet, R | 1 |
| Schnipper, L | 1 |
| Frei, E | 1 |
| Antman, K | 1 |
| Ishikawa, M | 1 |
| Okada, Y | 1 |
| Satake-Ishikawa, R | 1 |
| Kakitani, M | 1 |
| Kawagishi, M | 1 |
| Matsuki, S | 1 |
| Kusaka, M | 1 |
| Asano, K | 1 |
| Vokes, EE | 1 |
| Haraf, DJ | 1 |
| Drinkard, LC | 1 |
| Hoffman, PC | 1 |
| Ferguson, MK | 1 |
| Watson, S | 1 |
| Lane, NJ | 1 |
| Golomb, HM | 1 |
| Bissett, D | 1 |
| Harnett, AN | 1 |
| Habeshaw, T | 1 |
| Kaye, SB | 1 |
| Evans, D | 1 |
| Williams, M | 1 |
| Canney, PA | 1 |
| Chevallier, B | 1 |
| Merrouche, Y | 2 |
| Kerbrat, P | 1 |
| Genot, JY | 1 |
| Olivier, JP | 1 |
| Fizames, C | 1 |
| Hageboutros, A | 1 |
| Newman, EM | 1 |
| McAleer, C | 1 |
| Brennan, J | 1 |
| LaCreta, FP | 1 |
| Hudes, GR | 2 |
| Ozols, RF | 1 |
| O'Shaughnessy, JA | 2 |
| Denicoff, AM | 1 |
| Venzon, DJ | 1 |
| Pierce, LJ | 1 |
| Frame, JN | 1 |
| Bastian, A | 1 |
| Ghosh, B | 1 |
| Goldspiel, B | 2 |
| Miller, L | 1 |
| Ota, K | 1 |
| Ogawa, N | 1 |
| Kurihara, M | 1 |
| Akazawa, S | 1 |
| Ogawa, M | 1 |
| Tominaga, T | 1 |
| Konishi, T | 1 |
| Kumai, K | 1 |
| Huber, MH | 1 |
| Shirinian, M | 1 |
| Lippman, SM | 2 |
| Dimery, IW | 1 |
| Frankenthaler, RA | 1 |
| Hong, WK | 2 |
| Huan, SD | 1 |
| Aitken, SE | 1 |
| Stewart, DJ | 1 |
| Lamar, RE | 1 |
| Greco, FA | 1 |
| Johnson, DH | 2 |
| Murphy, PB | 1 |
| Hainsworth, JD | 2 |
| Aglietta, M | 1 |
| Monzeglio, C | 1 |
| Pasquino, P | 1 |
| Carnino, F | 1 |
| Stern, AC | 1 |
| Gavosto, F | 1 |
| Brambilla, C | 1 |
| Ferrari, L | 1 |
| Bonadonna, G | 1 |
| O'Reilly, SE | 1 |
| Gelmon, KA | 1 |
| Onetto, N | 1 |
| Parente, J | 1 |
| Rubinger, M | 1 |
| Page, RA | 1 |
| Plenderleith, IH | 1 |
| Demuynck, B | 1 |
| Beerblock, K | 1 |
| Varette, C | 1 |
| Soubrane, D | 1 |
| Marpeau, L | 1 |
| Pigné, A | 1 |
| Guillot, T | 1 |
| Krulik, M | 2 |
| Tessitore, J | 1 |
| Huberman, M | 1 |
| Alba, E | 1 |
| Sanchez-Chaparro, MA | 1 |
| Alonso, L | 1 |
| Ribelles, N | 1 |
| Ramon Delgado, J | 1 |
| Rueda, A | 1 |
| Pablo Tenllado, P | 1 |
| Solano, J | 1 |
| Urquiza, R | 1 |
| Ribas, A | 1 |
| Albanell, J | 1 |
| Bellmunt, J | 1 |
| Solé-Calvo, LA | 1 |
| Bermejo, B | 1 |
| Gallardo, E | 1 |
| Vidal, R | 1 |
| Vera, R | 1 |
| Eres, N | 1 |
| Carulla, J | 1 |
| Baselga, J | 1 |
| Klaassen, U | 2 |
| Wilke, H | 1 |
| Tolcher, A | 1 |
| Riseberg, D | 1 |
| Noone, M | 1 |
| Gossard, M | 1 |
| Jacobson, J | 1 |
| Chang, V | 1 |
| Keegan, P | 1 |
| Giusti, R | 1 |
| Cowan, KH | 1 |
| Chi, KH | 1 |
| Chan, WK | 1 |
| Shu, CH | 1 |
| Law, CK | 1 |
| Chen, SY | 1 |
| Yen, SH | 1 |
| Chen, KY | 1 |
| Schwartz, GK | 1 |
| Christman, K | 1 |
| Saltz, L | 1 |
| Casper, E | 1 |
| Quan, V | 1 |
| Bertino, J | 1 |
| Martin, DS | 1 |
| Colofiore, J | 1 |
| Kelsen, D | 1 |
| Jones, SE | 2 |
| Schottstaedt, MW | 1 |
| Duncan, LA | 1 |
| Kirby, RL | 1 |
| Good, RH | 1 |
| Mennel, RG | 1 |
| George, TK | 1 |
| Snyder, DA | 1 |
| Watkins, DL | 1 |
| Denham, CA | 1 |
| Hoyes, FA | 1 |
| Rubin, AS | 1 |
| Culine, S | 2 |
| Suc, E | 1 |
| Brunet, P | 1 |
| Becouarn, Y | 1 |
| Marty, M | 2 |
| Extra, JM | 1 |
| Seitz, JF | 2 |
| Negrier, S | 1 |
| Burki, F | 1 |
| Mousseau, M | 1 |
| Mahjoubi, M | 2 |
| MacKean, J | 1 |
| Burmeister, BH | 1 |
| Lamb, DS | 2 |
| Denham, JW | 2 |
| Primrose, J | 1 |
| Hallam, S | 1 |
| Ward, U | 1 |
| Illingworth, JM | 1 |
| Selby, PJ | 1 |
| Baldini, E | 1 |
| Tibaldi, C | 1 |
| Giannessi, P | 1 |
| Evangelista, G | 1 |
| Roncella, M | 1 |
| Spinelli, C | 1 |
| Meucci, C | 1 |
| da Prato, M | 1 |
| Conte, P | 1 |
| Okabo, S | 1 |
| Lee, M | 1 |
| Murase, N | 1 |
| Endo, M | 1 |
| Shimoju, K | 1 |
| Sakurazawa, K | 1 |
| Sugihara, K | 1 |
| Maruyama, M | 1 |
| Yabata, E | 1 |
| Ferrero, JM | 1 |
| Dufour, JF | 1 |
| Largillier, R | 1 |
| Creisson, A | 1 |
| Teissier, E | 1 |
| Machiavello, JC | 1 |
| Lallement, M | 1 |
| Monticelli, J | 1 |
| Abbes, M | 1 |
| Rowinsky, E | 1 |
| Smith, L | 1 |
| White, L | 1 |
| Drengler, R | 1 |
| Von Hoff, D | 1 |
| Peacock, N | 1 |
| Aylesworth, C | 1 |
| Burris, H | 1 |
| Ravdin, P | 1 |
| Bellet, R | 1 |
| Jeney, A | 1 |
| Kralovánszky, J | 1 |
| Kovács, P | 1 |
| Kish, JA | 1 |
| Wolf, MK | 1 |
| Schellhammer, PF | 1 |
| Hussain, MH | 1 |
| Einstein, AB | 1 |
| Crawford, ED | 1 |
| Maroun, JA | 2 |
| Cripps, C | 1 |
| Goel, R | 1 |
| Dahrouge, S | 1 |
| Boisvert, D | 1 |
| Kronawitter, U | 1 |
| Kemeny, NE | 2 |
| Blumgart, L | 1 |
| Charrier, S | 1 |
| Brain, E | 1 |
| Curé, H | 1 |
| van Praagh, I | 1 |
| Feillel, V | 1 |
| de Latour, M | 1 |
| Dauplat, J | 1 |
| Misset, JL | 2 |
| Iop, A | 1 |
| Cartei, G | 1 |
| Vigevani, E | 1 |
| Clocchiatti, L | 1 |
| Sibau, AM | 1 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| Tong, W | 1 |
| Harrison, J | 1 |
| Berkery, R | 1 |
| Hornedo, J | 1 |
| Sola, C | 1 |
| Solano, C | 1 |
| López López, J | 1 |
| García Conde, J | 1 |
| Goss, PE | 1 |
| Fine, S | 2 |
| Gelmon, K | 1 |
| Rudinskas, L | 1 |
| Ottaway, J | 1 |
| Myles, J | 1 |
| James, K | 1 |
| Paul, K | 1 |
| Rodgers, A | 1 |
| Pritchard, KI | 1 |
| Fishman, A | 1 |
| Chowers, M | 1 |
| Altaras, M | 1 |
| Beyth, Y | 1 |
| Lang, R | 1 |
| Marshall, JL | 1 |
| Richmond, E | 1 |
| DeLap, RJ | 2 |
| Raymond, E | 2 |
| Armand, JP | 2 |
| Hietanen, P | 1 |
| Teerenhovi, L | 1 |
| Joensuu, H | 1 |
| Etienne, MC | 1 |
| Pierrefite, V | 1 |
| Barberi-Heyob, M | 1 |
| Deporte-Fety, R | 1 |
| Darut-Jouve, A | 1 |
| Jolimoy, G | 1 |
| Belichard, C | 1 |
| Arnoud, L | 1 |
| Guerrin, J | 1 |
| Cox, JV | 2 |
| DeVore, RF | 1 |
| Pazdur, R | 1 |
| Rivkin, SE | 1 |
| Geyer, CE | 1 |
| Sandbach, J | 1 |
| Wolf, DL | 1 |
| Mohrland, JS | 1 |
| Elfring, GL | 2 |
| Valero, V | 3 |
| Theriault, RL | 3 |
| Azarnia, N | 1 |
| Fonseca, GA | 1 |
| Willey, J | 1 |
| Ewer, M | 1 |
| Walters, RS | 1 |
| Mackay, B | 1 |
| Podoloff, D | 1 |
| Booser, D | 1 |
| Lee, LW | 1 |
| Khandelwal, P | 1 |
| McIntyre, K | 1 |
| Mennel, R | 1 |
| Orr, D | 1 |
| Kirby, R | 1 |
| Agura, E | 1 |
| Duncan, L | 1 |
| Hyman, W | 1 |
| Roque, T | 1 |
| Regan, D | 1 |
| Schuster, M | 1 |
| Dimitrov, N | 1 |
| Garrison, L | 1 |
| Lange, M | 1 |
| Sweeney, T | 1 |
| Rieger, N | 1 |
| Mackay, J | 1 |
| Tan, EH | 1 |
| Chua, ET | 1 |
| Wee, J | 1 |
| Tan, T | 1 |
| Fong, KW | 1 |
| Ang, PT | 1 |
| Lee, KS | 1 |
| Lee, KM | 1 |
| Khoo-Tan, HS | 1 |
| Leong, SS | 1 |
| Ong, YK | 1 |
| Foo, KF | 1 |
| Sethi, VK | 1 |
| Chua, EJ | 1 |
| Ackland, SP | 2 |
| Burmeister, B | 1 |
| Walpole, E | 2 |
| Dady, P | 1 |
| Spry, NA | 1 |
| Singletary, SE | 2 |
| Booser, DJ | 2 |
| Ibrahim, N | 1 |
| Smith, TL | 2 |
| Asmar, L | 1 |
| Frye, D | 1 |
| Manuel, N | 2 |
| Kau, SW | 2 |
| McNeese, M | 1 |
| Strom, E | 2 |
| Hunt, K | 2 |
| Ames, F | 2 |
| Villalona-Calero, MA | 2 |
| Weiss, GR | 1 |
| Kraynak, M | 1 |
| Rodrigues, G | 1 |
| Drengler, RL | 2 |
| Reigner, B | 2 |
| Moczygemba, J | 1 |
| Burger, HU | 1 |
| Griffin, T | 1 |
| Rowinsky, EK | 2 |
| Bishop, JF | 2 |
| Dewar, J | 1 |
| Toner, GC | 1 |
| Smith, J | 1 |
| Tattersall, MH | 1 |
| Olver, IN | 2 |
| Ackland, S | 1 |
| Kennedy, I | 1 |
| Goldstein, D | 1 |
| Gurney, H | 1 |
| Levi, J | 1 |
| Stephenson, J | 1 |
| Canetta, R | 1 |
| Garden, AS | 1 |
| Glisson, BS | 1 |
| Ang, KK | 1 |
| Morrison, WH | 1 |
| Byers, RM | 1 |
| Geara, F | 1 |
| Clayman, GL | 1 |
| Shin, DM | 1 |
| Callender, DL | 1 |
| Khuri, FR | 1 |
| Goepfert, H | 1 |
| Peters, LJ | 1 |
| Bonnay, M | 1 |
| Bexon, A | 1 |
| Faivre, C | 1 |
| Lusinchi, A | 1 |
| Lasser, P | 1 |
| Eschwege, F | 1 |
| Anderson, N | 1 |
| Lokich, J | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Hidalgo, M | 1 |
| Hammond, LA | 1 |
| Diab, SG | 1 |
| Weiss, G | 1 |
| Garner, AM | 1 |
| Campbell, E | 1 |
| Davidson, K | 1 |
| Louie, A | 1 |
| O'Neil, JD | 1 |
| von Borstel, R | 1 |
| Kornek, GV | 3 |
| Schratter-Sehn, A | 1 |
| Marczell, A | 1 |
| Depisch, D | 3 |
| Karner, J | 1 |
| Krauss, G | 1 |
| Haider, K | 1 |
| Kwasny, W | 1 |
| Locker, G | 1 |
| Van Den Neste, E | 1 |
| de Valeriola, D | 1 |
| Kerger, J | 1 |
| Bleiberg, H | 2 |
| Kusenda, Z | 1 |
| Brassinne, C | 1 |
| Bartholomeus, S | 1 |
| Selleslags, J | 1 |
| Hennebert, P | 1 |
| Wythouck, H | 1 |
| Cazenave, I | 1 |
| Lefresne-Soulas, F | 1 |
| Piccart, M | 1 |
| Papadakou, M | 1 |
| Xidakis, E | 1 |
| Boukis, H | 1 |
| Poulis, A | 1 |
| Panagos, G | 1 |
| Lefantzis, D | 1 |
| Hsieh, CI | 1 |
| Liu, MC | 1 |
| Cheng, SH | 1 |
| Chen, CM | 2 |
| Tsou, MH | 1 |
| Huang, AT | 1 |
| Soori, GS | 1 |
| Oldham, RK | 1 |
| Dobbs, TW | 1 |
| Bury, MJ | 1 |
| Church, CK | 1 |
| DePriest, C | 1 |
| Gory-Delabaere, G | 1 |
| Brès, J | 1 |
| Gau, F | 1 |
| Constans, B | 1 |
| Nouguier-Soulé, J | 1 |
| Pronk, LC | 1 |
| Vasey, P | 1 |
| Sparreboom, A | 1 |
| Planting, AS | 1 |
| Gordon, RJ | 1 |
| Osterwalder, B | 2 |
| Westermann, AM | 1 |
| Taal, BG | 1 |
| Swart, M | 1 |
| Boot, H | 1 |
| Craanen, M | 1 |
| Gerritsen, WR | 1 |
| Rivellini, F | 1 |
| Di Gennaro, E | 1 |
| Mozzillo, N | 1 |
| Ionna, F | 1 |
| Manzione, L | 2 |
| Riva, C | 1 |
| Lavieille, JP | 1 |
| Schmerber, S | 1 |
| Cuisnie, O | 1 |
| Reyt, E | 1 |
| Figer, A | 1 |
| Seymour, M | 1 |
| Homerin, M | 1 |
| Hmissi, A | 1 |
| Boni, C | 1 |
| Freyer, G | 2 |
| Papamichael, D | 1 |
| Le Bail, N | 1 |
| Hendler, D | 1 |
| Wilson, C | 1 |
| Morvan, F | 1 |
| Bonetti, A | 1 |
| Droz, JP | 1 |
| Mignard, D | 1 |
| Awad, L | 1 |
| Ahmed, S | 1 |
| Vaitkevicius, VK | 1 |
| Du, W | 1 |
| Arlauskas, P | 1 |
| Gordon, C | 1 |
| Kellogg, C | 1 |
| Shields, AF | 1 |
| Blanke, C | 1 |
| Rosen, LS | 1 |
| Moore, MJ | 1 |
| Locker, PK | 1 |
| Pirotta, N | 1 |
| Madajewicz, S | 1 |
| Hentschel, P | 1 |
| Burns, P | 1 |
| Caruso, R | 1 |
| Fiore, J | 1 |
| Fried, M | 1 |
| Malhotra, H | 1 |
| Ostrow, S | 1 |
| Sugarman, S | 1 |
| Viola, M | 1 |
| Berney, CR | 1 |
| Rohner, S | 1 |
| Morel, P | 1 |
| Marti, MC | 1 |
| Aapro, MS | 1 |
| Alberto, P | 1 |
| Aschele, C | 1 |
| Guglielmi, A | 1 |
| Giuliani, R | 1 |
| Ravaioli, A | 1 |
| Lanfranco, C | 1 |
| Caroti, C | 1 |
| Arnoldi, E | 1 |
| Gallo, L | 1 |
| Pessi, MA | 1 |
| Cortesi, E | 1 |
| Grossi, F | 1 |
| Piazza, E | 1 |
| Bruzzi, P | 1 |
| Goldwasser, F | 1 |
| Gross-Goupil, M | 1 |
| Tigaud, JM | 1 |
| Di Palma, M | 1 |
| Marceau-Suissa, J | 1 |
| Yovine, A | 1 |
| Cvitkovic, E | 1 |
| Maindrault-Goebel, F | 1 |
| Carola, E | 1 |
| Gilles, V | 1 |
| Lotz, JP | 1 |
| Mabro, M | 1 |
| Molitor, JL | 1 |
| Izrael, V | 1 |
| Hügli, A | 1 |
| Sappino, AP | 1 |
| Anchisi, S | 1 |
| Mermillod, B | 1 |
| Schafer, P | 1 |
| Anguenot, JL | 1 |
| Bonnefoi, H | 1 |
| Cascinu, S | 1 |
| Casaretti, R | 1 |
| Catalano, V | 1 |
| Baldelli, AM | 1 |
| Hennequin, C | 1 |
| Salemkour, A | 1 |
| Mal, F | 1 |
| Boudet, MJ | 1 |
| Perniceni, T | 1 |
| Gayet, B | 1 |
| Maylin, C | 1 |
| Stipanov, M | 1 |
| Morrow, J | 1 |
| Rothenberg, M | 1 |
| Chinery, R | 1 |
| Shyr, Y | 1 |
| Coffey, R | 1 |
| Leach, SD | 1 |
| Beauchamp, RD | 1 |
| Tucci, A | 1 |
| Pizza, C | 1 |
| Selle, F | 1 |
| Landi, B | 1 |
| Cattan, S | 1 |
| Fonck, M | 1 |
| Flesch, M | 1 |
| Colin, P | 1 |
| Balosso, J | 1 |
| Ruszniewski, P | 1 |
| Schuell, B | 1 |
| Ulrich-Pur, H | 2 |
| Penz, M | 1 |
| Raderer, M | 2 |
| Lang, F | 2 |
| Schneeweiss, B | 1 |
| Lenauer, A | 2 |
| Cyjon, A | 1 |
| Neuman-Levin, M | 1 |
| Rakowsky, E | 1 |
| Greif, F | 1 |
| Belinky, A | 1 |
| Atar, E | 1 |
| Hardoff, R | 1 |
| Brenner, B | 1 |
| Sulkes, A | 1 |
| Chauvel, P | 1 |
| Courdi, A | 1 |
| Dassonville, O | 1 |
| Poissonnet, G | 1 |
| Vallicioni, J | 1 |
| Ettore, F | 1 |
| Falewee, MN | 1 |
| Santini, J | 1 |
| Schneider, M | 1 |
| Demard, F | 1 |
| Bensadoun, RJ | 1 |
| Fiebiger, W | 1 |
| Gedlicka, C | 1 |
| Pidlich, J | 1 |
| Webb, A | 1 |
| Massey, A | 1 |
| Bertucci, D | 2 |
| Stadler, WM | 1 |
| Chang, DZ | 1 |
| Olencki, T | 1 |
| Budd, GT | 1 |
| Peereboom, D | 1 |
| Ganapathi, R | 1 |
| Bukowski, R | 1 |
| Benson, AB | 1 |
| Hsieh, YC | 1 |
| Pentheroudakis, G | 1 |
| Lim, KC | 1 |
| Dunlop, DJ | 1 |
| Eatock, MM | 1 |
| Spielmann, M | 1 |
| Tubiana-Hulin, M | 1 |
| Mansouri, H | 1 |
| Bougnoux, Ph | 1 |
| Tubiana-Mathieu, N | 1 |
| Lotz, V | 1 |
| Eymard, JC | 1 |
| Rudin, CM | 1 |
| Kunkel, K | 1 |
| Holmlund, JT | 1 |
| Geary, RS | 1 |
| Dorr, FA | 1 |
| Ibrahim, NK | 1 |
| Rahman, Z | 1 |
| Walters, R | 1 |
| Rivera, E | 1 |
| Holmes, FA | 1 |
| Hoy, E | 1 |
| Frye, DK | 1 |
| McNeese, MD | 1 |
| Thomas, E | 1 |
| Berry, D | 1 |
| Kourousis, Ch | 1 |
| Tsetis, D | 1 |
| Athanasiadis, N | 1 |
| Venturini, M | 1 |
| Del Mastro, L | 1 |
| Garrone, O | 1 |
| Angiolini, C | 1 |
| Merlano, M | 1 |
| Bergaglio, M | 1 |
| Tolino, G | 1 |
| Lambiase, A | 1 |
| Baldini, A | 1 |
| Canavese, G | 1 |
| Rosso, R | 1 |
| Jagiello-Gruszfeld, A | 1 |
| Windle, R | 1 |
| Macpherson, S | 1 |
| Bell, PR | 1 |
| Steinberg, J | 1 |
| Gadalla, T | 1 |
| Levine, MN | 1 |
| Bramwell, V | 1 |
| Pritchard, K | 1 |
| Perrault, D | 1 |
| Findlay, B | 1 |
| Abu-Zahra, H | 1 |
| Warr, D | 1 |
| Arnold, A | 1 |
| Skillings, J | 1 |
| Crown, J | 1 |
| Jakubowski, A | 1 |
| Gordon, M | 1 |
| Gasparetto, C | 2 |
| Wong, G | 1 |
| Sheridan, C | 1 |
| Toner, G | 1 |
| Meisenberg, B | 1 |
| Botet, J | 1 |
| Futami, H | 1 |
| Jansen, R | 1 |
| MacPhee, MJ | 1 |
| Keller, J | 1 |
| McCormick, K | 1 |
| Longo, DL | 1 |
| Oppenheim, JJ | 1 |
| Ruscetti, FW | 1 |
| Wiltrout, RH | 1 |
| Petruzzelli, GJ | 1 |
| Johnson, JT | 1 |
| de Vries, EJ | 1 |
| Shimamura, M | 1 |
| Takigawa, T | 1 |
| Urabe, A | 1 |
| Okabe, T | 1 |
| Souza, LM | 1 |
| Takaku, F | 1 |
| Laver, J | 1 |
| Abboud, M | 1 |
| Gillio, A | 1 |
| Smith, C | 1 |
| O'Reilly, RJ | 1 |
| Moore, MA | 1 |
| LaCreta, F | 1 |
| Grillo-Lopez, AJ | 1 |
| Catalano, R | 1 |
| Comis, RL | 1 |
| Dalley, D | 1 |
| Woods, R | 1 |
| Aroney, R | 1 |
| Hughes, P | 1 |
| Cruickshank, D | 1 |
| McIntyre, KW | 1 |
| Unowsky, J | 1 |
| DeLorenzo, W | 1 |
| Benjamin, W | 1 |
| Engstrom, PF | 1 |
| MacIntyre, JM | 1 |
| Schutt, AJ | 1 |
| Douglass, HO | 1 |
| Woolley, PV | 1 |
| Ayoob, MJ | 1 |
| Smith, FP | 1 |
| Lokey, JL | 1 |
| DeGreen, P | 1 |
| Marantz, A | 1 |
| Schein, PS | 1 |
| Byfield, JE | 1 |
| Frankel, SS | 1 |
| Hornbeck, CL | 1 |
| Sharp, TR | 1 |
| Callipari, FB | 1 |
| Floyd, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients With Borderline Resectable Pancreatic Cancer[NCT01661088] | Phase 2 | 25 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic[NCT02195180] | Phase 2 | 141 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-08 | Completed | ||
| Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-l[NCT01161316] | Phase 2 | 194 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen[NCT01571284] | Phase 3 | 781 participants (Actual) | Interventional | 2012-05-30 | Completed | ||
| Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease[NCT00865709] | Phase 2 | 198 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients[NCT02972372] | 196 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer[NCT02025036] | Phase 3 | 249 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| Pharmacogenetic Risk Factors of Doxorubicin-Cyclophosphamide Chemotherapy Related Toxicities in Breast Cancer Patients[NCT04581967] | 100 participants (Anticipated) | Observational | 2020-10-15 | Recruiting | |||
| A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer[NCT00246571] | Phase 2 | 217 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients[NCT02829385] | Phase 2 | 53 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470] | Phase 3 | 1,226 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802] | 190 participants (Anticipated) | Observational | 2016-10-06 | Recruiting | |||
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial[NCT02610556] | Phase 2 | 130 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-11-21 | Recruiting | ||
| Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2021-06-15 | Active, not recruiting | ||
| A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857] | Phase 1/Phase 2 | 45 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers[NCT06135896] | Phase 2 | 98 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | ||
| Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508] | Phase 2 | 178 participants (Actual) | Interventional | 2018-09-04 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
| A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck[NCT04107103] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-03-19 | Recruiting | ||
| A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831] | Phase 2 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Industry decline to supply study drug) | ||
| TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)[NCT06163534] | 500 participants (Anticipated) | Observational [Patient Registry] | 2024-01-30 | Not yet recruiting | |||
| The Safety and Feasibility of Neoadjuvant Camrelizumab With Dalpiciclib for the Treatment of Resectable Esophageal or Head and Neck Squamous Cell Carcinoma：A Phase 1 Trial[NCT06109207] | Phase 1 | 12 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH)[NCT05459415] | 54 participants (Anticipated) | Interventional | 2022-06-22 | Active, not recruiting | |||
| Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies[NCT06061705] | 100 participants (Anticipated) | Interventional | 2023-12-30 | Not yet recruiting | |||
| 1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK[NCT04150900] | Phase 2 | 7 participants (Actual) | Interventional | 2020-01-13 | Active, not recruiting | ||
| A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion [NCT03356223] | Phase 2 | 25 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck[NCT00122460] | Phase 3 | 442 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Phase I Trial of Irinotecan, Cisplatin, and Fluorouracil in Patients With Advanced Solid Tumor Malignancies[NCT00005791] | Phase 1 | 0 participants | Interventional | 1999-10-31 | Completed | ||
| A Single-arm Study Evaluating the Relative Dose Intensity of IV CMF Given on Day 1 and Day 8 With Pegfilgrastim Support in Subjects With Stage I-III Breast Cancer[NCT00124111] | Phase 2 | 0 participants | Interventional | Completed | |||
| Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01245959] | Phase 3 | 476 participants (Anticipated) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Pharmacogenetics in Relation to Breast Cancer Outcomes in SWOG 8897[NCT00896623] | 1,577 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer[NCT00094809] | Phase 2 | 252 participants (Actual) | Interventional | 2003-02-01 | Completed | ||
| PAXG Out in the Country[NCT04480268] | Phase 4 | 175 participants (Anticipated) | Interventional | 2020-07-08 | Recruiting | ||
| First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287] | Phase 3 | 554 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment[NCT00457691] | Phase 3 | 768 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer[NCT01187212] | Phase 2 | 195 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer[NCT01658033] | Phase 2 | 72 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Phase I Study of Oxaliplatin, CPT-11, 5-FU and Leucovorin in Patients With Solid Tumors[NCT00005068] | Phase 1 | 0 participants | Interventional | 2000-01-31 | Completed | ||
| A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression[NCT00005908] | Phase 2 | 30 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| Clinical Trial of the Neoadjuvant Standard Chemotherapy 3 FEC 100 + 3 TAXOTERE Protocol Versus the Same Protocol Adapted as a Function of Clinical Response[NCT00425516] | Phase 2 | 264 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.[NCT01126138] | Phase 3 | 200 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658] | 200 participants (Anticipated) | Observational | 2010-11-30 | Recruiting | |||
| A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer[NCT00022698] | Phase 2 | 67 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma[NCT02289547] | Phase 3 | 184 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy[NCT00736944] | Phase 2 | 30 participants (Actual) | Interventional | 2008-12-19 | Completed | ||
| Prospective Registration of Head and Neck Cancer Patients for Clinical Data and Tissue Collection[NCT02546895] | 2,000 participants (Anticipated) | Observational | 2015-09-30 | Recruiting | |||
| Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)[NCT03943602] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449] | Phase 2 | 58 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Intermittent Every Other Days of 5 Shot-filgrastim Compared With Single Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy (Intermittent G-CSF 105)[NCT02685111] | Phase 2 | 22 participants (Actual) | Interventional | 2016-02-29 | Terminated | ||
| An Open Label, Randomised, Multicentre Study of Pegfilgrastim in Primary Versus Secondary Prophylaxis of Neutropenia as an Adjunct to Chemotherapy in Elderly Subjects With High Risk Breast Cancer.[NCT00117910] | Phase 3 | 0 participants | Interventional | 2002-10-31 | Completed | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined With Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer[NCT05424692] | 200 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer[NCT01856322] | Phase 2 | 3 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to The trial was prematurely closed due to lack of accrual.) | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study[NCT02007148] | Phase 2 | 51 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To estimate overall survival as a function of time from study enrollment. (NCT01661088)
Timeframe: up to 2 years
| Intervention | months (Median) |
|---|---|
| Study Treatment | 24.4 |
To estimate progression-free survival as a function of time from study enrollment. Progression is defined as at least a 20% increase in the LD (longest diameter) of the primary lesion or the appearance of one or more new lesions (NCT01661088)
Timeframe: up to 2 years
| Intervention | months (Median) |
|---|---|
| Study Treatment | 13.1 |
To determine the frequency of achieving an R0 resection using a neoadjuvant regimen of FOLFIRINOX followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine in patients with borderline resectable pancreatic cancer. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed. (NCT01661088)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Study Treatment | 52 |
"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 33 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 5.8 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 10.5 |
"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 25 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 15.5 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 19.6 |
Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.4 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.8 |
Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.9 |
(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Febrile neutropenia | Anal Fistula | Diarrhea | Hematemesis | Nausea | Peripheral ischemia | Vomiting | Fatigue | Laparoscopy surgery | Pain | Sepsis | Lung infection | Pneumonia | Hypernatremia | Neutrophil count decreased | Platelet count decreased | Anorexia | Dehydration | Hypokalemia | Back pain | Peripheral sensory neuropathy | Syncope | Dyspnea | Pleural embolism | Skin infection | Thromboembolic event | Abdominal pain | Enterocolitis | Hemorrhoids | G-tube infection | Neutropenic entercolitis | Alkaline phosphatase increased | |
| Arm A: FOLFIRINOX (HER2-negative) | 1 | 2 | 1 | 4 | 1 | 2 | 1 | 3 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 19 | 3 | 3 | 4 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD). (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | mL/min (Mean) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 71.4 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | participants (Number) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 182 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue - Baseline | Fatigue - Change at Cycle 3 | Fatigue - Change at Cycle 5 | Fatigue - Change at Cycle 7 | Fatigue - Change at Cycle 9 | Fatigue - Change at Cycle 11 | Fatigue - Change at Cycle 13 | Fatigue - Change at Cycle 15 | Fatigue - Change at Cycle 17 | Fatigue - Change at Cycle 19 | Fatigue - Change at Cycle 21 | Fatigue - Change at Cycle 23 | Fatigue - Change at Cycle 25 | Fatigue - Change at Cycle 27 | Fatigue - Change at Cycle 29 | Fatigue - Change at Cycle 31 | Fatigue - Change at Cycle 33 | Fatigue - Change at Cycle 35 | Fatigue - Change at EOT | Nausea and Vomiting - Baseline | Nausea and Vomiting - Change at Cycle 3 | Nausea and Vomiting - Change at Cycle 5 | Nausea and Vomiting - Change at Cycle 7 | Nausea and Vomiting - Change at Cycle 9 | Nausea and Vomiting - Change at Cycle 11 | Nausea and Vomiting - Change at Cycle 13 | Nausea and Vomiting - Change at Cycle 15 | Nausea and Vomiting - Change at Cycle 17 | Nausea and Vomiting - Change at Cycle 19 | Nausea and Vomiting - Change at Cycle 21 | Nausea and Vomiting - Change at Cycle 23 | Nausea and Vomiting - Change at Cycle 25 | Nausea and Vomiting - Change at Cycle 27 | Nausea and Vomiting - Change at Cycle 29 | Nausea and Vomiting - Change at Cycle 31 | Nausea and Vomiting - Change at Cycle 33 | Nausea and Vomiting - Change at Cycle 35 | Nausea and Vomiting - Change at EOT | Pain - Baseline | Pain - Change at Cycle 3 | Pain - Change at Cycle 5 | Pain - Change at Cycle 7 | Pain - Change at Cycle 9 | Pain - Change at Cycle 11 | Pain - Change at Cycle 13 | Pain - Change at Cycle 15 | Pain - Change at Cycle 17 | Pain - Change at Cycle 19 | Pain - Change at Cycle 21 | Pain - Change at Cycle 23 | Pain - Change at Cycle 25 | Pain - Change at Cycle 27 | Pain - Change at Cycle 29 | Pain - Change at Cycle 31 | Pain - Change at Cycle 33 | Pain - Change at Cycle 35 | Pain - Change at EOT | Dyspnoea - Baseline | Dyspnoea - Change at Cycle 3 | Dyspnoea - Change at Cycle 5 | Dyspnoea - Change at Cycle 7 | Dyspnoea - Change at Cycle 9 | Dyspnoea - Change at Cycle 11 | Dyspnoea - Change at Cycle 13 | Dyspnoea - Change at Cycle 15 | Dyspnoea - Change at Cycle 17 | Dyspnoea - Change at Cycle 19 | Dyspnoea - Change at Cycle 21 | Dyspnoea - Change at Cycle 23 | Dyspnoea - Change at Cycle 25 | Dyspnoea - Change at Cycle 27 | Dyspnoea - Change at Cycle 29 | Dyspnoea - Change at Cycle 31 | Dyspnoea - Change at Cycle 33 | Dyspnoea - Change at Cycle 35 | Dyspnoea - Change at EOT | Insomnia - Baseline | Insomnia - Change at Cycle 3 | Insomnia - Change at Cycle 5 | Insomnia - Change at Cycle 7 | Insomnia - Change at Cycle 9 | Insomnia - Change at Cycle 11 | Insomnia - Change at Cycle 13 | Insomnia - Change at Cycle 15 | Insomnia - Change at Cycle 17 | Insomnia - Change at Cycle 19 | Insomnia - Change at Cycle 21 | Insomnia - Change at Cycle 23 | Insomnia - Change at Cycle 25 | Insomnia - Change at Cycle 27 | Insomnia - Change at Cycle 29 | Insomnia - Change at Cycle 31 | Insomnia - Change at Cycle 33 | Insomnia - Change at Cycle 35 | Insomnia - Change at EOT | Appetite loss - Baseline | Appetite loss - Change at Cycle 3 | Appetite loss - Change at Cycle 5 | Appetite loss - Change at Cycle 7 | Appetite loss - Change at Cycle 9 | Appetite loss - Change at Cycle 11 | Appetite loss - Change at Cycle 13 | Appetite loss - Change at Cycle 15 | Appetite loss - Change at Cycle 17 | Appetite loss - Change at Cycle 19 | Appetite loss - Change at Cycle 21 | Appetite loss - Change at Cycle 23 | Appetite loss - Change at Cycle 25 | Appetite loss - Change at Cycle 27 | Appetite loss - Change at Cycle 29 | Appetite loss - Change at Cycle 31 | Appetite loss - Change at Cycle 33 | Appetite loss - Change at Cycle 35 | Appetite loss - Change at EOT | Constipation - Baseline | Constipation - Change at Cycle 3 | Constipation - Change at Cycle 5 | Constipation - Change at Cycle 7 | Constipation - Change at Cycle 9 | Constipation - Change at Cycle 11 | Constipation - Change at Cycle 13 | Constipation - Change at Cycle 15 | Constipation - Change at Cycle 17 | Constipation - Change at Cycle 19 | Constipation - Change at Cycle 21 | Constipation - Change at Cycle 23 | Constipation - Change at Cycle 25 | Constipation - Change at Cycle 27 | Constipation - Change at Cycle 29 | Constipation - Change at Cycle 31 | Constipation - Change at Cycle 33 | Constipation - Change at Cycle 35 | Constipation - Change at EOT | Diarrhoea - Baseline | Diarrhoea - Change at Cycle 3 | Diarrhoea - Change at Cycle 5 | Diarrhoea - Change at Cycle 7 | Diarrhoea - Change at Cycle 9 | Diarrhoea - Change at Cycle 11 | Diarrhoea - Change at Cycle 13 | Diarrhoea - Change at Cycle 15 | Diarrhoea - Change at Cycle 17 | Diarrhoea - Change at Cycle 19 | Diarrhoea - Change at Cycle 21 | Diarrhoea - Change at Cycle 23 | Diarrhoea - Change at Cycle 25 | Diarrhoea - Change at Cycle 27 | Diarrhoea - Change at Cycle 29 | Diarrhoea - Change at Cycle 31 | Diarrhoea - Change at Cycle 33 | Diarrhoea - Change at Cycle 35 | Diarrhoea - Change at EOT | Financial difficulties - Baseline | Financial difficulties - Change at Cycle 3 | Financial difficulties - Change at Cycle 5 | Financial difficulties - Change at Cycle 7 | Financial difficulties - Change at Cycle 9 | Financial difficulties - Change at Cycle 11 | Financial difficulties - Change at Cycle 13 | Financial difficulties - Change at Cycle 15 | Financial difficulties - Change at Cycle 17 | Financial difficulties - Change at Cycle 19 | Financial difficulties - Change at Cycle 21 | Financial difficulties - Change at Cycle 23 | Financial difficulties - Change at Cycle 25 | Financial difficulties - Change at Cycle 27 | Financial difficulties - Change at Cycle 29 | Financial difficulties - Change at Cycle 31 | Financial difficulties - Change at Cycle 33 | Financial difficulties - Change at Cycle 35 | Financial difficulties - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 29.16 | 7.35 | 8.40 | 9.54 | 7.89 | 11.30 | 8.33 | 7.41 | 6.70 | 8.93 | 10.39 | 10.80 | 7.66 | 9.66 | 11.67 | 14.07 | 15.15 | 14.44 | 12.31 | 5.88 | 6.68 | 6.98 | 6.61 | 6.20 | 8.97 | 6.82 | 6.85 | 3.45 | 6.56 | 3.99 | 7.87 | 4.02 | 7.25 | 1.67 | 13.33 | 3.03 | 3.33 | 6.64 | 20.47 | 2.68 | 2.52 | 3.00 | 2.72 | 6.64 | 5.16 | 7.26 | 9.39 | 8.74 | 7.25 | 8.33 | 5.75 | 5.07 | 4.17 | 10.00 | 7.58 | 6.67 | 10.85 | 13.45 | 3.63 | 5.75 | 6.98 | 6.89 | 8.19 | 6.36 | 3.58 | 5.16 | 6.78 | 3.79 | 4.04 | 1.23 | 3.03 | -1.75 | 16.67 | 16.67 | 16.67 | 6.53 | 24.15 | 0.37 | -0.08 | -2.37 | -0.24 | 2.56 | 0.65 | -2.19 | -1.92 | 1.64 | 0.74 | -0.93 | -0.00 | -1.52 | -3.33 | -4.44 | -6.06 | -3.33 | 5.31 | 17.38 | 9.10 | 9.02 | 9.84 | 9.98 | 14.53 | 10.67 | 10.74 | 8.91 | 9.84 | 13.04 | 12.38 | 11.49 | 15.94 | 15.00 | 15.56 | 15.15 | 16.67 | 12.03 | 12.71 | 2.42 | 3.77 | 2.63 | 5.35 | 4.42 | 4.58 | 4.92 | 5.43 | 8.33 | 6.06 | 9.26 | 5.75 | 1.45 | 6.67 | 22.22 | 12.12 | 10.00 | 3.78 | 10.37 | 11.72 | 10.85 | 14.63 | 11.44 | 15.46 | 11.26 | 11.02 | 10.34 | 15.25 | 14.07 | 18.52 | 10.34 | 13.64 | 16.67 | 20.00 | 18.18 | 30.00 | 7.31 | 20.12 | -1.83 | -1.32 | -0.99 | -0.49 | 3.30 | 1.11 | -0.27 | 0.77 | 1.67 | 4.44 | 2.94 | -4.60 | -2.90 | 0.00 | -2.22 | -3.03 | 0.00 | 2.97 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 0.77 | -0.02 | -0.03 | -0.04 | -0.05 | -0.07 | -0.05 | -0.06 | -0.05 | -0.05 | -0.09 | -0.14 | -0.08 | -0.08 | -0.08 | -0.12 | 0.02 | -0.05 | -0.11 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72.81 | -1.85 | -2.15 | -2.20 | -2.74 | -3.10 | -2.36 | -1.05 | -1.91 | -3.06 | -2.13 | -5.77 | -7.28 | -4.94 | -8.80 | -6.69 | -7.90 | -8.88 | -6.67 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 68.61 | -3.34 | -4.70 | -3.63 | -3.97 | -5.85 | -2.26 | -3.05 | -1.18 | -2.36 | -5.56 | -6.86 | -8.05 | -10.14 | -8.33 | -9.44 | -11.36 | -5.83 | -8.82 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical - Baseline | Physical - Change at Cycle 3 | Physical - Change at Cycle 5 | Physical - Change at Cycle 7 | Physical - Change at Cycle 9 | Physical - Change at Cycle 11 | Physical - Change at Cycle 13 | Physical - Change at Cycle 15 | Physical - Change at Cycle 17 | Physical - Change at Cycle 19 | Physical - Change at Cycle 21 | Physical - Change at Cycle 23 | Physical - Change at Cycle 25 | Physical - Change at Cycle 27 | Physical - Change at Cycle 29 | Physical - Change at Cycle 31 | Physical - Change at Cycle 33 | Physical - Change at Cycle 35 | Physical - Change at EOT | Role - Baseline | Role - Change at Cycle 3 | Role - Change at Cycle 5 | Role - Change at Cycle 7 | Role - Change at Cycle 9 | Role - Change at Cycle 11 | Role - Change at Cycle 13 | Role - Change at Cycle 15 | Role - Change at Cycle 17 | Role - Change at Cycle 19 | Role - Change at Cycle 21 | Role - Change at Cycle 23 | Role - Change at Cycle 25 | Role - Change at Cycle 27 | Role - Change at Cycle 29 | Role - Change at Cycle 31 | Role - Change at Cycle 33 | Role - Change at Cycle 35 | Role - Change at EOT | Emotional - Baseline | Emotional - Change at Cycle 3 | Emotional - Change at Cycle 5 | Emotional - Change at Cycle 7 | Emotional - Change at Cycle 9 | Emotional - Change at Cycle 11 | Emotional - Change at Cycle 13 | Emotional - Change at Cycle 15 | Emotional - Change at Cycle 17 | Emotional - Change at Cycle 19 | Emotional - Change at Cycle 21 | Emotional - Change at Cycle 23 | Emotional - Change at Cycle 25 | Emotional - Change at Cycle 27 | Emotional - Change at Cycle 29 | Emotional - Change at Cycle 31 | Emotional - Change at Cycle 33 | Emotional - Change at Cycle 35 | Emotional - Change at EOT | Cognitive - Baseline | Cognitive - Change at Cycle 3 | Cognitive - Change at Cycle 5 | Cognitive - Change at Cycle 7 | Cognitive - Change at Cycle 9 | Cognitive - Change at Cycle 11 | Cognitive - Change at Cycle 13 | Cognitive - Change at Cycle 15 | Cognitive - Change at Cycle 17 | Cognitive - Change at Cycle 19 | Cognitive - Change at Cycle 21 | Cognitive - Change at Cycle 23 | Cognitive - Change at Cycle 25 | Cognitive - Change at Cycle 27 | Cognitive - Change at Cycle 29 | Cognitive - Change at Cycle 31 | Cognitive - Change at Cycle 33 | Cognitive - Change at Cycle 35 | Cognitive- Change at EOT | Social - Baseline | Social - Change at Cycle 3 | Social - Change at Cycle 5 | Social - Change at Cycle 7 | Social - Change at Cycle 9 | Social - Change at Cycle 11 | Social - Change at Cycle 13 | Social - Change at Cycle 15 | Social - Change at Cycle 17 | Social - Change at Cycle 19 | Social - Change at Cycle 21 | Social - Change at Cycle 23 | Social - Change at Cycle 25 | Social - Change at Cycle 27 | Social - Change at Cycle 29 | Social - Change at Cycle 31 | Social - Change at Cycle 33 | Social - Change at Cycle 35 | Social - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 81.79 | -3.73 | -3.95 | -4.62 | -4.36 | -6.99 | -4.99 | -3.54 | -5.10 | -5.68 | -5.70 | -7.87 | -5.75 | -6.59 | -7.67 | -9.33 | -5.45 | -10.00 | -11.16 | 79.91 | -6.26 | -5.66 | -6.68 | -6.55 | -8.76 | -7.36 | -7.18 | -9.58 | -9.84 | -9.78 | -10.65 | -10.92 | -10.14 | -10.83 | -14.44 | -15.15 | -15.00 | -12.11 | 78.96 | 1.14 | 0.74 | 1.58 | 1.69 | 0.08 | 0.93 | 2.51 | 2.91 | 1.39 | 0.06 | 1.75 | 4.98 | 1.57 | 2.64 | 1.30 | 0.25 | -0.00 | -2.87 | 86.90 | -1.77 | -1.87 | -1.99 | -2.18 | -4.27 | -2.83 | -2.28 | -3.45 | -5.00 | -5.56 | -5.71 | -6.90 | -5.80 | -6.67 | -5.56 | -10.61 | -11.67 | -4.98 | 80.57 | -2.05 | -2.86 | -4.78 | -4.56 | -7.09 | -5.56 | -6.18 | -5.56 | -5.28 | -5.56 | -7.62 | -4.60 | -2.17 | -5.00 | -7.78 | -1.52 | -1.67 | -9.01 |
Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hyponatremia: All Grades | Hyponatremia: Grades 3-4 | Hypernatremia: All Grades | Hypernatremia: Grades 3-4 | Hypocalcemia: All Grades | Hypocalcemia: Grades 3-4 | Hypercalcemia: All Grades | Hypercalcemia: Grades 3-4 | Hypokalemia: All Grades | Hypokalemia: Grades 3-4 | Hyperkalemia: All Grades | Hyperkalemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 181 | 32 | 75 | 1 | 213 | 5 | 52 | 2 | 121 | 16 | 166 | 10 |
Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Anaemia: All Grades | Anaemia: Grades 3-4 | Thrombocytopenia: All Grades | Thrombocytopenia: Grades 3-4 | Leukopenia: All Grades | Leukopenia: Grades 3-4 | Neutropenia: All Grades | Neutropenia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 535 | 14 | 293 | 13 | 532 | 72 | 450 | 227 |
Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Chloride| Chloride>ULN | BUN | BUN>ULN | UREA | UREA>ULN | LDH | LDH>ULN | Total proteins | Total proteins>ULN | | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 135 | 217 | 41 | 83 | 60 | 250 | 79 | 423 | 162 | 77 |
Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine: All Grades | Creatinine: Grades 3-4 | Hyperbilirubinemia: All Grades | Hyperbilirubinemia: Grades 3-4 | AST: All Grades | AST: Grades 3-4 | ALT: All Grades | ALT: Grades 3-4 | Alkaline phosphatase: All Grades | Alkaline phosphatase: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 161 | 2 | 130 | 9 | 342 | 12 | 270 | 10 | 465 | 23 |
A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No delay and no dose modification | Any delay and/or dose modification | Delay only | Delay and Aflibercept modified | Delay and FOLFIRI modified | Delay and Aflibercept and Folfiri modified | Only Aflibercept modified | Only FOLFIRI modified | Both Aflibercept and FOLFIRI modified | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 119 | 660 | 163 | 39 | 308 | 97 | 5 | 43 | 5 |
The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| INR<1.5 | INR>=1.5 to <3 | INR>=3 to <5 | INR>=5 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 106 | 0 | 2 | 2 |
Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Hypoglycemia: All Grades | Hypoglycemia: Grades 3-4 | Hyperglycemia: All Grades | Hyperglycemia: Grades 3-4 | Hypoalbuminemia: All Grades | Hypoalbuminemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 90 | 6 | 403 | 30 | 241 | 6 |
Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Proteinuria with hematuria | Proteinuria with hypertension | Proteinuria with hematuria and hypertension | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72 | 4 | 3 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 286 | 123 | 54 | 5 |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Any TEAE (All Grades) | Any TEAEs (Grades 3-4) | Any serious TEAE | Any serious related TEAE | Any TEAE leading to death | Any TEAE (permanent treatment discontinuation) | Any TEAE (premature treatment discontinuation) | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 769 | 609 | 272 | 159 | 47 | 208 | 104 |
Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is < or = 1. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| UPCR<=1 | UPCR>=1 to <=2 | UPCR>=2 to <=3 | UPCR>3 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 265 | 51 | 24 | 27 |
Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) was first documented or to the date of death, whichever occurred first according to Response Evaluation Criteria in Solid Tumors (RECIST). Subjects still having CR or PR and alive at the time of analysis were censored at their last date of tumor evaluation. CR was defined as disappearance of tumor lesions, PR as a decrease of at least 30% and PD as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks
| Intervention | months (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 7.5 |
| Matching Placebo + mFOLFOX6 | 6.7 |
Overall response of a subject was defined as the best tumor response (Complete Response (CR) or Partial Response (PR)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 45 |
| Matching Placebo + mFOLFOX6 | 61 |
Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00865709)
Timeframe: From randomization of the first subject until 33 months later.
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 535 |
| Matching Placebo + mFOLFOX6 | 552 |
Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression or death due to any cause, whichever occurred first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | Months (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 9.1 |
| Matching Placebo + mFOLFOX6 | 8.7 |
Time to progression (TTP) was defined as the time from date of randomization to disease progression. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | Months (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 9.2 |
| Matching Placebo + mFOLFOX6 | 9.0 |
Time in months from the date of randomization to date of death due to any cause. OS was calculated as (date of death minus randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | months (Median) |
|---|---|
| Sunitinib | 9.4 |
| Standard of Care | 10.5 |
Probability that the participants will survive at end of 1 year from the first dose of study treatment. Calculated using data collected from baseline until death (up to 3 years after first dose of study medication). Probability calculated from Kaplan-Meier estimate. (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | ratio (Number) |
|---|---|
| Sunitinib | 0.376 |
| Standard of Care | 0.446 |
Blood samples were collected to enumerate the number of total CECs and sVEGFR1, sVEGFR2 and sVEGFR3 protein expression and/or cellular viability. (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=42, 48) | Cycle 1, Day 15 (n=28, 37) | Cycle 2, Day 1 (n=33, 35) | Cycle 2, Day 15 (n=7, 5) | Cycle 3, Day 1 (n=27, 25) | Cycle 3, Day 15 (n=4, 1) | Cycle 4, Day 1 (n=3, 5) | Cycle 5, Day 1 (n=2, 2) | EOT (n=18, 18) | |
| Standard of Care | 1176.92 | 1199.32 | 1048.31 | 852.96 | 509.75 | 231.80 | 976.79 | 2031.67 | 1087.94 |
| Sunitinib | 944.67 | 630 | 512.39 | 1310.86 | 390.09 | 923.85 | 169.24 | 145.68 | 477.83 |
Blood samples were collected to enumerate the number of total CTCs and insulin growth factor 1R positive (IGF-1R+) CTCs (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/7.5 mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=33, 28) | Cycle 1, Day 15 (n=20, 16) | Cycle 2, Day 1 (n=19, 17) | Cycle 2, Day 15 (n=3, 7) | Cycle 3, Day 1 (n=8, 15) | Cycle 3, Day 15 (n=2, 4) | Cycle 4, Day 1 (n=2, 5) | Cycle 5, Day 1 (n=2, 3) | EOT (n=17,4) | |
| Standard of Care | 17.71 | 10.69 | 3.18 | 0.86 | 10.60 | 0 | 0.60 | 0.33 | 3 |
| Sunitinib | 119.76 | 183.60 | 189 | 33.33 | 36.50 | 40.50 | 61 | 19.50 | 55 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.02 | 29.4 | 32.3 | 33.4 | 28.5 | 40.4 | 30.9 | 36.1 | 21.3 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.14 | 94.9 | 94.4 | 91.6 | 78.6 | 105 | 82.2 | 84.2 | 63.6 |
Ctrough = plasma concentration of SU012662 prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 29.9 | 37.2 | 37.3 | 39.8 | 40.1 | 38.7 | 41.9 | 28.6 |
Ctrough = plasma concentration of sunitinib prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 67.5 | 73.4 | 69.8 | 69.3 | 65.3 | 68.7 | 58.4 | 64.0 |
Ctrough = plasma concentration of total drug (Sunitinib + SU012662) prior to study drug administration dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 97.4 | 111 | 107 | 109 | 105 | 107 | 100 | 92.5 |
Time in months from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00246571)
Timeframe: Time from first response to disease progression up to 3 years from first dose
| Intervention | months (Median) | |
|---|---|---|
| Core radiology assessment (n=3,7) | Investigator's assessment (n=10,12) | |
| Standard of Care | NA | 4.6 |
| Sunitinib | 3.0 | 3.6 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.12 | 65.53 | 62.09 | 58.20 | 50.03 | 64.61 | 51.25 | 48.07 | 42.23 |
Plasma concentrations of sKIT were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=49, 35) | Cycle 4 Day 1 (n=33, 27) | Cycle 5 Day 1 (n=28, 19) | Cycle 7 Day 1 (n=9, 8) | End Of Treatment (n=49, 11) | |
| Standard of Care | 62232.81 | 65843.75 | 63582.86 | 62885.19 | 54811.05 | 56237.50 | 72854.55 |
| Sunitinib | 61862.65 | 44987.88 | 30855.10 | 25887.88 | 21696.07 | 18166.67 | 25004.08 |
Plasma concentrations of sPlGF were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=15, 11) | Cycle 2 Day 1 (n=11, 9) | Cycle 3 Day 1 (n=5, 4) | Cycle 4 Day 1 (n=2, 3) | Cycle 5 Day 1 (n=1, 3) | Cycle 7 Day 1 (n=1, 1) | End Of Treatment (n=5, 0) | |
| Standard of Care | 37.23 | 36.24 | 40.08 | 33.23 | 51.83 | 38.50 | 0 |
| Sunitinib | 36.96 | 168.05 | 72.16 | 144.60 | 118.30 | 176.60 | 87.54 |
Plasma concentrations of sVEGF-A were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 66) | Cycle 2 Day 1 (n=67, 50) | Cycle 3 Day 1 (n=49, 37) | Cycle 4 Day 1 (n=33, 28) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 10) | End Of Treatment (n=49, 12) | |
| Standard of Care | 151.49 | 170.43 | 129.31 | 129.88 | 126.97 | 115.58 | 94.76 |
| Sunitinib | 152.28 | 455.17 | 265.56 | 274.94 | 324.09 | 241.78 | 294.66 |
Plasma concentrations of sVEGFR3 were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=48, 35) | Cycle 4 Day 1 (n=32, 27) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 9) | End Of Treatment (n=48, 10) | |
| Standard of Care | 25857.19 | 24515.83 | 29034.86 | 27929.63 | 32949 | 32004.44 | 29194 |
| Sunitinib | 24124.82 | 16299.70 | 14459.38 | 13702.81 | 16345.36 | 24795.56 | 26746.46 |
"Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause. PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death)." (NCT00246571)
Timeframe: Baseline, every 6 weeks until disease progression or death (up to 3 years from first dose)
| Intervention | Months (Median) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 2.7 | 2.5 |
| Sunitinib | 2.0 | 1.7 |
Objective response based assessment of confirmed response (CR) or confirmed partial response (PR) according to RECIST. CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with a greater than or equal to (≥) 30% decrease in the sum of the longest dimensions (SLD) of the target lesions taking as a reference the baseline SLD. (NCT00246571)
Timeframe: Baseline until response or disease progression (up to 3 years from first dose)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 6.7 | 11.5 |
| Sunitinib | 2.7 | 8.8 |
"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/FOLFIRI | 11.1 |
| Aflibercept/FOLFIRI | 19.8 |
"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 12.06 |
| Aflibercept/FOLFIRI | 13.50 |
"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 4.67 |
| Aflibercept/FOLFIRI | 6.90 |
Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo
| Intervention | participants (Number) | |
|---|---|---|
| At least one positive sample in the ADA assay | At least one positive sample in the NAb assay | |
| Aflibercept/FOLFIRI | 8 | 1 |
| Placebo/FOLFIRI | 18 | 2 |
"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Treatment-Emergent Adverse Event (TEAE) | Serious TEAE | TEAE leading to Death | TEAE causing permanent treatment discontinuation | |
| Aflibercept/FOLFIRI | 606 | 294 | 37 | 164 |
| Placebo/FOLFIRI | 592 | 198 | 29 | 73 |
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 35.6 |
| Chemotherapy Alone | 19.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 81.1 |
| Chemotherapy Alone | 60.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00122460)
Timeframe: time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 4.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00122460)
Timeframe: time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 10.1 |
| Chemotherapy Alone | 7.4 |
"Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 3.3 |
Please refer to Adverse Events section for further details (NCT00122460)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 218 |
| Chemotherapy Alone | 208 |
"Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 4.8 |
| Chemotherapy Alone | 3.0 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 50.74 | 52.68 | 55.30 |
| Chemotherapy Alone | 45.15 | 45.48 | 42.49 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 62.14 | 64.64 | 61.27 |
| Chemotherapy Alone | 62.05 | 60.67 | 65.72 |
Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 2 |
| Placebo | 8 |
Dose delay or reduction in chemotherapy doses due to neutropenia (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 5 |
| Placebo | 26 |
Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 41 |
| Placebo | 53 |
Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC < 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 3 |
| Placebo | 10 |
Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) < 1 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 16 |
| Placebo | 51 |
Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) <0.5 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 13 |
| Placebo | 17 |
Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of neutropenia (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 7 |
| Placebo | 9 |
Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 34 |
| Placebo | 37 |
Kaplan-Meier estimate of the median time to disease progression or death (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Days (Median) |
|---|---|
| Pegfilgrastim (Neulasta) | 318 |
| Placebo | 322 |
Death from any cause through the end of the follow-up period (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 47 |
| Placebo | 49 |
DR was defined as the time from the first objective documentation of CR or PR that was subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 30.1 |
| FOLFIRI + Placebo | 39.0 |
Objective disease response: participants with a confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
| Intervention | Participants (Number) |
|---|---|
| FOLFIRI + Sunitinib | 124 |
| FOLFIRI + Placebo | 128 |
OS was defined as the time from randomization to the date of death due to any cause. OS data were censored on the day following the date of the last contact at which the patient was known to be alive. (NCT00457691)
Timeframe: Baseline up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 87.9 |
| FOLFIRI + Placebo | 85.9 |
PFS defined as time from date of randomization to date of first documentation of objective tumour progression or death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: First dose of study treatment up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 33.6 |
| FOLFIRI + Placebo | 36.6 |
"EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problem); 3 indicates worst health state (eg, confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed and results in total score range -1.11 to 1.000; higher score indicates better health state." (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 0.04 | 0.04 | 0.03 | 0.05 | 0.05 | 0.09 |
| FOLFIRI + Sunitinib | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | 0.01 |
EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 3.3 | 4.3 | 6.6 | 4.3 | 4.0 | 9.0 |
| FOLFIRI + Sunitinib | 1.0 | 1.7 | 1.8 | 3.8 | -0.9 | -1.6 |
Symptom Interference score is comprised of the sum 6 function items from MDASI core (general activity, walking, work, mood, relations with other people, and enjoyment of life). Participant asked to rate how much symptoms have interfered in past 24 hours; each item rated from 0 to 10, with 0=did not interfere and 10=interfered completely; lower scores indicated better outcome (range: 0 to 60). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | -1.3 | -1.7 | -1.2 | -0.2 | -1.7 | -1.0 |
| FOLFIRI + Sunitinib | 0.0 | -0.1 | 0.2 | -0.5 | 2.1 | 3.1 |
Symptom Intensity score is comprised of the sum of 13 MDASI core items (ie, pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling). Participant asked to rate severity of each symptom at their worst in past 24 hours; each item rated from 0 to 10, with 0=symptom not present and 10=as bad as you can imagine; lower scores indicated better outcome (range: 0 to 130). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until end of treatment (EOT)/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 0.4 | 0.9 | 1.8 | 2.7 | 1.2 | -2.7 |
| FOLFIRI + Sunitinib | 1.7 | 0.8 | 1.0 | 0.7 | 0.8 | 5.0 |
Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00005908)
Timeframe: 6 years
| Intervention | Participants (Number) |
|---|---|
| Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine | 9 |
| Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine | 20 |
Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years
| Intervention | Participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine | 8 | 2 |
| Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine | 7 | 13 |
Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years
| Intervention | Participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Dose A & B-Cohort 1 & 2-Arm 1 & 2-Docetaxel & Capecitabine | 8 | 13 |
Overall response rate is defined as the percentage of participants with a CR (complete disappearance of all target lesions), PR (a 30% decrease in the sum of the longest diameter of target lesions) determined by clinical measurements per the Response Evaluation Criteria in Solid Tumors (RECIST) and/or a complete pathologic response (disappearance of all invasive tumor pathologically or presence of ductal carcinoma in situ) per the Chevallier criteria. For details about the RECIST or Chevallier criteria see the protocol link module. (NCT00005908)
Timeframe: 6 years
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Complete pathologic response | |
| Dose A & B-Cohort 1 & 2-Arm 1& 2-Docetaxel & Capecitabine | 31 | 59 | 10 |
The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented. Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Number) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 12.45 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 12.68 |
Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented. It was analyzed for responders only. Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 7.0 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.7 |
Overall Survival is defined as the time from start of treatment to the date of death. Participants who did not die were censored at the last date the participant was known to be alive. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 22.9 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 20.5 |
Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first. (NCT00022698)
Timeframe: Up to Month 12
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 67 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 71 |
Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression. If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 6.1 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.6 |
The time to objective response is defined as the time from start of treatment to the date of first objective response. Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 5.5 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 4.3 |
Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 5.8 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.3 |
An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | Number of participants (Number) | |||
|---|---|---|---|---|
| Any AEs | SAEs | Deaths During Study | Deaths During Follow-up | |
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 15 | 10 | 0 | 13 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 52 | 25 | 3 | 23 |
| Total Participants (Cohort 1 + Cohort 2) | 67 | 35 | 3 | 36 |
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| CR | PR | |
| Cohort 1, Initial Regimen:(Capecitabine + Irinotecan) | 7 | 40 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 2 | 42 |
"Clinical exam included laryngoscopy in office or operating room.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 16 |
"Clinical exam included laryngoscopy in office or operating room.~Partial response rate (PR) defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 |
Time from complete response to death from any cause, to disease progression or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 93.529 |
Time from diagnosis to death or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 83.960 |
Time from initiation of induction chemotherapy to death due to disease progression, to disease progression, or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 38.675 |
(NCT00736944)
Timeframe: completion of the first 10 patients induction chemotherapy
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic reaction/hypersensitivity | Other allergic reaction:cipro | Other allergic reaction:hives | Hypotension | INR | Fatigue | Alopecia | Chelitis | Dry skin | Rash | Rash:acneiform | Rash:penile (unconfirmed HSV) | Anorexia | Colitis | Constipation | Dehydration | Dental:teeth | Diarrhea | Hemorrhoids | Nausea | Taste alteration | Vomiting | Other:soft stools | Hemoglobin | Leukocytes (WBC) | Lymphopenia | Neutrophils (ANC) | Platelets | Hemmorrhage:nose | Alkaline phosphatase | SGPT (ALT) | Infection other:sinus infection | Edema:limb | Albumin, low | Calcium, low | Magnesium, low | Potassium, low | Potassium, high | Sodium, low | Phosphorus | Dizziness | Mood alteration:anger | Neuropathy:sensory (peripheral) | Vision-photophobia | Pain:thigh | Pain:tumor pain | Hiccoughs (hiccups) | Obstruction/stenosis of airway:trachea | Creatinine | GFR | Renal failure | Thrombosis/thrombus/embolism | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 1 | 1 | 1 | 1 | 1 | 10 | 5 | 1 | 1 | 1 | 7 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 9 | 1 | 1 | 1 | 8 | 8 | 8 | 8 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 4 | 3 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 |
"Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 11 | 7 |
"Clinical exam included laryngoscopy in office or operating room.~Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 13 | 17 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 14 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 17 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 61 | 39 | 0 |
| CT Scan | 30 | 48 | 22 |
| FDG-PET/CT | 36 | 56 | 8 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 43 | 57 | 0 |
| CT Scan | 14 | 50 | 36 |
| FDG-PET/CT | 24 | 66 | 10 |
"In the future, primary tumor site, nodal, and OTR by VCR (CR-x or PR-x = Y or N) will be compared with response based on CT scan (CR-x or PR-x = Y or N) using a test for difference in paired, binary values. Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests.~We are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 53 | 47 | 0 |
| CT Scan | 33 | 41 | 26 |
| FDG-PET/CT | 32 | 61 | 7 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 2 | 4 | 1 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 | 0 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 4 | 1 | 2 | 0 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 19 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 12 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 10 | 11 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 4 | 14 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
27 reviews available for fluorouracil and Neutropenia
| Article | Year |
|---|---|
Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; East A | 2023 |
Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Databases, Bibliographic; Disease | 2018 |
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Fluorouracil; Humans | 2018 |
Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil.
Topics: Administration, Cutaneous; Aged; Angioedema; Antimetabolites, Antineoplastic; Cheilitis; Fluorouraci | 2018 |
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2018 |
Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, | 2019 |
[A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
Topics: Aged; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehy | 2013 |
The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brea | 2015 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combine | 2016 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2008 |
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2009 |
Unanticipated toxicity to capecitabine.
Topics: Antimetabolites, Antineoplastic; Black or African American; Breast Neoplasms; Capecitabine; Deoxycyt | 2009 |
A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2011 |
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Epirubicin | 2012 |
Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.
Topics: Adenoviridae; Aged; Anemia; Animals; Antimetabolites, Antineoplastic; Bystander Effect; Carcinoma, N | 2012 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2013 |
[Prevention and treatment for adverse events induced by chemotherapy].
Topics: Anaphylaxis; Antineoplastic Agents; Brain Diseases; Cisplatin; Docetaxel; Fluorouracil; Humans; Neop | 2002 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap | 2002 |
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2002 |
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic | 2004 |
[The role of taxanes for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2005 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1997 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1998 |
322 trials available for fluorouracil and Neutropenia
| Article | Year |
|---|---|
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2022 |
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiothe | 2020 |
Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neopla | 2019 |
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa | 2020 |
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal N | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne | 2020 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-F | 2017 |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine | 2017 |
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colore | 2018 |
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacologica | 2018 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Femal | 2017 |
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diseas | 2018 |
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2019 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2013 |
A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capeci | 2013 |
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Topics: Ablation Techniques; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineop | 2013 |
Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; | 2013 |
The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neop | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, A | 2013 |
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2013 |
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2013 |
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2013 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothera | 2013 |
Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2014 |
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2014 |
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclopho | 2014 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; | 2014 |
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian Peo | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2014 |
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Colorectal Neoplas | 2014 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2014 |
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Col | 2014 |
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Area Under Curve; Carcinoma, | 2016 |
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2016 |
A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Doce | 2015 |
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Be | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2016 |
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineo | 2016 |
A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Drug Administration Schedule; F | 2008 |
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2008 |
[Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2008 |
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2009 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diseas | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort | 2009 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Diseas | 2009 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Stud | 2009 |
Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; DNA Primers; DNA Repair; Docetaxel; F | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino | 2009 |
Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Fema | 2009 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Dige | 2009 |
A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progre | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas | 2009 |
Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2009 |
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Belgium; Breast Neopla | 2009 |
Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2010 |
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cycloph | 2010 |
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le | 2009 |
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; B | 2010 |
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Adult; Aged; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2010 |
Randomized comparison of fluorouracil plus cisplatin vs. cisplatin as an adjunct to radiation therapy in stage IIB-IVA squamous cell carcinoma of the cervix: pilot study.
Topics: Antimetabolites, Antineoplastic; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 2009 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2009 |
A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2010 |
[Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2009 |
Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetax | 2010 |
[Equalization of breast cancer chemotherapy at general hospital( II )-evaluation of safety in FEC and TC regimens].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Ciprofloxa | 2009 |
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2010 |
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 2009 |
Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; H | 2010 |
Comparison of the short-term efficacy of two inductive chemotherapy regimens for locally advanced nasopharyngeal caricinoma: docetaxal plus carboplatin versus 5-fluorouracil plus carboplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Fluorouracil; | 2010 |
Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 2010 |
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 2011 |
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplas | 2011 |
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2010 |
Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Pr | 2010 |
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2010 |
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy | 2010 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2010 |
A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2011 |
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2012 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclon | 2010 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dia | 2011 |
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal | 2011 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; D | 2011 |
Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin | 2011 |
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2012 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2012 |
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2012 |
[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian Peopl | 2012 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2012 |
Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Clock | 2011 |
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2011 |
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2011 |
The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
Topics: Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dietary Supplement | 2012 |
Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Fr | 2012 |
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2012 |
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabe | 2012 |
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Do | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2012 |
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2012 |
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Diseas | 2012 |
Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2012 |
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capeci | 2012 |
[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2013 |
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2013 |
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2002 |
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2002 |
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2002 |
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrh | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progress | 2002 |
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2002 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2002 |
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2003 |
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Fema | 2003 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplas | 2003 |
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2003 |
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bilirubin; Creatinine; Dose-Response Relationship, Dru | 2003 |
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sched | 2003 |
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non- | 2003 |
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; | 2003 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal | 2003 |
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2003 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; D | 2004 |
A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; | 2004 |
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2004 |
Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Respo | 2004 |
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit | 2004 |
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; | 2004 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap | 2004 |
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 2004 |
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2004 |
Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Doxorubici | 2004 |
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 2004 |
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2004 |
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyt | 2004 |
Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubic | 2004 |
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2004 |
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neopla | 2004 |
Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2004 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cycloph | 2005 |
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2005 |
[Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relati | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; D | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2005 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carbo | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Respo | 2005 |
Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relatio | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2005 |
A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposid | 2005 |
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cisplat | 2005 |
Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2005 |
[The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bio | 2005 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; D | 2005 |
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; | 2006 |
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Docetaxel; Dose- | 2006 |
Granulocyte function is stimulated by a novel hexapeptide, WKYMVm, in chemotherapy-treated cancer patients.
Topics: Adult; Aged; Bacterial Infections; Blood Bactericidal Activity; Cells, Cultured; Cisplatin; Dose-Res | 2006 |
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2006 |
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo | 2006 |
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony sti
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2006 |
Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dose Fra | 2006 |
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
[Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Ne | 2006 |
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
[Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2006 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin | 2007 |
[Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2006 |
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisp | 2007 |
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2007 |
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Anti | 2008 |
[10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2007 |
A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Dr | 2008 |
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2008 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2006 |
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2008 |
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2008 |
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Disease-Fre | 2007 |
[Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Topics: Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransfer | 2007 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2008 |
A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Injections, | 1983 |
Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Fluoroura | 1983 |
Use of methotrexate and 5-FU for recurrent head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diarrhea; Drug Therapy, Combination | 1982 |
Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Immuno | 1980 |
The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Transplantation; Bre | 1993 |
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1995 |
Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamid | 1995 |
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1995 |
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1995 |
A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1994 |
[A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration | 1995 |
Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil | 1994 |
5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fluorouracil; Humans; Leucovorin; Ma | 1994 |
Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administrat | 1993 |
Carboplatin in combination as first-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami | 1993 |
Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1993 |
Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1993 |
Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 1996 |
Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 1996 |
Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1996 |
Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 1995 |
A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Doxoru | 1996 |
Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 1996 |
Growth factor allows effective dose-intensive regimen in advanced breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1995 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colon | 1997 |
Concurrent chemoradiation for oesophageal cancer: factors influencing myelotoxicity.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther | 1996 |
A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neop | 1997 |
Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemothe | 1997 |
[A randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP 5-FU and dl-leucovorin for colorectal cancer].
Topics: Adenocarcinoma; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
Docetaxel in combination with fluorouracil: study design and preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, | 1997 |
The French experience with infusional 5-FU in gastric and pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bio | 1996 |
Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
Metastatic breast cancer: treatment with fluorouracil-based combinations.
Topics: Adult; Aged; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Di | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resist | 1997 |
[Multicentric prospective, randomized study of the role of filgrastim (G-CSF) after transplant of hematopoietic progenitor cells mobilized with G-CSF in patients with cancer of the breast].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modal | 1997 |
Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1997 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 1999 |
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 1999 |
Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1999 |
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1999 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biliru | 1999 |
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1999 |
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis | 1999 |
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Topics: Acetates; Adult; Antimetabolites, Antineoplastic; Cytoprotection; Diarrhea; Dose-Response Relationsh | 2000 |
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2000 |
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diar | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2000 |
Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2000 |
Chemo-biotherapy with 5-fluorouracil, leucovorin, and alpha interferon in metastatic carcinoma of the colon--a Cancer Biotherapy Research Group [CBRG] phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; | 2000 |
Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardia; Doxorubicin; Dr | 2000 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 2000 |
Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycyti | 2000 |
Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Arteries; Bleo | 2000 |
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2000 |
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2000 |
Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubic | 2000 |
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies.
Topics: Abdominal Pain; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dinoprost; Do | 2001 |
Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response | 2001 |
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease- | 2001 |
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2001 |
Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug R | 2001 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2001 |
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2002 |
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chr | 2001 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2001 |
Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progressio | 2001 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; DNA, Antise | 2002 |
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2002 |
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2002 |
Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 1992 |
A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fema | 1992 |
A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.
Topics: Adult; Aged; Blood Glucose; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combinati | 1991 |
Chemotherapy of large bowel carcinoma--fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1985 |
190 other studies available for fluorouracil and Neutropenia
| Article | Year |
|---|---|
Results of the observational prospective RealFLOT study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2021 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 2021 |
Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrast | 2022 |
Effect of concomitant use of G-CSF and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Filgrastim; Fluorouracil; Gran | 2022 |
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Ir | 2022 |
Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Diseases, M | 2022 |
Search for nutritional and inflammatory marker ratios to predict neutropenia in FEC therapy for breast cancer: A retrospective observational study.
Topics: Biomarkers; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neutropeni | 2022 |
Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Incidence; Irinotecan; Leucovo | 2022 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
The
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Genotype; Humans | 2023 |
Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy.
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Australia; Bayes Theorem; Diarrhea; | 2023 |
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Capecitabine; Col | 2023 |
Prophylactic piperacillin administration in pediatric patients with solid tumors following different intensities of chemotherapy.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain | 2020 |
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Fr | 2020 |
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2020 |
Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2020 |
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2020 |
Retrospective study evaluating the safety of administering pegfilgrastim on the final day of 5-fluorouracil continuous intravenous infusion.
Topics: Adult; Aged; Aged, 80 and over; Female; Filgrastim; Fluorouracil; Gastrointestinal Neoplasms; Humans | 2021 |
Rash and neutropenia after the administration of oxaliplatin and 5-fluorouracil plus calcium folinate injection: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Exanthema; Fluorouracil; Humans; Leucovorin; Male; M | 2020 |
FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Glucuro | 2020 |
A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2021 |
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2021 |
Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 2021 |
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diar | 2021 |
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Ch | 2017 |
Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2017 |
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Area Under Curve; Blood Platelets; Cisplatin; Doc | 2017 |
Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Ci | 2017 |
PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2017 |
Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Filgrastim; Fluo | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2018 |
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area.
Topics: Adult; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan | 2018 |
[Prognostic value of chemotherapy-induced neutropenia in metastatic colon cancer patients undergoing first-line chemotherapy with FOLFOX].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; | 2017 |
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B | 2018 |
Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Chemoradioth | 2017 |
Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Survival; Drug | 2018 |
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluo | 2017 |
[Neoadjuvant chemotherapy with concurrent chemoradiotherapy in the treatment of nasopharyngeal cancer: Southern Tunisian experience].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2018 |
Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Ci | 2018 |
Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esoph | 2018 |
Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fe | 2018 |
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related | 2018 |
[Impact of Primary Prophylaxis with Pegfilgrastim on Clinical Outcomes in Patients with Advanced Esophageal Cancer Receiving Chemotherapy with Docetaxel, Cisplatin ,and 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrast | 2018 |
Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal N | 2019 |
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; | 2019 |
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; | 2019 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2013 |
Predictive value of baseline plasma D-dimers for chemotherapy- induced thrombocytopenia in patients with stage III colon cancer: a pilot study.
Topics: Adult; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curv | 2013 |
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2015 |
Association of creatinine clearance with neutropenia in breast cancer patients undergoing chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Creatinine; Cyclophosphamide; Doxo | 2013 |
Cisplatin plus capecitabine as first-line chemotherapy for recurrent or metastatic head and neck squamous cell cancer: experience outside of a trial setting.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine | 2013 |
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2013 |
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2014 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |
Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Diarrhea; Disease- | 2013 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Campto | 2013 |
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis | 2013 |
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2013 |
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Databases, Factual; Female; Fluorou | 2014 |
Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epi | 2014 |
Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluo | 2013 |
Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Blood Pressure; Cell Line, Tumor; | 2015 |
Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus.
Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Diabetes Mellitus, Experimental; | 2015 |
[Neoadjuvant chemotherapy using epirubicin, cyclophosphamide and fluorouracil: neutropenia and elevation of transaminase, and their management].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fema | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2016 |
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; | 2015 |
[Clinical Investigation of the Effects of Filgrastim BS1 on Neutropenia Following Oral Cancer Chemotherapy (TPF Therapy)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Filgrastim; Fluo | 2015 |
Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease-Free Sur | 2015 |
Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2015 |
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2016 |
Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.
Topics: Adult; Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cohort Studies; | 2016 |
Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Dise | 2016 |
Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2016 |
A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Disease-Free Survival; Drug Therapy, Combi | 2016 |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition | 2016 |
Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Sur | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; | 2017 |
Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutition Diso | 2017 |
[Influence of Next-Day Administration of Pegfilgrastim after FEC100 Chemotherapy in Japanese with Breast Cancer on Neutrophil Count].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epi | 2017 |
Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Che | 2009 |
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2009 |
[Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationsh | 2009 |
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplast | 2010 |
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capeci | 2009 |
[Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fl | 2009 |
[Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junctio | 2009 |
Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2011 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; | 2010 |
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cros | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; De | 2011 |
[Comparison of glucan and galactomannan tests with real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model].
Topics: Animals; Antigens, Fungal; Aspergillus fumigatus; beta-Glucans; Bronchoalveolar Lavage Fluid; Diseas | 2010 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal | 2011 |
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2011 |
Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2010 |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fema | 2012 |
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemot | 2012 |
[Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2012 |
Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2011 |
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; | 2012 |
Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Beva | 2012 |
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Topics: Adverse Drug Reaction Reporting Systems; Capecitabine; Data Mining; Deoxycytidine; Diarrhea; Fluorou | 2012 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2012 |
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dr | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carb | 2012 |
Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Proto | 2013 |
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Exons; Female; Flu | 2002 |
Pasteurella multocida infection in a post-chemotherapy neutropenic host following cat exposure.
Topics: Aged; Animals; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2002 |
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Topics: Alopecia; Antimetabolites, Antineoplastic; Area Under Curve; Diarrhea; Drug Eruptions; Female; Fever | 2002 |
An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora.
Topics: Antifungal Agents; Child; Dose-Response Relationship, Drug; Escherichia coli; Feces; Female; Flucyto | 2003 |
Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Bone Marrow Cells; Colo | 2003 |
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer.
Topics: Adult; Age of Onset; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoth | 2003 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2004 |
[Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Male; Met | 2004 |
Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia.
Topics: Animals; Antineoplastic Agents; Aspergillosis; Aspergillus fumigatus; Combined Modality Therapy; Flu | 2005 |
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chola | 2005 |
[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2004 |
[Role of an exclusive concomitant radio-chemotherapy treatment in non operable esophageal cancer: results of a 10-year experience in Antoine-Lacassagne Center].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2005 |
[Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibil | 2005 |
A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Topics: Adult; Aged; Anemia, Hypochromic; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anti | 2005 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2006 |
[FOLFOX].
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoroura | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Admin | 2006 |
Efficacy and feasibility of cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2006 |
A prospective investigation of chemotherapy-induced neutropenia and quality of life.
Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 2006 |
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2007 |
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Adm | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2007 |
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2007 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2007 |
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplas | 2008 |
Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Co | 2008 |
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Cape | 2008 |
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian Peop | 2007 |
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Cy | 1984 |
Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; F | 1982 |
High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule.
Topics: Adenocarcinoma; Aged; Allopurinol; Brain Diseases; Drug Administration Schedule; Drug Evaluation; Dr | 1982 |
Clostridium septicum abscess in hepatic metastases: successful medical management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1994 |
Pharmacological effects of recombinant human granulocyte colony-stimulating factor modified by polyethylene glycol on anticancer drug-induced neutropenia in mice.
Topics: Animals; Cyclophosphamide; Drug Evaluation, Preclinical; Female; Fluorouracil; Granulocyte Colony-St | 1994 |
High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Brain Neoplasms; | 1994 |
5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia; Carcinoma, Hepatocellular; Disease P | 1996 |
[A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 1997 |
Effect of ethyldeoxyuridine on 5-fluorouracil-induced neutropenia.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxyuridine; Female; Fluorouracil; Leukocyte Count; Male; | 1996 |
Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report.
Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enterocolitis; Fluorouracil; Human | 1997 |
Clinical and pathological response to primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
Aztreonam plus piperacillin--empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aztreonam; Bacterial | 1998 |
Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as | 1996 |
Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer.
Topics: Adult; Aged; Agranulocytosis; Alopecia; Ambulatory Care; Antineoplastic Combined Chemotherapy Protoc | 1999 |
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Digestive System; Dihydrouracil Dehydrogenase (NADP); | 1999 |
[Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, | 1999 |
Neutropenic proctosigmoiditis complicating breast cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clostridium Infections; | 1999 |
Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 1999 |
Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 1999 |
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopla | 1999 |
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
[Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choriocarcino | 1999 |
Moving beyond fluorouracil for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2000 |
[Chemotherapy with cisplatinum, carboplatin and 5FU-folinic acid, followed by concomitant chemo-radiotherapy in unresectable esophageal carcinomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modali | 2001 |
[Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2001 |
Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Ph | 2001 |
Neutropenia associated with metronidazole.
Topics: Agranulocytosis; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Metronidazole; | 1979 |
Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Topics: Animals; Carcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule | 1990 |
Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin | 1990 |
Synergistic effect of dolichyl phosphate and human recombinant granulocyte colony-stimulating factor on recovery from neutropenia in mice treated with anti-cancer drugs.
Topics: Agranulocytosis; Animals; Antineoplastic Agents; Colony-Stimulating Factors; Dolichol Phosphates; Do | 1988 |
Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy.
Topics: Animals; Antigens, CD34; Antigens, Differentiation; Bone Marrow; Bone Marrow Cells; Combined Modalit | 1989 |
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chro | 1989 |
Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1989 |
Enhancement of antibacterial resistance of neutropenic, bone marrow-suppressed mice by interleukin-1 alpha.
Topics: Adjuvants, Immunologic; Agranulocytosis; Animals; Bacterial Infections; Bone Marrow; Cyclophosphamid | 1989 |
A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil.
Topics: Adult; Aged; Allopurinol; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Granu | 1985 |
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man.
Topics: Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Nausea; Neoplasms; Neutr | 1985 |